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Abstract 
In 2015, the WHO recorded lower respiratory infections as the leading cause of mortality 
by infection worldwide (World Health Organization 2017). Streptococcus pneumoniae is 
just one bacterial species responsible for this burden. This pathogen is managed through 
using antibiotics, however it’s recognised that pathogens can rapidly adapt to the 
selective pressure of antibiotics and acquire resistant mechanisms. Therefore, as the 
affliction of AMR grows wider, alternative treatments for bacterial infections are 
urgently required. One suggested method involves the development of host-based 
therapies. This requires a thorough understanding of host-pathogen interactions, to 
appropriately control host immune responses without causing excessive inflammation 
or host damage. This is particularly important for bacteria such as S. pneumoniae, which 
frequently colonise hosts without causing serious disease. 
Metabolism has emerged as a key regulator of innate immune responses, particularly 
macrophages activated with the bacterial component LPS (O’Neill et al. 2016); however, 
few studies have sought to uncover the importance of metabolism during macrophage 
challenge with live bacteria. Therefore, the work reported herein aimed to understand 
how S. pneumoniae modulates murine macrophage metabolism, with a view to honing 
host responses to improve infection outcome, as a potential alternative to antibiotics. 
This thesis outlines the optimisation and use of Seahorse XF Analysis and NMR 
Spectroscopy, to understand changes in macrophage metabolism, following stimulation 
with S. pneumoniae compared to the pro-inflammatory macrophage stimulus LPS. I have 
also addressed the use of glycolytic inhibitors, to probe the importance of glucose 
metabolism in regulating macrophage effector functions, such as phagocytosis and 
cytokine release. My principal finding is that S. pneumoniae does not induce the same 
metabolic changes as recorded for LPS in the literature. I propose that bacterial 
stimulation induces distinct macrophage activation phenotypes that depend on tailored 
host-pathogen interactions, which are likely to be unique for different pathogens of 
interest. 
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Chapter 1 - Introduction  
1.1. Antimicrobial Resistance  
1.1.1. Early antibiotic discovery 
In 1928, Sir Alexander Fleming serendipitously discovered penicillin (Fleming 1929). 
Howard Florey and Ernst Chain then purified this compound, enabling it to be used to 
treat clinical bacterial infections, and saving millions of lives during World War II. This 
discovery is now considered as one of the biggest medical breakthroughs of the 20th 
century (Kardos & Demain 2011; Neushul 1993). Despite this, during his Nobel Lecture, 
Fleming foretold the principal of antibiotic resistance with the following statement: 
 “It is not difficult to make microbes resistant to penicillin in the laboratory by 
exposing them to concentrations not sufficient to kill them, and the same thing has 
occasionally happened in the body. The time may come when penicillin can be bought by 
anyone in the shops. Then there is the danger that the ignorant man may easily 
underdose himself and by exposing his microbes to non-lethal quantities of the drug, 
make them resistant.” (Fleming 1964). 
A century on and hundreds of antibiotics are now available, but with many classes facing 
bacterial resistance (Clatworthy et al. 2007). Antimicrobial Resistance (AMR) is the 
overarching term for when a microorganism becomes resistant to an antimicrobial 
compound, with which it was originally treated; for example, Staphylococcus aureus was 
previously treated with methicillin, however, this drug is now administered more 
selectively, since the emergence of methicillin-resistant S. aureus (MRSA) in the 1960s 
(Jevons 1961; Cetin 1962). AMR has been forecast to cost the globe $100 trillion by 2050, 
if no further action is taken, which could increase the death doll by 10 million lives each 
year – equating to an estimated increase of one person every three seconds (Taylor et 
al. 2014). During the 1940s-1960s, a time referred to as the ‘Golden Era of Antibiotic 
Discovery’, many antibiotics were isolated through screening of soil samples, as 
demonstrated by Selma Waksman and his work with Streptomyces (Walsh & Wencewicz 
2014; Lewis 2013). However, after 20 years no new antibiotics had been identified and 
resistance was already emerging, which instead prompted the chemical manipulation of 
current antibiotics and target compounds. The last major antibiotic class identified in 
1986 were the lipopeptides, specifically the drug Daptomycin (Lewis 2013; Steenbergen 
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et al. 2005). However, regardless of advances in scientific technologies – including the 
ability to sequence and profile bacterial genomes – new approaches to AMR are still 
urgently required. 
 
1.1.2. Modern antibiotic discovery and new antimicrobial approaches  
Despite the increasing burden of AMR, pharmaceutical industries were not investing in 
the development of new antimicrobials. It can cost up to $800million for a drug to reach 
market, making it clear why drugs for chronic diseases or long term usage were a more 
attractive pipeline (Norrby et al. 2005; O’Neill 2015). Pharmaceuticals therefore focused 
their efforts on drugs that provided better return, to recover the costs of research and 
development, from basic bench science through to clinical trials, whilst also making 
profits on sales (Cole 2014). This idea of money versus morals caused increasing debate, 
and governing bodies have since implemented plans and incentives to increase research 
into antimicrobial strategies. For example, in 2015 alone, the World Health Organization 
(WHO), United States and G7 Health Ministers all launched action plans to develop AMR 
research (World Health Organization 2015; The White House Administration 2015; G7 
Gesundheitsministertreffen 2015). In 2014, economist Jim O’Neill chaired the UK 
independent review on AMR, with the final report published in 2016, detailing the 
ensuing devastation AMR will cause if left unchallenged, with recommended actions 
suggested to be carried out on a global scale (O’Neill 2016). This review also prompted 
the Industry Declaration by Pharmaceutical, Biotechnological and Diagnostic companies, 
calling for governments to reform the market of antimicrobials and diagnostics (Review 
on Antimicrobial Resistance 2016). With this financial and collaborative support, the 
search for new antimicrobials is now back on the rise. One example of new technologies 
in recent antimicrobial studies can be demonstrated by (Ling et al. 2015). There had 
been no new antibiotic classes founded for over 30 years, but the advanced technology 
used by Ling et al. to grow unculturable soil organisms, resulted in the identification of 
the novel antimicrobial Teixobactin (Ling et al. 2015). 
Whilst an increase in antimicrobial and therapeutic enhancements are recommended in 
the O’Neill review, they also suggest that the development of vaccines and alternatives 
to antimicrobials are conducted (O’Neill 2016). One alternative method could be to 
target the host immune system, as opposed to targeting bacteria; for example, by 
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boosting natural host immune responses to better fight infection. This requires a 
thorough understanding of immune responses and the interplay with bacteria 
(Czaplewski et al. 2016). With this approach to AMR, valuable insight could be achieved 
into how ‘healthy’ people remain healthy and why the immune system can result in 
illness, even during colonisation with commensal bacteria. The understanding of host-
pathogen interactions could provide information on how to promote more efficient 
immune responses, or how to hinder the initial interaction of bacteria with their hosts, 
and prevent bacteria from colonising, thriving, and causing disease when in association 
with our bodies. This is very much the view of the University of Sheffield’s Florey 
Institute: researching the host-pathogen interactions of S. aureus and S. pneumoniae, 
with a view to identifying novel antimicrobial strategies, using the notion of bench-to-
bedside research (The University of Sheffield 2015). The work reported herein focuses 
specifically on the pathogen S. pneumoniae and its interaction with cell cultures, as a 
model of pneumococcal respiratory infection. 
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1.2. S. pneumoniae 
S. pneumoniae is a Gram-positive human-commensal bacterium that is commonly found 
in the upper respiratory tract (Gray 1980). However, given the opportunity it can cause 
disease - for example, when opposed by a weakened host immune response, as is 
typically observed in children, the elderly and immunocompromised. In these 
individuals, the bacterium colonises the lower respiratory environment, induces disease 
and disseminates through the blood (van der Poll & Opal 2009; Weiser 2010). S. 
pneumoniae causes a wide range of diseases, including meningitis, bacteraemia, otitis 
media (Musher 1992), and it is a leading cause of community-acquired pneumonia. It is 
also a cause of infectious exacerbations in Chronic Obstructive Pulmonary Disease 
(COPD), which was previously recorded to affect between 30-80% of patients (Garau & 
Calbo 2008; Garcia-Vidal et al. 2009), although more recent estimates have since been 
below 20% (Williams et al. 2017; Lin et al. 2016). In 2000, it was estimated that 14.5 
million cases of serious pneumococcal disease were recorded, with more than 800,000 
of these resulting in deaths of children under the age of five (World Health Organization 
2011). With such high mortality and the increasing spread of AMR, S. pneumoniae is still 
one of the leading causes of death by infection, worldwide. 
 
1.2.1. S. pneumoniae virulence factors 
S. pneumoniae uses a combination of different virulence techniques, to successfully 
colonise, invade and infect different tissue niches (van der Poll & Opal 2009), with a large 
proportion of genes having been acquired through horizontal transfer, from both 
genetic recombination and mobile genetic elements (Chaguza et al. 2015). The genome 
of S. pneumoniae is roughly two million base pairs and contains between 1,500-1,800 
core genes, which are commonly shared across serotypes (Tettelin et al. 2001; 
Makarewicz et al. 2017; Chaguza et al. 2015). These genes are likely to transcribe 
proteins that contribute to essential functions, including viability, core metabolic 
pathways, colonisation, and expression of virulence factors, such as the pneumolysin 
toxin, autolysin, hyaluronidase, and metal ion transporter channels (Obert et al. 2006). 
A large component of the genome regulates metabolic function and its consequences, 
for example the ability to withstand oxidative stress (Tettelin et al. 2001; Aberdein et al. 
2013). The genome also consists of variable regions, which are also referred to as 
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accessory regions (ARs) or regions of diversity. Whilst virulence factors have been noted 
to cluster at ARs, they are not exclusively transcribed within these regions (Obert et al. 
2006), and differential expression of virulence determinants is suggested to be 
dependent on the serotype and infection site, with no definitive or distinguishable trend 
for ARs noted during invasive infections (Ogunniyi et al. 2002; Blomberg et al. 2009). In 
this section, two key virulence factors are described in detail, with further factors also 
discussed briefly. 
 
1.2.1.1. Polysaccharide capsule 
The pneumococcal capsule is arguably the most important virulence factor for the 
pathogenicity of the pneumococcus. It plays a fundamental role in the pathogens ability 
to colonise, invade and disseminate from the respiratory tract to other tissues. It 
supports bacterial evasion of phagocytosis, as the capsule coats the external surface of 
the bacterium, hiding pneumococcal surface structures that would otherwise be bound 
or identified by complement and antibodies of the host immune response (Kalin 1998). 
The capsule also restricts mucosal clearance of the pathogen, as it is highly negatively 
charged and exerts a strong electrostatic repulsion against mucosal surfaces (Nelson et 
al. 2007). Further to this, capsular size and viscosity have been shown to influence 
colonisation of the bacterium; pneumococci with thinner, transparent capsules are 
shown to be more successful during binding of the host, in early colonisation and biofilm 
formation, whilst thicker, opaque capsules promote a more planktonic phenotype and 
are better suited for tissue invasion and pathogen dissemination. It is reported that 
many pneumococcal variants have the ability to switch between these two capsule 
types, through displaying phase variation (Weiser et al. 1994). Currently, there are over 
90 different capsular polysaccharide variants recorded (Bentley et al. 2006; Geno et al. 
2015), and it has been shown that non-encapsulated strains are more susceptible to 
immune clearance and present a loss of virulence compared to their encapsulated 
counterparts (Hyams et al. 2010). That said, increasing numbers of non-encapsulated 
strains have been isolated from patients with conjunctivitis and otitis media, and in rare 
cases of invasive pneumococcal disease (Keller et al. 2016). This capsule is also the 
principal target for current pneumococcal vaccines, as discussed later in this section.  
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1.2.1.2. Pneumolysin 
Pneumolysin is the 53kDa cholesterol-dependent pore-forming toxin produced by S. 
pneumoniae, which shows strong similarity to the Clostridium perfringens toxin, 
perfringolysin. Pneumolysin is released by the bacterium as a soluble monomer, 
consisting of four domains and with primarily β-sheet structures. These monomer units 
bind to cholesterol in host cell lipid membranes, where they oligomerise to a 30-50 
subunit pore, with a diameter of up to 450Å (Gilbert et al. 1999). When present in high 
enough concentrations, the pores leach the contents of host cells, and induce cell death 
through lysis (Van Pee et al. 2016; Hirst et al. 2004). The toxin is usually found in the 
cytoplasm of the bacteria, and is considered to be released through autolysis of the 
bacterium via the autolysin LytA; however the mechanism of its release is still widely 
debated as it has also been shown to occur independently of LytA (Balachandran et al. 
2001). Aside from it’s pore-forming capabilities, pneumolysin has been reported to 
cause other pathological effects at lower concentrations, including the inhibition of 
epithelial ciliary action, the stimulation of cytokine production by immune cells, and 
activation of T-cell subsets (Hirst et al. 2004). The toxin has also been shown to play an 
important role in the ability of pneumococci to replicate and disseminate in the alveolar 
environment and in the activation of complement in vivo (Rubins et al. 1995). Further to 
this, it is proposed that pneumolysin can promote biofilm formation of pneumococci, 
independent of its pore-forming ability (Shak et al. 2013). Interestingly non-haemolytic 
pneumolysin mutants of S. pneumoniae have been isolated from patients with invasive 
pneumococcal disease, demonstrating that a functional pore-forming toxin is not 
necessarily required for virulence, and may also confer a selective advantage for 
dissemination and survival in the host bloodstream (Kirkham et al. 2006; Harvey et al. 
2011) 
 
1.2.1.3. Other virulence factors and mechanisms 
Sheltered beneath the polysaccharide capsule, S. pneumoniae has an array of surface 
proteins that contribute to bacterial virulence. These include LPXTG-anchored proteins, 
such as neuraminidase and hyaluronidase, and choline binding proteins, including LytA 
and the pneumococcal surface proteins PspA and PspC (PspC also known as CbpA). The 
sialidase enzyme, neuraminidase, has been shown to be important in removal of glycan 
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sugars from host receptors, in order to aid bacterial adhesion to host cell surfaces, 
particularly to cells of the epithelium (Brittan et al. 2012). Likewise, hyaluronidase has 
been suggested to break down extracellular matrix components, to aid spread of 
infection between tissues (Kadioglu et al. 2008). Meanwhile, PspA and PspC are 
important for interference of the host complement response, and for binding lactoferrin 
and the complement regulator Factor H, respectively (Mitchell & Mitchell 2010; 
Kadioglu et al. 2008). This allows extended evasion of opsonophagocytosis and hinders 
host clearance of the bacterium. The expression of pneumococcal surface lipoproteins 
is vital in pro-inflammatory activation of immune cells, including macrophages 
(Tomlinson et al. 2014). Additionally, natural IgM antibodies to pneumococcal surface 
proteins are known to be effective in opsonising S. pneumoniae TIGR4 in the absence of 
capsular antibodies (Wilson et al. 2017), although further work is required to confirm 
this for other serotypes. Lastly, external to the capsular environment, some 
pneumococcal variants present a pilus, which is suggested to play a role in binding, 
adherence and pro-inflammatory stimulation of the host (Barocchi et al. 2006).  
Whilst the pneumococcus has a plethora of ways to prevent phagocytosis and immune 
evasion, the bacterium can still be phagocytosed by immune cells. In this intracellular 
environment, the bacterium has further strategies to prevent killing by the host. In the 
nasopharynx, S. pneumoniae kills competing bacteria through the release of hydrogen 
peroxide and uses the manganese-containing superoxide dismutase, MnSOD, to oppose 
damage to itself; this therefore allows S. pneumoniae to also resist oxidative killing 
mechanisms induced in the phagolysosome of host cells (Yesilkaya et al. 2000). The 
bacterium is also equipped to impede oxidative killing by other factors, including the 
pyruvate oxidase, SpxB, which generates further reactive oxygen species (ROS) but 
prevents ATP depletion (Pericone et al. 2003); the nicotinamide adenine dinucleotide 
(NADH) oxidase, Nox, which converts free oxygen into water to avoid it being used for 
ROS generation (Yu et al. 2001); and the pneumococcal surface antigen protein complex, 
PsaABC, which transports manganese required for MnSOD function, in association with 
the thiol peroxidase PsaD (McAllister et al. 2004; Tseng et al. 2002). 
In addition to roles in virulence, some metabolic enzymes have been shown to locate at 
the cell walls of S. pneumoniae, S. agalactiae and S. pyogenes, including glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), glucose-6-phosphate isomerase and enolase 
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(D’Costa et al. 2000; Ling et al. 2004). These enzymes have been proposed to support 
functions in adhesion and binding of host factors, such as plasminogen and epithelial 
cell surfaces (Henderson & Martin 2011; Daniely et al. 2006). This is puzzling, as most of 
these proteins do not have sequences or motifs targeting them to this region, and 
therefore requires further research to understand their full purpose here. However, it 
has been shown that these cytoplasmic proteins could provide immunogenicity and a 
potential avenue for vaccine targeting (Zysk et al. 2000).  
 
1.2.1.4. Pneumococcal metabolism 
S. pneumoniae is a fermentative anaerobe, that heavily depends on sugar metabolism 
for biosynthesis, growth and virulence. It completely lacks the genes required for 
respiration and only a few genes of the Krebs cycle are found in specific pneumococcal 
serotypes; that said, a functional ATPase is present and genomic analysis of strain TIGR4 
has shown the potential for synthesis and utilisation of up to 14 amino acids (Tettelin et 
al. 2001). Like many lactic acid bacteria, S. pneumoniae obtains its energy requirements 
most efficiently from carbohydrates, including compounds such as glucose, galactose 
and mannose, which feed the Embden-Meyerhof glycolytic pathway; however this 
typically depends on what is available to the bacterium in its environmental niche 
(Hoskins et al. 2001). The bacterium can sense and utilise sugars in the local 
environment via carbon catabolite repression (CCR), a process that silences genes of 
metabolic enzymes when they are not required – i.e. when they cannot process the 
sugars currently available. A key regulator of this process is catabolite control protein A, 
CcpA, which is important in steering the appropriate metabolic changes for colonisation 
in the nasopharynx (Iyer et al. 2005). In the nasopharynx, free glucose is limited, so the 
bacterium utilises glycosidases to cleave glycans from the epithelium and mucosal 
surfaces; whilst in the blood stream and inflammatory environments, glucose is present 
in much higher concentrations and is readily used by the bacterium (Shelburne et al. 
2008; Philips et al. 2003). 
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1.2.2. Therapy for S. pneumoniae infections  
To treat pneumococcal infections, antibiotics are the method of choice. However, AMR-
pneumococcal strains have already emerged against major antibiotics, including 
penicillin, the macrolides, tetracyclines and fluoroquinolones (Adam 2002; Gill et al. 
1999; Riedel et al. 2007). The patient and site of infection can influence the course of 
antibiotic treatment – for example, there are different approaches for an elderly patient 
with meningitis, versus an infant with community-acquired pneumonia. Treatment 
methods can also be influenced by patient allergy history, as some people are allergic to 
penicillin. The choice of antibiotic can additionally be influenced by geographical trends 
of resistance; for example, penicillin resistance has previously been shown to vary 
considerably between different countries, with the percentage of resistant clinical 
isolates in 1989 shown to be below 3% for England, but up to 5% in France, 44% in Spain 
and 57% in Hungary (Appelbaum 1992). However, where susceptible, the main method 
of treatment is with -lactam antimicrobials such as penicillin and amoxicillin. It is also 
suggested that the chosen drugs should be ones that lower the propensity for driving 
resistance, particularly in regions where resistance is already high (Riedel et al. 2007). In 
the case of bacterial pneumonia, oral amoxicillin is the first line antibiotic used to treat 
previously healthy infants, children and adolescents, whilst penicillin or intravenous 
ampicillin are chosen to treat more severe cases, and ceftriaxone or cefotaxime used for 
meningitis. Some infections by strains with raised minimum inhibitory concentrations 
(MIC) to penicillin may still be treated with a cephalosporin, but meningitis may require 
use of other agents, such as vancomycin, which doesn't get into the cerebrospinal fluid 
very well, or in combination with linezolid. With penicillin allergy, macrolides or 
doxycycycline may be used for milder infections (Bradley et al. 2011; Mandell et al. 
2007).  
Strategies to prevent pneumococcal disease at the community level have largely 
focused on vaccination strategies. Currently, there are two main vaccines used against 
the pneumococcus: the pneumococcal conjugate vaccine (PCV) and the pneumococcal 
polysaccharide vaccine (PPV). PCV13 contains the capsular polysaccharide of thirteen of 
the most prominent, clinically observed strains in severe paediatric infections and most 
adult cases. The polysaccharides are conjugated to the non-toxic but highly 
immunogenic diphtheria toxin protein, CRM197, which acts to provoke a strong T-cell-
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dependent immune response to the polysaccharides. This in turn induces a mature B-
cell response with class switching, immunological memory and the production of life-
long immunity via antibody production. The vaccine is suitable for children under the 
age of five, and healthy adults between the ages of 18-65 (U.S. Department of Health 
and Human Services 2013). However, the vaccine only covers a small proportion of 
existing serotypes, and the composition of the vaccine does not match prevailing 
serotypes as closely in other regions of the world, such as Africa and Asia (Johnson et al. 
2010). The PCV13, however, not only reduces invasive pneumococcal disease (eg. 
bacteraemia), but also cases of pneumonia. Alternatively, the PPV23 vaccine contains 
the purified polysaccharides of 23 pneumococcal serotypes, but provides a lower 
immunogenicity: the vaccine provokes T-cell independent responses but fails to 
generate immunological memory, whilst memory B-cell production is weak and a 
vaccine booster is required every 5 years, especially if the patient is at high risk of S. 
pneumoniae infection (Schwarz & Pauksens 2013; NHS Choices 2016; Centers for 
Disease Control and Prevention 2016). PPV23 is the recommended vaccine for older 
adults and some patients with co-morbidities. With continued cases of pneumococcal 
disease due to replacement of vaccine colonising strains with other non-vaccine 
serotypes (Dagan 2009), and with the number of identifiable S. pneumoniae serotypes 
considered to be greater than 90, vaccination strategies alone are not able to produce 
complete protection or full, cost-effective control of pneumococcal disease. 
Additionally, some groups are shown to have reduced responses to vaccines, such as the 
elderly or those with significant immune-compromised conditions, (Ljungman 2012; 
Park & Nahm 2011). In view of the limited number of capsular types that can be covered 
with capsule-based vaccines and the potential replacement of vaccine serotypes with 
non-vaccine serotypes, significant research efforts have focused on trying to develop 
PPVs to target specific proteins, for examples pneumolysin or PsPA, which would not be 
restricted to specific serotypes (Ginsburg et al. 2012). 
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1.3. The immune system  
The human body has evolved to protect the host against bacterial infections and their 
associated complications, not just through physical barriers such as the skin and mucosal 
surfaces, but also through the development of a functional immune system. Immunity 
can be divided into two main systems: innate or adaptive. The innate immune system 
acts rapidly using non-specific mediators, such as the complement system and 
phagocytic cells, including macrophages and neutrophils, which phagocytose and kill 
invading pathogens. Key features of the innate immune system are the development of 
rapid and broad responses to a range of microbial structures. On the other hand, the 
adaptive immune system acts over a much longer timescale, using specific mediators 
such as antibodies, B-cells and T-cells, which provide immune memory for subsequent 
infections (Murphy et al. 2012). The adaptive immune response is much more specific, 
and acts against very precise antigenic determinants. Although the immune system has 
been classically divided in this way, the identification of lymphoid subsets that 
contribute to innate immune responses, and the identification of innate immune 
memory through epigenetic modifications have started to blur this classical division 
(Netea et al. 2015; Quintin et al. 2014). 
Immune cells are produced through a procedure known as haematopoiesis, a term that 
describes the growth and proliferation of different blood cell lineages from 
haematopoietic precursor cells (Murphy et al. 2012). This process begins in the yolk sac 
soon after development and shifts transiently to the liver during the emergence of blood 
circulation. Prior to birth, the niche of blood cell progenitors moves again to the bone 
marrow and thymus, where they remain throughout adulthood (Jagannathan-Bogdan & 
Zon 2013). The common progenitor that gives rise to all immune cells is the pluripotent 
haematopoietic stem cell, which are located within bone marrow. From this point, the 
stem cells divide into more specialised groups, which mirror the division of immunity. B-
cells and T-cells, found in adaptive immunity, are produced through the emergence of 
the common lymphoid progenitor, whilst the common myeloid progenitors give rise to 
further progenitors for megakaryocytes, erythrocytes and granulocytes, which become 
platelets, red blood cells and neutrophils, macrophages and monocytes respectively 
(Murphy et al. 2012). 
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Interactions by commensal bacteria, formation of the microbiome, and development of 
the immune system are of key interest, as a fine balance must be achieved to limit 
bacterial replication and prevent bacterial spread or tissue invasion that could then lead 
to clinical disease, whilst also preventing inappropriate inflammation and the tissue 
injury associated with inappropriate immune activation (Ivanov & Littman 2011). 
Receptors and regulatory pathways of immune cells are essential for this purpose, as 
defects in key, rapid cellular mediators have been shown to decrease bacterial 
clearance, resulting in bacterial outgrowth and increased susceptibility to invasive 
disease. An example of this can be demonstrated by modulation of receptor family 
signalling, such as those involving the Toll-like receptors (TLR), which are stimulated by 
microbial and danger-associated stimuli (Albiger et al. 2005; Ku et al. 2007). Innate 
immune functions are therefore carefully controlled by expression of recognition 
receptors and their downstream signalling pathways, to produce an appropriate 
cytokine and inflammatory response, both to commensal flora and following dynamic 
changes in the microbiome, including acquisition of potentially pathogenic strains. The 
focus of work in this thesis considers the importance of one innate immune cell, the 
macrophage, and the role of changes in metabolism on its innate function. 
 
1.3.1. Macrophages 
The role and function of macrophages can be traced back to the discovery of 
phagocytes, by Élie Metchnikoff, who was jointly awarded the Nobel Prize in Medicine 
in 1908. Metchnikoff described the active internalisation, vacuole acidification and 
destruction of foreign bodies in leukocytes (Gordon 2008; Metchnikoff & Binnie 1906). 
During this time, it was thought that the sole function of the macrophage was to clear 
infection and debris, hence the direct Greek translation of ‘big eater’; however, it is now 
more recognised that macrophages have additional roles in wound healing and tissue 
homeostasis (Wynn et al. 2013). Macrophages are a highly conserved component of the 
innate immune system, dating back 500 million years and found in organisms such as 
starfish that lack a vascular system (Gordon 2008; Metchnikoff & Binnie 1906). 
Macrophages arise from two sources – the maturation of monocytes that have migrated 
from the bloodstream to specific tissue environments via chemotactic gradients, and 
also embryonically derived mature macrophages that persist independently from the 
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vasculature and self-sustain within tissues (Epelman et al. 2014; Hashimoto et al. 2013). 
Different tissue macrophage populations have different origins; the tissue macrophages 
that make up the brain (microglia) are derived from a yolk-sac progenitor, while those 
forming alveolar macrophage are derived from haematopoietic liver cell progenitors, 
and those forming gut macrophages are predominantly derived from blood-derived 
monocytes (Epelman et al. 2014). The variation in origin and environmental niche 
underpins the heterogeneity in tissue macrophage populations, with adaptations to 
patrol different tissue niches, including the liver (Kupffer cells), intestine, blood 
(monocytes) and bone (osteoclasts). These mononuclear phagocytic cells ingest foreign 
particles, engulfing them in an increasingly acidified vacuole, where they are degraded 
and the antigens redirected to the outer cell membrane for antigen presentation at the 
surface. Degradation products can also be used to activate pattern recognition 
receptors (PRRs), macrophage signalling and cytokine release, which causes 
downstream recruitment of neutrophils, dendritic cells and T-cells, and induce 
inflammation (Gordon & Taylor 2005; Murphy et al. 2012). Alveolar macrophages (AMs) 
are particularly important for bacterial clearance and immune responses in the lungs 
and airways, preventing migration, excessive growth and translocation of 
microorganisms from the upper to lower respiratory tract. Upon aspiration of bacteria, 
resident AMs are among the first immune cells to respond at the site. It is critical that 
macrophages not only act rapidly, but also appropriately, as pneumonia can result from 
inappropriately activated host immune responses, either resulting in a reduced or 
excessive response (Murphy et al. 2012). Macrophages phagocytose, kill and degrade 
pathogens, but also facilitate secondary antigen presentation and regulate 
inflammatory responses via the release of cytokines and immune mediators, and 
through the induction of apoptosis and efferocytosis of apoptotic cells (Savill et al. 1993; 
Lee et al. 2009).  
 
1.3.2. Pathogen recognition 
During initial interactions with pathogens, macrophages use a range of receptors to 
rapidly sense and respond to the presence of infection (Opitz et al. 2010). They are 
suitably adapted to this through a variety of cell surface, intracellular and secretory 
receptors (Taylor et al. 2005). Many receptors involved in this process of pathogen 
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detection are known as pattern recognition receptors (PRRs). These are germ-line 
encoded, fixed within the genome, and are central to rapid recognition of both non-self 
and endogenous ‘danger signals’ released by injured cells. These receptors detect 
conserved and/or essential pathogen structures, otherwise known as pathogen-
associated molecular patterns (PAMPs). Some example PAMPS include 
lipopolysaccharide (LPS), and CpG motifs in DNA and dsRNA (Koppe et al. 2012). PRRs 
are also capable of detecting danger-associated molecular patterns (DAMPs), which are 
host-derived products released upon cell injury or death – for example extracellular ATP 
or proteins usually only found in the cell cytoplasm (Newton & Dixit 2012).  
 
One of the largest families of membrane PRRs are the TLRs. It has been cited that TLR2, 
TLR4 and TLR9 are important for immune detection of S. pneumoniae, via detection of 
lipoproteins, pneumolysin and pneumococcal DNA respectively (Albiger et al. 2007; 
Malley et al. 2003; Tomlinson et al. 2014). These receptors signal via MyD88-dependent 
pathways to induce mature cytokine secretion (Takeda & Akira 2001; Marr et al. 2003). 
PRRs are also present in the intracellular environment, and include NOD-like Receptors 
(NLRs) and RIG-1-like Receptors (RLRs). NOD2 is a sensor of peptidoglycan muramyl 
peptide fragments from both Gram-positive and Gram-negative bacteria. It has been 
shown to be activated during S. pneumoniae infection and is also important for TLR2-
mediated clearance of bacteria (Davis et al. 2011). The pneumococcal toxin, 
pneumolysin, can activate the NLRP3 inflammasome, a multimolecular complex that 
promotes cleavage and activation of Caspase-1, to allow proteolytic cleavage and 
mature release of IL-1β; however the mechanism by which the toxin reaches the 
cytoplasmic environment is still unconfirmed (McNeela et al. 2010). That said, the 
pneumolysin toxin aids NOD1 activation in synergistic infections of epithelial cells, in 
association with bacteria such as Haemophilus influenzae, suggesting that pore 
generation could assist the transport of peptidoglycan fragments into the intracellular 
environment (Ratner et al. 2007). Finally, it is also suggested that S. pneumoniae DNA 
could be detected by intracellular DNA sensors, via stimulator of interferon genes 
(STING)-mediated pathways and receptors such as melanoma differentiation-associated 
protein 5 (MDA5), but this is yet to be validated (Koppe et al. 2012; Ishikawa & Barber 
2008). 
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Following interaction with bacterial stimuli, macrophages initiate signal transduction 
pathways to stimulate the production of cytokines, cause an acute-phase inflammatory 
response and recruit other cells, such as neutrophils, T-cells, innate lymphoid cells and 
dendritic cells, to the site. By doing this, it increases the number of immune cells to the 
area, to help clear the infection more efficiently. The cytokines released are typically 
pro-inflammatory and include IL-1β, IL-6, IL-8, IL-12 IFNα/β, TNF-α and IL-18, most of 
which are transcribed via NF-κB and/or IRF3 pathways (Opitz et al. 2010).  
 
1.3.3. Phagocytosis 
Following detection and binding of bacteria (or of another foreign particle) to the 
surface of the macrophage, receptors that recognise and bind the bacterium start to 
cluster at the site, binding to their cognate ligands on the bacterial surface. This prompts 
actin polymerisation and pseudopodial membrane extension, whereby the membrane 
gradually envelops the bacterium, fusing at the distal region – thus resulting in the 
formation of a bacterium-containing phagosome (Murphy et al. 2012). Crosstalk 
between GTPases, such as Dynamin-2, and actin are important for macrophage early 
phagosome formation, including the initial pseudopodial formation and later scission of 
the budding cavity from the cell membrane (Marie-Anaïs et al. 2016). Furthermore, 
Phosphatidlinositol 3-Kinase (PI3K) is required for the formation of pseudopodia, 
suggesting a role for PI3K in outer membrane insertion, to prepare for phagocytosis (Cox 
1999). Following phagosome formation, progressive acidification then occurs via fission 
and fusion with lysosomal compartments, like that seen for the endocytic pathway. 
Phagosomal maturation can be traced via compartment acidification and the loss or 
accumulation of markers typically found in early endosomes, late endosomes and 
lysosomes. For example, early endosome fusion accumulates the GTPase Rab5, early 
endosome antigen-1 (EEA1) and vacuolar ATPases; late endosome and lysosome fusion 
then see acquisition of Rab7, Rab9, lysosome-associated membrane proteins (LAMPs) 
and cathepsin D (Trimble & Coppolino 2005). The result is an acidified compartment of 
roughly pH 4.5-5.0 that contains antimicrobial factors, as discussed later. A brief 
overview of this phagocytic process is demonstrated in Figure 1.1. 
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Figure 1.1: An overview of phagocytosis 
In this diagram, phagocytosis is demonstrated in four simplified stages: (1) An opsonised 
bacterium is recognised via binding of antibodies to macrophage FcRs, with other ligands 
also binding their corresponding receptors, to induce receptor clustering, membrane 
extension and actin polymerisation; (2) the macrophage membrane engulfs the pathogen, 
before it encapsulates it in an intracellular phagosome; (3) the phagosome matures and 
eventually fuses with lysosomes, forming the phagolysosome; (4) the bacterium is degraded 
in the phagolysosome, by antimicrobial factors. After this, the microbial fragments are either 
processed and presented via Major Histocompatibility Complexes, or egested to the 
extracellular environment (not shown here) 
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In the case of S. pneumoniae, the polysaccharide capsule and other virulence factors 
impair bacterial binding and phagocytosis. Therefore other components of the immune 
system come into play here – specifically antibodies and the complement system. During 
pneumococcal challenge, antibodies bind to conserved and specific antigen epitopes on 
the bacterium, via the variable Fab immunoglobulin (Ig) region. This helps to promote 
opsonophagocytosis through binding of the antibody Fc region to Fc-receptors on 
phagocyte surfaces (Gordon et al. 2000). Antibodies are elicited to a range of 
pneumococcal structures during infection (Wilson et al. 2017), however, only capsular 
antibodies are currently implemented in licensed vaccines strategies (Bruyn 1992; 
Aliberti et al. 2014). Components of complement also opsonise and agglutinate bacteria, 
to promote efficient phagocytosis and bacterial clearance. The complement cascade can 
be activated via three main pathways: classical, alternative and lectin. The classical 
pathway, activated in part via IgM, is the most important pathway for innate recognition 
of S. pneumoniae (Brown et al. 2002). In its absence, mice are particularly susceptible to 
septicaemia following bacterial challenge. This pathway determines the proportion of 
bacteria binding C3 and is facilitated by binding of component C1q to conserved Fc 
regions of antigen-bound IgM or IgG (Brown et al. 2002). The classical pathway is also 
activated by C-reactive protein (CRP), in the absence of antibodies, as CRP can bind 
pneumococcal surfaces and activate complement independently (Kaplan & Volanakis 
1974; Mold et al. 2002). C1q activation can also be achieved through directly binding 
bacterial surfaces (Albertí et al. 1993; Brown et al. 2002), and by SIGN-R1, a C-type lectin, 
after interacting with pneumococcal polysaccharides (Kang et al. 2006). The lectin 
pathway shows similarity to the classical pathway, but with the use of mannose-binding 
lectins in the place of C1q activation (Murphy et al. 2012). During pneumococcal 
challenge, activation of the lectin pathway is driven by Ficolin A and Collectin-11 (Ali et 
al. 2012). Lastly, the alternative pathway has dual function, with roles in both bacterial 
recognition and in amplification of the classical and lectin pathways. The alternative 
pathway is a key determinant of the amount of C3 binding on pneumococci (Brown et 
al. 2002). It is constitutively active at low levels, via spontaneous hydrolysis of C3 (Noris 
& Remuzzi 2013), which allows C3b deposition on bacterial surfaces. Activation of the 
alternative pathway is important in opsonising pneumococcal surfaces with C3b, for 
effective uptake and bacterial clearance (Xu et al. 2001). S. pneumoniae activates all 
three complement activation pathways, which converge at C3b formation, to induce 
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opsonophagocytosis and inflammatory response activation through release of the 
chemotactic factor C5a (Andre et al. 2017). The polysaccharide capsule inhibits binding 
of IgG and CRP, limiting C3b/iC3b (a proteolytically inactive cleavage product of C3b) 
binding via the classical pathway, while also inhibiting alternative pathway amplification 
of C3b binding (Hyams et al. 2010). Pneumolysin, primarily through inhibition of the 
classical pathway but also through inhibition of the alternative pathway, and the surface 
protein PsPA, through both classical and alternative pathways, also inhibit complement 
deposition on the bacterial surface (Yuste et al. 2005). 
 
1.3.4. Antimicrobial killing mechanisms 
1.3.4.1. Phagolysosome acidification 
During maturation of the phagolysome, vacuolar ATPases are accumulated, which aid 
the acidification of this compartment to roughly pH 4.5-5.0, through pumping of H+ into 
the phagosome. H+ are also acquired through fusion of phagosomes with lysosomes, 
which contain a high concentration of these ions. Not only does this create an 
antagonistic environment for bacteria, reducing microbial growth and causing a loss of 
viability, but it also prompts activation of enzymes that aid bacterial degradation and 
work optimally at low pH, such as lysozyme (Ip et al. 2010). A number of pathogens, 
including species of Mycobacterium, Salmonella and Leishmania, have evolved 
mechanisms to hinder this phagosomal maturation and intracellular killing (Kinchen & 
Ravichandran 2008). 
 
1.3.4.2.Oxidative antimicrobial strategies 
Macrophage signalling receptors can activate a ‘respiratory burst’, which induces 
increased oxygen intake, along with the assembly and activation of nicotinamide 
adenine dinucleotide phosphate (NADPH)-dependent oxidase (NOX2) at the 
phagosomal membrane, to produce superoxide (O2-) (Slauch 2011). NOX2 is a heme-
binding protein consisting of multiple subunits, one of which forms a transmembrane 
channel, through which electrons are passed from NADPH to oxygen (Yang et al. 2011). 
O2- can also be converted to hydrogen peroxide, either spontaneously or via superoxide 
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dismutase. These reactive oxygen species (ROS) can act as bactericidal factors in the 
lysosome environment (Slauch 2011). Macrophage ROS production is much lower than 
that seen in neutrophils; therefore an alternative role for this burst could be to produce 
hydrogen peroxide as a secondary signalling messenger, for pathways such as MAPK, 
JNK and ERK (Iles & Forman 2002).  
Phagocytes are also capable of reactive nitrogen species (RNS) production, via the 
inducible nitric oxide synthase (iNOS, also referred to as NOS2), which is expressed 
during inflammatory activation of macrophages (Rath et al. 2014). iNOS is a homodimer, 
with each subunit comprised of a reductase domain, which transfers electrons from 
NADPH to flavin carriers. These electrons are then passed onto the haem of the 
oxygenase domain, which binds cofactor BH4 and the substrate L-arginine. The enzyme 
uses oxygen, L-arginine and electrons from NAPDH, to produce L-citrulline and Nitric 
Oxide (NO) (Förstermann & Sessa 2012). NO can also be generated via endothelial NOS 
(eNOS) in lung macrophages during pneumococcal infection (Yang et al. 2014). NO can 
combine with other ROS species to form highly oxidising compounds; for example 
peroxynitrite (ONOO-), which has been identified within the phagosome after NO 
reaction with O2- (Prolo et al. 2014). Both ROS and RNS are powerful oxidising agents, 
which attack bacterial structures and components such as DNA, lipids and proteins 
(Paiva & Bozza 2014). As pneumococci have been shown to resist peroxide killing, the 
efficacy of ROS-mediated killing has been questioned (Pericone & Park 2003), 
emphasising the potential importance of alternative strategies, such as those involving 
RNS. 
 
1.3.4.3. Non-oxidative antimicrobial strategies 
Aside from ROS and RNS production, the macrophage utilises peptides and proteins as 
antimicrobial factors. One of the most widely characterised enzymatic groups are the 
Cathepsins. These papain family proteases are produced as inactive zymogens, which 
are either auto-activated within the lysosome, as a result of the low pH, or through 
cleavage by other proteases (Weiss & Schaible 2015). There are more than 10 members 
in humans, all with varied functions in both innate and adaptive immunity, including 
pathogen killing, TLR signalling, antigen presentation and apoptosis (Conus & Simon 
2010). Cathepsins B, D, G and S have specifically been demonstrated to interact with 
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and aid microbial killing in a range of innate immune cells, including neutrophils, 
macrophages and dendritic cells (Bewley et al. 2011; Steinwede et al. 2012; Hole et al. 
2012). Further enzymes found in the lysosome include glycosylases, phospholipases and 
nucleases, and also the peptidoglycan degrading enzyme lysozyme (Weiss & Schaible 
2015). These mechanisms collectively kill and degrade the bacterium, allowing remnants 
to be secreted and/or presented on the cell surface via interaction with major 
histocompatibility proteins (MHCs). These proteins bind the bacterial antigens in the 
lysosome and are re-directed to the macrophage surface, where they activate naïve T-
cell and B-cell responses (Harding & Geuze 1992). Finally, the macrophage matrix 
metalloprotease protein MMP12 has also been shown to localise to murine 
phagolysosomes, and aids bacterial degradation through disruption of cell wall 
structures (Houghton et al. 2009). 
In addition to destructive enzymes, macrophages also contain a number of antimicrobial 
peptides, many of which can disrupt bacterial membrane formation and integrity, 
and/or inhibit other processes such as DNA and protein synthesis (Paustian 2013). The 
main antimicrobial peptides in macrophages are the cathlecidins and defensins. Only 
one cathlecidin gene is present in humans and mice, both of which are produced as pro-
forms that require cleavage, to give the active peptides LL-37 and CRAMP respectively 
(Gallo et al. 1997). Human cathlecidin LL-37 can induce elevated phagocytic clearance 
(Wan et al. 2014), aid intracellular killing of several Mycobacterium species (Sonawane 
et al. 2011) and is also thought to control LPS-induced responses to prevent endotoxic 
shock (Hancock & Diamond 2000). Similarly, defensins are also produced in a pro-
peptide form, requiring cleavage. α- and β-defensins were initially isolated from tissue 
secretions and are documented as a component of neutrophil granules; however 
expression of β-defensins does also occur in macrophages, and is shown to increase 
during stimulation with LPS (Duits et al. 2002). β-defensins have antimicrobial properties 
including to S. mutans, E. coli, P. gingivalis and C. albicans (De Smet & Contreras 2005), 
and they are suggested to act as a chemoattractant for macrophages (Soruri et al. 2007). 
Human β-defensins 2 and 3 are induced in epithelial cells by pneumococci (Scharf et al. 
2012), but less is known concerning their roles in macrophages. In addition to peptides, 
macrophages have also been noted to produce bioactive lipids, such as Leukotriene B4. 
This is a derivative of arachidonic acid lipid metabolism, which can trigger a number of 
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host responses, including phagocytosis, NOX2 activation and the release of lysosomal 
enzymes and peptides (Flamand et al. 2007). 
A further antimicrobial mechanism regards sequestering of key nutrients by the host, 
also referred to as nutritional immunity. An example of this is the import and export of 
metal ions. One of the most widely characterised channels belongs to the natural 
resistance associated membrane protein 1 (NRAMP1), which is thought to co-localise 
with LAMP1 in the late endosome (Cellier et al. 2007). NRAMP1 uses the proton gradient 
of the lysosome to pump out divalent iron and manganese cations, which are required 
for bacterial metabolism, hence limiting their intracellular viability (Flannagan et al. 
2015). In addition to this, the toxicity caused by transition metals is utilised by 
macrophages, as they are shown to increase their uptake and lysosomal accumulation 
of both copper and zinc ions during inflammatory activation (Stafford et al. 2013; White 
et al. 2009). It is thought that these metal ions compete with ions in bacterial structures 
and proteins, starving the bacteria of key resources; for example, elevated zinc has been 
shown to outcompete and starve S. pneumoniae of manganese, which is required for 
PsaA function (McDevitt et al. 2011). 
 
1.3.4.4. Apoptosis-associated killing 
After phagocytosis has occurred and the macrophage has attempted to eradicate the 
ingested S. pneumoniae, either all bacteria will have been cleared, or viable intracellular 
bacteria may remain in phagolysosomes. For this reason, Dockrell et al. have suggested 
that a high intracellular pneumococcal burden can induce macrophage apoptosis as a 
final resort to prevent further bacterial replication, dissemination and disease 
progression (Ali et al. 2003; Dockrell et al. 2003a). They propose this switch to be 
regulated by the anti-apoptotic mitochondrial protein Mcl-1, which is down-regulated 
at late infection time points (after 16 hours sustained phagocytosis), causing loss of 
inner mitochondrial transmembrane potential, (m), mitochondrial outer membrane 
permeabilisation, cytochrome c release and subsequent apoptosis (H. M. Marriott et al. 
2005). Bewley et al. further propose a role for the lysosomal protease, cathepsin D, in 
regulating this apoptotic response during pneumococcal infection, therefore forming a 
link between phagosome maturation and apoptotic killing (Bewley et al. 2011). Marriott 
et al have shown how this could be a mechanism preventing excessive inflammation 
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during pneumococcal infection in vivo (Dockrell et al. 2001; Marriott et al. 2006). 
Apoptosis-associated killing has also been shown during Mycobacterium tuberculosis 
infection, whereby apoptosis is activated either through TNFα-mediated pathways 
during low bacterial load, or through caspase-independent mechanisms following high 
intracellular burden (Lee et al. 2006). In this infection model, it is suggested that Mcl-1 
and cathepsins again have roles in regulating apoptosis to limit bacterial burden (Sly et 
al. 2003). A similar mechanism of programmed cell death for host defence is also 
thought to occur during Yersinia infection of macrophages, whereby the bacterial 
virulence factor, YopJ, induces apoptosis through activation of receptor-interacting 
protein kinase 1 (RIPK1) (Peterson et al. 2017). 
 
1.3.5. Macrophage polarisation 
Macrophages can adopt different phenotypic features, depending on the cytokine or 
external stimulus they are faced with. When exposed to IFNy or bacterial products such 
as LPS, macrophages develop a pro-inflammatory, activated phenotype - also referred 
to as an M1 phenotype or classically-activated macrophages (CAMs) - whereas in the 
presence of IL-4 or IL-13 they develop an anti-inflammatory phenotype - also referred 
to as an M2 phenotype or alternatively-activated macrophages (AAMs) (Mosser & 
Edwards 2008). These names were originally adopted as the M1 and M2 subsets are 
similar to the activation of Th1 and Th2 cells, with similar patterns of pro-inflammatory 
or anti-inflammatory cytokines, and similar functional roles (Mills 2012). CAMs and 
AAMs were formerly thought to have predominant roles in inflammation and wound 
healing respectively, however their roles are now understood to be more diverse and 
include functions in immune regulation, cancer and chronic diseases (Murray et al. 2014; 
Mosser & Edwards 2008). The two polar activation states are often distinguished 
through differences in transcription factors, such as increased STAT6 in CAMs and 
increased STAT1 in AAMs, cytokine release including TNFα in CAMs and IL-10 for AAMs, 
and also via differences in metabolic pathways, such as that seen specifically for arginine, 
as discussed later in this chapter (Murray et al. 2014). Despite these findings, 
macrophages are extremely plastic and the CAM/AAM phenotypes mostly resemble two 
extremes of a variable phenotypic spectrum, with subtypes of these two groups also 
blurring the categorisation of activated cells (Mosser & Edwards 2008). In August 2013, 
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researchers in this field called for urgent clarity and new nomenclature, regarding 
specific stimulations and more appropriate terminology surrounding CAM/AAM-like 
cells (Murray et al. 2014); that said, further verification and shared best practice is still 
on-going. In the respiratory environment, AMs are thought to be relatively quiescent 
when associated with the respiratory epithelium (Lambrecht 2006), however their 
distinct activation status can depend on the health and lifestyle of the individual, or the 
model system in question. For example, increased inflammation and modulation of AM 
activation has been shown in smoking individuals (Woodruff et al. 2005) and patients 
with lung diseases such as COPD (Barnes et al. 2003), whilst reduction in specific 
macrophage activation responses are seen following viral infection (Didierlaurent et al. 
2008). This therefore makes it difficult to predict the exact activation or polarisation 
status of AMs  in vivo in any given patient population, since there are diverse stimuli that 
can modulate macrophage activation in health and disease, and many variations in 
activation state with transcriptional profiling (Mosser & Edwards 2008). 
In this thesis, the interest lies predominantly with macrophages stimulated with LPS, as 
this type of activation is important for priming microbicidal responses and inducing a 
common host response, which closely resembles CAM activation (Benoit et al. 2008). It 
has been used as a reference for CAM and provides a suitable comparison for these 
studies, in view of the extensive literature on its effects on macrophages. It is likely, 
however, that specific changes could be pathogen-specific and therefore may not 
strictly replicate an LPS-induced CAM phenotype. This was shown to be the case by Nau 
et al. who used a DNA microarray to assess the activation status of cells, after 
stimulation with LPS, versus challenge with a range of individual bacterial determinants 
or whole bacteria (Nau et al. 2002). Here, a common host response was observed, 
including changes in expression for receptors and signalling pathways, but with unique 
differences seen between different bacterial stimulations, particularly regarding 
released cytokine profiles (Nau et al. 2002). Additionally, some features of AAM 
polarisation, as opposed to CAM polarisation, have been shown to occur during 
macrophage infection with certain bacteria, including C. burnetii (Marie Benoit et al. 
2008) and S. pyogenes (Goldmann et al. 2007). This therefore challenges the idea of a 
common macrophage response to bacteria and suggests that a greater understanding 
of specific host-pathogen interactions is required, with comparisons made to LPS and 
other well-characterised CAM stimuli.  
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1.4. Metabolism  
All life requires energy, and metabolism can be considered to encompass all chemical 
reactions that occur within a living system - be that a single prokaryotic cell or a complex 
eukaryotic organism. It encompasses a wide range of topics, from simple carbon 
pathways, such as those in bacteria, through to multicellular metabolic demands, for 
example as required in tumour growth and proliferation. Metabolic reactions can 
typically be classed into two groups: anabolic, describing the formation of cellular 
components that requires energy, such as DNA and proteins, and catabolic, describing 
the degradation of constituents, such as organic matter or carbohydrates which is often 
accompanied by the release of energy (Fromm & Hargrove 2012). This energy 
production comes in the form of the biologically universal energy carrier, adenosine 
triphosphate (ATP). Two of the major pathways that contribute to animal ATP 
production are glycolysis, located in the cellular cytoplasm, and the Krebs cycle (also 
known as the tricarboxylic acid cycle, or TCA), located in the mitochondria. See Figure 
1.2 for an overview of these two pathways, or Figure 1.3 for detailed pathways of 
glycolysis and the pentose phosphate pathway (PPP). 
The field of metabolism has become of increasing interest since Nobel Laureate Otto 
Warburg formed his hypothesis on the metabolism of cancer cells. In the 1920s, 
Warburg et al. noted an increased fermentation and conversion of glucose to lactate in 
tumour cells, as compared to healthy controls (Warburg et al. 1927). He postulated that 
tumour cells shift their energy production primarily towards fermentation - the splitting 
of glucose to lactic acid, also referred to as anaerobic glycolysis. It was unclear why 
anaerobic glycolysis would occur during plentiful oxygen supply, as complete oxidation 
of glucose through respiration yields far greater amounts of ATP, and would better 
provide for the large energy demand of proliferating or active cells. However, it is now 
thought that upregulation of glycolysis is much quicker than boosting mitochondrial 
respiration, as this simply requires induction of enzymatic pathways, as opposed to 
mitochondrial biogenesis – a much longer and more energy-intensive process. So, whilst 
boosting glycolysis may seem inefficient, ATP production can occur much faster. 
Furthermore, glycolysis also presents a benefit as it produces many biosynthetic 
precursors, supporting pathways such as amino acid and fatty acid synthesis, which are 
required for proliferating cells – although the latter aspect is more important for 
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proliferating cells, like cancer cells or replicating T-cells than macrophages, which usually 
do not proliferate (Heiden et al. 2009; O’Neill et al. 2016).  
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Figure 1.2: Glycolysis and Krebs Cycle metabolism 
An overview of glucose metabolism, from initial entry to oxidative phosphorylation. Glucose 
first enters the cell via a GLUT transporter protein (typically GLUT1). To commit the 
molecule to glycolysis and prevent efflux of the compound, glucose is first phosphorylated. 
It then undergoes several enzymatic reactions, which both cost and produce ATP, as shown. 
The product, pyruvate, can either be transported out of the cell in the form of lactate, or 
enter the Krebs cycle. An alternative route for Glucose-6-Phopsphate is to enter the Pentose 
Phosphate Pathway (PPP), which produces intermediates for nucleotide biosynthesis. The 
Krebs cycle is critical in forming reducing equivalents, such as NADH, which can be used for 
oxidative phosphorylation. It does this through processing carbohydrates, to release carbon 
dioxide and water. These intermediates can also feed into or from other metabolic and 
biosynthetic pathways (not shown). Oxidative phosphorylation is comprised of the electron 
transport chain, linked to an ATP Synthase (ATPase). Reducing equivalents donate their 
electrons, which are shuttled across the membrane, via Complexes I-IV, and used to pump 
hydrogen ions across the membrane. The ATPase, also referred to as Complex V, then uses 
this proton gradient to produce ATP, as the hydrogen ions travel back across the membrane 
through the pore. (FBP = Fructose-1,6-bisphosphate; PEP = Phosphoenolpyruvate; α-KG = 
α-ketoglutarate; IMS = Inter membrane space; IMM = Inner mitochondrial membrane) 
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Figure 1.3: Glycolysis and Pentose Phosphate Pathway (PPP) metabolism 
Details of the pathways for glycolysis (green) and the PPP (orange), highlighting enzymes, 
intermediates, and key interlinking regions in both. This demonstrates the interconnectivity 
of the pathways, and stages at which reducing equivalents are either used or produced, in 
the form of ATP, NADH or NAPDH. 
(ATP = adenosine triphosphate, PFK = phosphofructokinase, PFK2 = phosphofructokinase-2, 
G3P = glyceraldeyde-3-phosphate, NADH = nicotinamide adenine dinucleotide, NADPH = 
nicotinamide adenine dinucleotide phosphate, PEP = phosphoenolpyruvate) 
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1.4.1. The field of immunometabolism 
Since Warburg’s hypothesis, the role of metabolism in cancer has become evident and 
his work has prompted research into the importance of metabolic changes in other 
fields. For example, in 1981 Chandra noted that obesity damages immune responses, 
and this has since been associated with an increased migration of macrophages to 
adipose tissue, where a constitutively pro-inflammatory environment is produced 
(Chandra 1981; Mosser & Edwards 2008). This diverts immunological and metabolic 
resources from other parts of the body. Roles for metabolism have also been seen in 
chronic diseases such as arthritis and asthma, and in increased susceptibilities to other 
diseases including neurodegeneration and cancer (Mathis & Shoelson 2011). With this 
amplified interest in metabolism, a new research field has developed over the last 
decade: the field of immunometabolism. Immune cells must respond appropriately to 
foreign signals or stimuli, but it is now clear that they must also adapt their responses 
depending on the nutrients or metabolites available in their local and intracellular 
environments, and also use these changes in metabolism to prime functional responses 
(Schertzer & Steinberg 2014). 
 
1.4.1.1. Immunometabolic studies in innate immune cells 
In the same way cancer cells demonstrate a metabolic switch from oxidative 
phosphorylation (OXPHOS) to glycolysis, macrophages, dendritic cells, T-cells and other 
immune subsets also follow this pattern during immune activation. Proinflammatory 
activation can alter their cellular metabolism in favour of glycolysis (Krawczyk et al. 
2010; Newsholme et al. 1986; Tannahill & O’Neill 2011; Wahl et al. 2012). This could 
help prime cells for infection and classical activation by amplifying glycolytic ATP 
production and synthesis of biosynthetic precursors for amino acids and lipids, whilst 
promoting the production of cytokines (Donnelly & Finlay 2015; Vazquez et al. 2010). 
This switch may also be vital for cells in hypoxic conditions that need to respond to 
stimuli in limited oxygen availability, for example in abscesses or the lung environment 
during infection. Hypoxia has also been shown to extend monocyte and macrophage 
survival whilst enhancing glycolytic metabolism (Roiniotis et al. 2009). 
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1.4.1.2. LPS-induced metabolic changes of macrophages 
CAMs and AAMs display different metabolic phenotypes, and metabolism could be a 
leading factor in controlling the phenotypic switch. For example, Freemerman et al. and 
Haschemi et al. have shown that increasing glycolysis in macrophages can induce a pro-
inflammatory CAM state, whereas shutting off key glycolytic pathways will cause an anti-
inflammatory AAM state and increases to OXPHOS (Freemerman et al. 2014; Haschemi 
et al. 2012). Additionally, one of the most discernible differences between these 
phenotypes is the metabolism of arginine: following classical activation, cells utilise 
arginine to produce NO via iNOS, whereas AAMs use arginase to metabolise arginine to 
ornithine, which can then be used in pathways required for cell proliferation (Rath et al. 
2014). Much of the literature concerning M1-like metabolic changes has used LPS as a 
primary, bacteria-derived stimulus, therefore this switch has become relatively well 
characterised (O’Neill et al. 2016). In contrast, relatively little has been studied with live 
bacteria or other defined microbial components. 
After LPS stimulation of murine macrophages, glucose uptake and transcription of the 
GLUT1 transporter are rapidly upregulated to increase glycolytic and PPP flux (Fukuzumi 
et al. 1996). It has also been suggested that Hexokinase-II associates with mitochondrial 
ATPases, to directly obtain ATP for the phosphorylation of glucose; however, literature 
supporting this idea is currently only shown in dendritic cells, and it’s existence in 
macrophages is still to be proven (Everts et al. 2014; Shulga & Pastorino 2016). Other 
enzymes shown to be involved in this switch, following LPS stimulation of murine 
macrophages, includes: the sedoheptulose kinase CARKL, which is downregulated 
following LPS stimulation (Haschemi et al. 2012); the pyruvate kinase M2 isoform, which 
forms a dimer and associates with HIF1α to induce IL-1β and glycolytic enzyme 
transcription (Palsson-Mcdermott et al. 2015); the ubiquitous isoform of 6-
phosphofructokinase, PFKFB3, which maintains high levels of Fructose-2,6-
bisphosphate, an allosteric activator of glycolytic flux (Ruiz-García et al. 2011); and 
monocarboxylate transporter 4, which is considered as vital for exporting lactate from 
cells during increased glycolysis (Tan, Xie, Banerjee, et al. 2015). The enzyme 
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) has also been implicated in post-
transcriptional repression of TNFα mRNA, after LPS stimulation of THP-1 cells; this 
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interaction is not accessible during increases to glycolytic metabolism and G3PDH 
activity, allowing translation of TNFα to occur (Millet et al. 2016). 
Despite an increase in glycolysis there is no concomitant increase in the Krebs cycle to 
utilise the pyruvate generated; instead, the cycle breaks at two points, resulting in the 
accumulation of citrate and succinate (O’Neill et al. 2016). Citrate can then be used to 
supplement fatty acid synthesis, or be converted to aconitate, which feeds into itaconic 
acid production. Itaconic acid has been shown to have bactericidal activity by inhibiting 
the glyoxylate shunt – a pathway required for bacterial growth in bacteria expressing 
isocitrate lyase, such as M. tuberculosis and P. aeruginosa (Michelucci et al. 2013). 
Itaconic acid has also shown to inhibit succinate dehydrogenase, further amplifying the 
accumulation of succinate and inhibition of mitochondrial respiration (Lampropoulou et 
al. 2016). Citrate levels are also maintained through the aspartate-arginosuccinate shunt 
(AAAS), which combines the urea cycle and Krebs cycle, to increase nitric oxide 
production, required for antimicrobial activity (Mills & O’Neill 2016). The accumulation 
of succinate after LPS stimulation is important in stabilising the transcription factor 
HIF1α for glycolytic enzyme up-regulation and in increasing IL-1β release (Tannahill et 
al. 2013). It is also suggested to play an important role as an intracellular signal and in 
succinylation of metabolic enzymes, including lactate dehydrogenase and 
glyceraldehyde-3-phosphate dehydrogenase (Du et al. 2012; Tannahill et al. 2013). As 
Krebs cycle flux is arrested, concentrations of succinate are augmented through 
alternative pathways, such as the gamma-aminobutyric acid (GABA) shunt and 
glutamine-dependent anaplerosis (Tannahill et al. 2013; Jha et al. 2015). The oxidation 
of succinate has further been shown as important for driving the CAM phenotype and 
specifically in repurposing of mitochondria for ROS production (Mills et al. 2016). 
In parallel with increased glycolysis, LPS stimulation of macrophages induces an increase 
in the PPP – a source of NADPH and nucleotide precursors. In CAMs, NAPDH is required 
by NADPH oxidase to produce ROS, and to maintain cellular redox, which is considered 
to be important in regulating inflammatory cytokine release (Haschemi et al. 2012). 
Finally, mitochondrial respiration is also downregulated following LPS stimulation. It has 
been shown that mitochondria instead shift their function towards ROS production, and 
can localise to phagolysosomes, to help killing of internalised bacteria (West et al. 2011). 
Figure 1.4 summarises these metabolic changes, after LPS stimulation of macrophages.  
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Figure 1.4: Metabolic changes after LPS stimulation of macrophages 
Highlights of the metabolic changes to glycolysis, the PPP, Krebs cycle and oxidative 
phosphorylation during LPS stimulation of macrophages. Green indicates upregulation or 
an increase in metabolism/metabolites, whilst Red indicates a downregulation or decrease 
in metabolism/metabolites. The list in the bottom left corner indicates other changes 
caused by LPS stimulation (see results text for further details). 
(GLUT = Glucose Transporter; PFKFB3 = 6-Phosphofructo-2-kinase/fructose-2,6-
bisphosphatase isoform; PKM2 = Pyruvate Kinase M2 isoform; MCT4 = Monocarboxylate 
transporter 4; CARKL = Carbohydrate kinase-like (sedoheptulose kinase); SDH = Succinate 
Dehydrogenase; FBP = Fructose-1,6-bisphosphate; PEP = Phosphoenolpyruvate; AAAS = 
Aspartate-Arginosuccinate Shunt; α-KG = α-ketoglutarate; GABA = Gamma-aminobutyric 
acid shunt; IMS = Inner membrane space; IMM = Inner mitochondrial membrane) 
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1.4.1.3. Relevance of LPS-induced metabolism in infection studies 
At present, most of the literature on macrophage immunometabolism has focused on 
the use of LPS, a Gram-negative bacterial component, to induce a pro-inflammatory 
CAM status. Comparatively few studies have considered how this relates to the actual 
interplay between the host and whole, live pathogens of interest – particularly with 
regards to Gram-positive bacteria. Some studies considering the metabolic changes of 
host cells have instead focused on intracellular pathogens, such as S. enterica (Bowden 
et al. 2009) and M. tuberculosis (Shi et al. 2015). Eisenreich et al. have previously 
reviewed this field, in the context of limiting nutrient sources during intracellular 
infection of host cells: they highlight that pathogenic factors can interfere with host 
metabolism and antibacterial killing of phagolysosomes – this has been shown for 
factors SidK in L. pneumophila and PtpA in M. tubercuolosis both of which inhibit the 
host vacuolar ATPase to prevent phagosome acidification (Eisenreich et al. 2013). They 
also emphasise that cancer cell line models should be avoided, as these cells present an 
augmented metabolism compared to primary cell lines, with increased basal glycolysis 
and decreased basal OXPHOS (Eisenreich et al. 2013; Portnoy et al. 2016). That said, 
Lachmandas et al. recently compared human monocyte responses to LPS, versus 
stimulation with a TLR2 agonist or bacterial lysates from E. coli, S. aureus or M. 
tuberculosis (Lachmandas et al. 2016). Metabolic rates, enzyme gene expression and 
cytokine release were all compared following these stimulations, with the Gram positive 
bacterium S. aureus typically showing reduced responses compared to LPS. This 
provides an insight into the differences between singular TLR responses and more 
complex bacterial stimulation; that said, minimal details were provided by this 
publication regarding the preparation of bacterial components, therefore further 
evidence must be sought, and demonstrated in other immune cells types and for other 
bacterial species.  
 
1.4.2. Methods of studying metabolism 
Metabolism can be evaluated at a basic level using simple biochemical techniques: for 
example, the removal of metabolic substrates can be used to establish dependence, 
such as the removal of glucose or glutamine in a cell culture system, whilst gene 
knockouts for specific metabolic enzymes, transporters or transcription factors can be 
 51 
used to establish more specific roles in distinct metabolic pathways. That said, many 
genetic knock-out models suffer from redundancy, so can provide smaller, different 
effects than expected (Kafri et al. 2009). Other direct methods of tracing metabolism 
include measuring uptake, utilisation or production of specific substrates, with many 
commercial suppliers now providing kits for such assay set-ups (Sigma-Aldrich Co. LLC. 
2017; Promega UK 2017). A further method could be to assess changes in metabolic 
gene transcription or protein expression of metabolic enzymes, also referred to as the 
metabolic transcriptome and proteome respectively. For example, expression of the 
glucose transporter GLUT1 could be used to indicate changes in glycolytic status (Zhao 
et al. 2008).  
More complex methods of studying metabolism are now starting to emerge: much like 
other –omics strategies, metabolomics aims to consider global changes in biological 
systems, with a view to characterising all small molecule metabolites, also known as the 
metabolome. This is an important measure of the metabolic phenotype and is 
considered to be indicative of the total metabolic status - with integration of gene and 
protein expression, metabolite concentrations and enzyme activities, all contributing to 
these metabolomic measures (Nielsen 2003). The metabolome is the closest 
representation of the cellular phenotype and is a practical candidate for understanding 
the phenotypic differences observed between diseases. Two of the most widely used 
metabolomic techniques are Mass Spectrometry (MS) and Nuclear Magnetic Resonance 
(NMR) Spectroscopy. Both methods can be used for untargeted metabolomic 
assessment. However MS currently dominates the field, due to its higher sensitivity and 
tandem separation processes, using techniques such as gas or liquid chromatography 
(Dunn & Ellis 2005). NMR Spectroscopy has alternative benefits, as it is very reproducible 
and can aid identification of unknown compounds through structure elucidation 
(Markley et al. 2017). It is also beneficial in tracing isotope-labelled substrates through 
pathways, such as a glycolysis – which is a traditional method of tracing metabolic 
pathway flux (Di Gialleonardo et al. 2016). 
 
1.4.2.1. Seahorse Extracellular Flux Analysis 
To understand the role of metabolism in cellular function, research has increasingly 
shifted towards omics strategies: from genomics and transcriptomics, through to 
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proteomics and now metabolomics. However, each of these strategies are typically 
representative of a snapshot in time, and limited quantitative information can be given, 
with comparisons usually made between independent experimental conditions or 
subsets (Winter & Krömer 2013; Cascante & Marin 2008). Consequently, techniques 
have been developed to enable estimations of metabolism in real time, to study real 
time production and consumption of metabolites, otherwise known as metabolic flux or 
fluxomics.  
One of the simplest fluxomic technologies, introduced to bioscience research in 2006, is 
the Seahorse Extracellular Flux (XF) Analyser - now owned by Agilent Technologies. This 
technology measures changes in oxygen pressure and media acidity as readouts of 
metabolism. Oxygen pressure changes are referred to as the Oxygen Consumption Rate 
(OCR) and provide an indicator of mitochondrial respiration, whilst pH changes are 
referred to as Extracellular Acidification Rate (ECAR) and provide an indirect measure of 
glycolysis. The technique allows real-time and dynamic assessment of live cell cultures 
without the use of labelled substrates, by creating a small, transient micro-chamber 
between a patented-design cell culture microplate and a sensor cartridge. An example 
of this set-up is shown in Figure 1.4A. Cellular respiration and glycolysis cause 
measurable changes to the concentrations of oxygen and free protons in this micro-
chamber respectively, which can be measured by built-in fluorescent probes located in 
the sensor cartridge, also referred to as the ‘flux plate’. These probes are lowered to 
within 200m of the bottom of the well and are supported by small grooves in the cell 
microplate, to prevent crushing or damaging the cells. The micro-chamber holds a 
volume of approximately 7l.  
To analyse ECAR or OCR of a living system, the user programs the Seahorse Analyser to 
cycle through mixing, waiting and measuring processes. As previously described, the 
measuring is performed by lowering of the probes to create a micro-chamber. Whilst 
cells metabolise, an acidified and anaerobic media is produced within this restricted 
portion of the microplate. This media must then be mixed and re-equilibrated to restore 
the original baseline detection levels of oxygen and hydrogen, prior to subsequent cycles 
and measurements being taken. To do this, the machine pushes the flux plate 
continuously up and down for several minutes, encouraging mixing of the media. A wait 
period then follows, allowing passive equilibration and settling of the media, ready for 
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the next cycle to start. Mixing and waiting stages should prevent a hypoxic or acidic local 
environment from being artificially induced during the assay. In addition to the sensor 
probes, the flux plate contains four infection ports, which provide an integrated drug 
delivery system. These can be used to pneumatically inject compounds of interest, to 
observe their effects on cellular metabolism in real-time. Agilent also supply a range of 
kits, to test specific metabolic pathways, including the Mitochondrial (Mito) Stress Test 
and Glycolysis (Glyco) Stress Test kits, which allow defined and related ways of 
metabolically profiling cell cultures that measure respiration and glycolysis respectively 
(Romero et al. 2017; Agilent Technologies 2017b). The assay profile for the Glycolysis 
Stress Test is shown in Figure 1.4B, highlighting the metabolic quantification that can be 
calculated from this type of XF Analysis. 
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Figure 1.5: Mechanics of Seahorse XF analysis and metabolic profiling using the 
Glycolysis Stress Test 
A) The mechanics of Seahorse XF analysis, with a focus on the cell microplate and 
sensor cartridge. Cells are seeded into the bottom of the wells (yellow) and covered 
with unbuffered media. The two sensor probes are indicated (blue and red), for 
oxygen and hydrogen sensing respectively. Four injection ports are also attached to 
the sensor cartridge (only three shown here), allowing simple injection of 
compounds, to stimulate cells during the assay. 
(Image reprinted from Ferrick et al. (2008), Advances in measuring cellular 
bioenergetics using extracellular flux, Vol 13, Issue 5-6, Pages 268-274) 
Copyright (2018) with permission from Elsevier (Licence no. 4265340479632). 
B) The Glycolysis Stress Test assay profile, highlighting the three recommended 
injections for profiling glucose metabolism. Coloured areas also demonstrate 
quantifiable measures that can be calculated from this data (2-DG = 2-deoxyglucose) 
(Image reprinted from Glycolysis Stress Test User Manual, with permission of Agilent 
Technologies UK & Ireland) 
B 
A 
 55 
The Seahorse XF Analyser has been applied to a variety of research fields, including 
cancer, neurology, obesity, cardiovascular disease, immunology, and infection studies. 
The breadth of publications utilising this technique has since prompted Agilent to 
produce their own publication database, aiding ease of protocol and information sharing 
even further (Agilent Technologies 2017c). In the field of innate immune studies, the XF 
analyser has been used to consider the metabolism of dendritic cells (Everts et al. 2014), 
monocytes and macrophages (Haschemi et al. 2012; Tannahill et al. 2013). It has been 
shown that macrophages, including bone marrow-derived macrophages (BMDMs), 
increase glycolytic metabolism following stimulation with LPS and the conversion to a 
CAM phenotype, and this has been measured via Seahorse XF assessment (Haschemi et 
al. 2012; Tannahill et al. 2013; Tan, Xie, Banerjee, et al. 2015; Palsson-Mcdermott et al. 
2015). Within this literature, metabolic changes to LPS stimulation have been traced in 
real time (Everts et al. 2014; Haschemi et al. 2012), and after both short-term and 
prolonged exposure (Van den Bossche et al. 2015; Haschemi et al. 2012; Tannahill et al. 
2013). Significant increases in glycolysis are measured in all cases, providing 
reproducible methodologies and consistent results that can be taken forward when 
studying LPS-stimulated macrophage responses, as a control and a point of reference 
when examining the metabolic responses following pneumococcal stimulation of 
BMDMs. Furthermore, this point of reference is important since few studies have shown 
if these metabolic changes are the case during live bacterial infection or, more 
specifically, with infection by Gram-positive, extracellular bacteria such as S. 
pneumoniae. Instead, research has mainly focused on the burden of intracellular 
bacteria, such as S. typhimurium (Rosenberger et al. 2000) and L. monocytogenes (Cohen 
et al. 2000), and the use of other approaches such as transcriptomics and proteomics. 
Bacteria present a multitude of PAMPs and stimuli, to which macrophages must respond 
and the cellular responses could be very different to those seen for singular stimuli – for 
example the interaction of TLR4 with free LPS versus whole bacteria containing multiple 
PAMPS could result in very different downstream patterns of activation (Moore et al. 
2000). Therefore the Seahorse XF Analysis should provide valuable insight into both 
immediate and long-term changes in macrophage metabolism, specifically glycolysis 
and oxidative respiration, following stimulation with LPS versus S. pneumoniae. 
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1.4.2.2. NMR Spectroscopy 
NMR Spectroscopy is a technique typically used by chemical, biological and physical 
researchers to study the properties and arrangements of atoms, in different chemical 
states.  The technique utilises the idea that all atomic nuclei have their own magnetic 
properties and nuclear spin, and that they are capable of absorbing and reemitting 
electromagnetic radiation. This atomic phenomenon is known as NMR.  
Biological NMR Spectroscopy typically uses atoms that have a nuclear spin integer of ½, 
as these atoms are not only electrically charged, but can only be found in either one of 
two states: a high energy or low energy state. The most commonly used atoms in 
biological experiments are 1H and 13C - although other atoms with quadrupolar nuclei 
and spin integers of >½ can also be used, including 2H and 18O (Marion 2013). When held 
within an external magnet, the magnetised nuclei will either precess in the same 
direction as the magnetic field, the low energy +½ state, or in the opposite direction to 
the field, in the high energy –½ state (Thompson 1990). In a compound or mixture, not 
all nuclei will be in the same spin state, but by using a carefully administered dose of 
electromagnetic radiation, all nuclei can be excited from one energy state to another, 
and the radiation they emit as they return to a thermally equilibrated state can be 
recorded. These electromagnetic doses can also be clustered into a pulse sequence, and 
with more radiation being applied, a greater number of excited nuclei are observed - 
until the point of saturation (Bothwell & Griffin 2011). The emitted electromagnetic 
signals are recorded as free induction decays (FIDs) which can be mathematically 
converted into a frequency domain, using a Fourier Transformation. This then directly 
relates to the number of excited atoms in the sample (Bothwell & Griffin 2011). This 
alone would not be much use, as it would just appear as one large peak. However, 
electrons surrounding each nucleus reduce the magnetic field experienced by each 
atom. The electron shields are unique to not only the atom in question, but also its 
chemical environment and configuration in space. Therefore, a great amount of detail 
can be obtained about the locations and/or orientations of atoms in complex mixtures 
(Thomas 1998; Thompson 1990). Each atom will absorb a characteristic frequency, and 
the resonance emitted will shift depending on the chemical environment it is situated – 
this is referred to as δ (chemical shift) and it is represented on the x-axis of 1D spectra. 
The typical unit of measure on the x-axis is parts per million (ppm). This is the frequency 
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observed but normalised to the size of the applied magnet field and in relation to a 
reference standard, such as Trimethylsilyl propionate (TSP) or 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS). This allows comparisons to be made between spectra 
from different strength magnets and from different occasions (Bothwell & Griffin 2011). 
Information from the Fourier transform is displayed as a 1D spectral plot, with intensity 
on the y-axis and frequency (ppm) on the x-axis.  Figure 1.6 shows a flow diagram of the 
processes for producing a 1D-NMR spectrum.  
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Figure 1.6: NMR spectroscopy data acquisition – from electromagnetic radiation to 
a transformed 1D spectra 
A) Nuclei (represented by black dots) are excited to a high energy state and the 
electromagnetic (EM) emissions (represented by wavy lines) are recorded over time, 
as the nuclear energies relax back to an equilibrium state.  
B) The radiofrequency (RF) waves are summed, to give a free induction decay (FID) 
over time. FIDs provide information from four parameters: (1) intensity of signals; (2) 
frequencies observed; (3) half-life of signals; (4) signal phase. Each of these 
parameters can be optimised to provide stronger and better resolution spectra.    
C) A Fourier transform is used to mathematically convert the FID into a 1D spectra, 
demonstrating intensity on the y-axis and frequency (in ppm) on the x-axis. This 
removes the time domain from the presented spectra. 
(Image reprinted from Bothwell et al. (2011), An introduction to biological nuclear 
magnetic resonance spectroscopy, Vol 86, Pages 493-510) 
Copyright (2018) with permissions from John Wiley and Sons (Licence no. 
4390760891278) 
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NMR spectroscopy has applications in a wide range of fields, but the focus of this thesis 
is its use in metabolomics. Metabolomics is the study of all metabolites in a sample, with 
a view to assessing changes between different stimuli, genetic modifications, or 
experimental stresses. This provides an observation of the dynamic metabolic system, 
at a snapshot in time (Cascante & Marin 2008). Tracing the metabolome is thought to 
provide information on the phenotype of a living system, as metabolic changes depend 
on differences in the genome, proteome, exposome and all other factors and influences 
affecting the local environment (Fiehn 2002). Approaches in metabolomics have already 
been shown in testing of crops and food products, through to medical diagnostics and 
in the potential for personalised healthcare (Collino et al. 2013; Wishart 2008). MS and 
NMR Spectroscopy techniques have currently dominated interest, with both techniques 
providing individual benefits. Whilst NMR has a lower sensitivity than MS, NMR has high 
reproducibility, it allows for compound structure elucidation when finding unknown 
compounds, and typically requires much simpler sample preparation than MS (Dunn & 
Ellis 2005).  
To date, biologically relevant studies have focused on blood, tissue, and urine samples 
from patients to assess for metabolic markers of disease (Mamas et al. 2011). The use 
of metabolic biomarkers have been shown for a range of diseases, including cancer, 
diabetes, cardiovascular and neurodegenerative diseases (Emwas et al. 2013), however, 
it seems that comparatively few have focused on infectious diseases. For example, 
Weiner et al. have looked at the influence of M. tuberculosis infection on patient blood 
serum metabolites and have identified twenty metabolites which could help serve 
specific diagnosis of tuberculosis (Weiner et al. 2012), whilst Shin et al. have considered 
the changes to organ metabolomics in mouse models of tuberculosis (Shin et al. 2011). 
Interestingly, Slupsky et al. have used NMR Spectroscopy for considering changes in 
urinary metabolite profiles of patients with pneumococcal pneumonia, with 
comparisons made to profiles from patients infected with other pathogens, such as H. 
influenzae, or with other lung diseases, such as asthma (Slupsky et al. 2009; Slupsky 
2010). A study by Chiu et al. has shown that biomarkers of S. pneumoniae metabolism, 
such as 3-hydroxybutyrate, could be used to study the progression of infant pneumonia 
in pleural fluid samples (Chiu et al. 2016). Also, a broader study by Gupta et al. has 
distinguished Gram-positive from Gram-negative bacteria in urines of both healthy and 
individuals with urinary tract infections (UTI), which aims to help bacterial identification, 
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diagnosis and trajectory of recovery. These examples demonstrate the progression and 
ambition of this field, using a variety of sample types to understand the metabolic 
signatures of host-pathogen interactions. It shows the potential to identify specific 
pathogens responsible for UTIs, and consequently to avoid over prescription of 
antibiotics and tailor more precise patient treatments. 
Although clinical studies dominate in the field of NMR metabolomics, it has also been 
used to consider metabolic changes in vitro, using cell cultures. It is shown that different 
cell types exhibit characteristic and individual metabolic patterns (Urenjak et al. 1993). 
This could aid the identification and quantification of different cells types in 
heterogenous populations, such as those involved in 3D cell cultures or tissue models. 
In terms of macrophage metabolism, studies have utilised both whole cells (Ramm 
Sander et al. 2013) and cell extracts (Stuckey et al. 2005), to consider the role of lipid 
and non-lipid metabolites respectively. The sample type and preparation method can 
considerably influence the resulting spectra, regarding both the content detected and 
the signal-noise ratio, therefore identifying a suitable procedure can depend on the 
research question involved. For example, Lamour et al. considered the metabolic 
changes of the intracellular and extracellular environments of macrophages, both in the 
presence of CAM/AAM stimulation and during L. major infection (Lamour et al. 2012). 
Three different sample preparation methods were required - for the internal, external 
and isolated bacterial samples - and a longer acquisition time was required for the cell 
extracts, as they contained smaller concentrations compared to the extracellular culture 
environment. This was the first study of this kind, to consider metabolic changes of 
activated macrophages using NMR metabolomics. 1H-NMR spectroscopy should 
therefore provide a global overview of changes to metabolism, with the ability to 
identify highly reproducible metabolic signatures between different cell types and 
stimulatory conditions. 
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Aims and Hypotheses 
The aim of this project was to characterise the changes to metabolism, in macrophages 
exposed to S. pneumoniae, and to relate these to responses seen following macrophage 
stimulation with LPS. It was also to determine the functional consequences of these 
metabolic changes to key innate immune functions. This would help establish the 
importance of specific metabolic changes, to the host responses seen during the host-
pathogen interaction, and would reveal whether metabolism mediates changes 
associated with classical activation during the macrophage response to S. pneumoniae 
 
The project objectives were to: 
1) Optimise and use the Seahorse XF Analyser to assess changes in glycolytic 
metabolism, during S. pneumoniae infection, compared to LPS 
2) Optimise and use NMR Spectroscopy to evaluate global changes in 
metabolites, during S. pneumoniae infection, compared to LPS 
3) Measure changes in macrophage effector functions following inhibition of 
glycolytic metabolism during S. pneumoniae infection 
 
The hypotheses of this project were: 
1) S. pneumoniae challenge induces changes in metabolism that are comparable 
to those seen for LPS stimulation, such as a shift towards glycolytic metabolism. 
2) Macrophage effector functions during S. pneumoniae challenge are dependent 
on a glycolytic switch, as seen during LPS stimulation. 
  
 62 
  
 63 
Chapter 2 - Materials and Methods 
2.1. Materials and reagents 
Material Supplier Catalogue no. 
2',7'-dichlorodihydrofluorescein diacetate (DCF-
DA) 
ThermoFisher D399 
2-Deoxy-D-Glucose (2DG) Sigma D4601 
4-Amino-5-Methylamino-2',7'-Difluorofluorescein 
Diacetate (DAF-FM) 
ThermoFisher D23842 
Accutase cell detachment solution Merck Millipore SCR005 
BioWhittaker® Dulbecco’s Modified Eagle Medium 
(DMEM) 
Lonza BE12-604F 
BioWhittaker® Penicillin-Streptomycin stock Lonza 17-602E 
Blood Agar Plates (made in-house by technical team) 
Carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone (FCCP) 
Sigma C2920 
Clarity™ Western ECL substrate Bio-Rad 1705061 
Color Prestained Protein Ladder (Broad range) New England 
Biolabs 
P7711S 
DC Protein Assay Kit Bio-Rad 5000116 
Dehydroepiandrosterone (DHEA) Sigma (Cerilliant) D-063 
Fetal Bovine Serum, South America Origin 
(Heat-inactivation carried out in-house) 
Biosera FB-1001 
Gentamicin (Cidomycin) Sanofi (from NHS Pharmacy) 
HPLC-Grade Methanol Fisher Scientific A452-1 
IL-6 Mouse ELISA Kit ThermoFisher 88-7064-88 
L929-cell conditioned media (made in-house by technical team) 
Latex beads, fluorescent red Sigma L3030 
LPS (E. coli R515) Enzo Life Sciences ALX-581-007-
L001 
Oligomycin A (Oligo) Sigma 75351 
Oxoid Brain-Heart Infusion Broth ThermoScientific CM1135 
Paraformaldehyde Sigma P6148 
Penicillin Sigma P3032 
Phenol-free RPMI Sigma R7509 
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Phosphate Buffered Solution (PBS) Lonza BE17-517Q/12 
Pneumovax®23 Merck (from NHS Pharmacy) 
Polycloncal Goat Anti-mouse HRP antibody Dako P0447 
Purified Anti-α-Tubulin antibody, mouse 
monoclonal 
Sigma T6199 
Purified Mouse Anti-mouse COX-2 antibody BD Biosciences 610204 
Purified Mouse Anti-mouse iNOS antibody BD Biosciences 610432 
Recombinant Murine IL-4 PeproTech 216-16 
Saponin Sigma S7900 
Seahorse XF24 FluxPak Agilent 100850-001 
Sodium Iodoacetate (Iodo) Sigma I2512 
TNFα Mouse ELISA Kit ThermoFisher 88-7324-88 
Vectashield Mounting Medium VWR 101098-044 
 
2.2. Cell culture  
2.2.1. Murine bone marrow-derived macrophages (BMDMs) 
Wild type mice were killed by cervical dislocation and sprayed with disinfectant. The skin 
around the abdomen was cut and pulled down over the hind legs to expose the femurs 
and tibias. Bones were removed by cutting at the hip and ankle joints. Murine bone 
marrow cells were isolated by removing all tissue from the bones, cutting them at each 
end and flushing the bone marrow cells out using ~5ml Dulbecco’s Modified Eagle 
Medium (DMEM) with L-glutamine and 4.5g/L glucose, supplemented with 100U/ml 
Penicillin, 100µg/ml Streptomycin, 10% Heat-Inactivated Fetal Calf Serum (HIFCS) and 
10% L929 cell-conditioned media. Cells were plated at 2x105 cells/ml in T75 flasks or 24-
well plates, and incubated at 37°C with 5% CO2 for five days. After this time, non-
adherent cells were discarded and media changed every other day, with antibiotics 
removed from the media during the seven days preceding experimental use. For some 
experiments, coverslips were placed in 24-well plates prior to seeding, to allow adherent 
cells to be used for staining and microscopy.  All cells were cultured for at least 12-14 
days, to allow cells to differentiate and non-adherent, non-differentiated cells to be 
removed before use. 
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2.2.2. Human monocyte-derived macrophages (MDMs) 
Blood isolation was carried out at the Royal Hallamshire Hospital. 300ml blood was 
collected in blood bags from consenting donors by a trained member of staff. Blood bags 
contained the anticoagulant Citrate Phosphate Dextrose Adenine. All donors were given 
an information sheet and signed both a consent and a screening form. These are filed in 
the Infectious Diseases Department. Monocyte isolation from human blood was 
conducted by a member of the departmental technical team with ethical approval from 
South Sheffield Regional Ethics Committee (07-Q2305/7). Blood was decanted into 
T75ml tissue culture flasks and 25ml from each donor layered onto 12.5ml Ficoll-Paque 
in 50ml Falcon tubes. Blood was centrifuged at 1500 rpm for 23 minutes with no braking. 
Cell layers were isolated and added to clean 50ml tubes and centrifuged at 1000 rpm for 
13 minutes. Supernatants were discarded, and pellets resuspended in 10ml Roswell Park 
Memorial Institute (RPMI) media, with 10% heat-inactivated foetal bovine serum. 
Peripheral blood mononuclear cells were then counted using a haemocytometer and 
further diluted in media to 2x106cells/ml prior to plating out. 
 
2.2.3. Reseeding cells 
BMDMs were grown in T75 flasks for at least twelve days prior to re-seeding. Media was 
removed from flasks and washed with 5ml PBS. After completely removing the PBS, 5ml 
accutase cell detachment solution was added and incubated in 5% CO2 at 37°C for 15 
minutes. Following this time, cells normally detach from the flask and can be seen 
floating in suspension, but they can be encouraged to loosen with gentle pipetting if 
required. The cell suspension was centrifuged at 200g for 10 minutes, the supernatant 
was discarded and cells were resuspended in 5ml DMEM with 10% HIFCS and 10% L929 
cell-conditioned media. The cell concentration was measured using a haemocytometer, 
and cells were diluted to the desired density before plating into 24-well, 6-well or XF Cell 
Culture Microplates.  
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2.3. Bacterial culture 
2.3.1. S. pneumoniae 
S. pneumoniae serotype 2 strain D39 was obtained from Prof. Tim Mitchell (University 
of Birmingham). Long-term storage of bacteria was on Protect multi-purpose cryobeads 
(Technical Service Consultants, UK) stored at -80°C. The bacterial stock was prepared by 
streaking of a bead onto a blood agar plate and incubating at 37°C with 5% CO2 
overnight. The following day 50ml Brain-Heart Infusion Broth (BHI) with 20% HIFCS was 
prepared and separated into two 25ml universals. Ten bacterial colonies were selected 
from the blood agar plate and mixed into one of the universals, whilst the second tube 
acted as the blank. Universals were incubated at 37°C with 5% CO2 for 4-7 hours with 
shaking. After the first four hours, 1ml from each universal was pipetted into cuvettes 
for reading by photospectrometer. The Optical Density (OD) of the D39-containing broth 
was measured at 610nm, with the broth without bacteria used as a blank. Readings were 
taken every half an hour until an OD of 0.6 was reached, which is in S. pneumoniae log-
stage growth. Once the bacteria had grown to this density, the universals were removed 
from the incubator and 1ml aliquots of the bacteria were taken and stored at -80°C. 
When required, these aliquots were rapidly defrosted, spun and washed with PBS prior 
to use. 
 
2.3.2. Opsonisation with mouse immune serum 
For sufficient bacterial internalization of S. pneumoniae by murine BMDMs, bacteria 
were opsonized with mouse immune serum (mIS) containing antibodies against this 
bacterium. Balb/c mice were immunized with a combination of Pneumovax®23 
(23μg/mouse) and anti-CD40 monoclonal antibody (50μg/mouse). Mice were left for at 
least 4 weeks to mount an immune response. They were then bled, and serum pooled 
from multiple mice. The mIS was kept at -80°C in 25μl aliquots and defrosted 
immediately before use. 
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2.3.3. S. pneumoniae infection 
For live bacterial infections a 1ml D39 aliquot was rapidly thawed from -80°C, spun at 
9000rpm for 3 minutes and re-suspended in 1ml PBS. This was repeated twice, and the 
final pellet resuspended in 225μl DMEM with 25μl mIS. Bacteria were opsonized using 
this serum, by incubating at 37°C with shaking for 30 minutes. Once opsonized, bacteria 
were pelleted by centrifugation at 3400rpm for 3 minutes and washed in 1ml PBS. 
Bacteria were washed a further two times in PBS, and finally re-suspended in 990µl 
DMEM with 10% HIFCS. Cells in 24-well plates were washed twice with 1ml PBS prior to 
replacing with 0.5ml DMEM with 10% HIFCS in each well. Bacteria were added to give 
an estimated Multiplicity of Infection (MOI) of 10, while control cells were mock-
infected with equal volumes of media. Cells were then placed on ice for one hour, in 
order to increase adhesion of bacteria to macrophage surface membranes. After this 
initial hour, cells were then transferred to 37°C for three hours. At 4 hours, all wells were 
washed twice with PBS and, where indicated, extracellular bacteria were eradicated by 
treating with 1ml DMEM with 20ug/ml Gentamycin and 40U/ml Penicillin, and 
incubating at 37°C for 30 minutes. Cells were washed with PBS to remove residual 
antibiotics, and fresh media added before returning cells to 37°C until the desired time 
point. 
A Miles-Misra viable count (MM-VC) was used to assess the true concentration of 
bacteria, and to calculate the actual MOI after each infection procedure. For this, eight 
10-fold serial dilutions of the re-suspended bacteria were performed, by taking 100 µl 
of the solution and serially diluting in 900µl PBS. A blood agar plate was divided and 
labeled into eight segments, before three 10µl droplets of each dilution were plated 
onto separate areas of the plate. This was incubated overnight and counted the 
following day, to allow calculation of the bacterial aliquot concentration in cfu/ml. To 
heat-kill the bacteria, the 1ml D39 aliquot was heated to 70°C in a heat block for 40 
minutes, prior to washing and opsonizing as above, with the MM-VC used to confirm 
loss of bacterial viability. 
An R6 unencapsulated S. pneumoniae strain was also used, where stated in the results 
text. This strain was obtained from Dr. Andrew Fenton at the University of Sheffield. It 
did not require opsonisation but otherwise followed the same infection procedure as 
above. 
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2.3.4. Bacterial internalisation assay  
Cells were infected and assessed after several hours. At defined time points, eight 1:10 
serial dilutions of the cell culture media were made, to identify the number of viable 
bacteria in the extracellular environment. Three 10µl droplets of each dilution were 
plated onto separate areas of a blood agar plate and incubated at 37°C overnight. The 
media was then removed and cells washed three times with 1ml PBS, before adding 1ml 
DMEM with 20μg/ml Gentamycin and 40U/ml Penicillin, and incubating at 37°C for 30 
minutes to kill any remaining extracellular bacteria. After this time, media was removed, 
and cells washed three times with 2ml PBS, to remove all residual antibiotic. Two 1:5 
serial dilutions were made from the final PBS wash, after antibiotic treatment, to check 
that all extracellular bacteria had been killed. These were again plated onto agar plates 
as described previously. The final PBS wash was removed, and 250μl 2% saponin in PBS 
added to each well and incubated for a further 15 minutes (0.02% saponin in distilled 
water was also trialled). Following this, 750μl PBS was added to each well, and then 
scraped with a pipette tip and vigorously pipetted onto, in order to lyse the cells. Two 
final 1:5 serial dilutions were made, to assess numbers of bacteria seen within the 
intracellular environment. Once more, these were plated onto agar plates and left to 
incubate overnight. The following day, blood agar plates were counted for colonies and 
cfu calculations made for each of the cell environments and conditions. 
 
2.4. Metabolic assays 
2.4.1. Seahorse XF24 Extracellular Flux Analysis 
The day prior to each Seahorse assay, the XF24 Flux Assay Plate was prepared, by filling 
each well of the Utility plate with 1ml XF Calibrant and submerging the Sensor Cartridge 
into the solution. The Utility plate and submerged Sensor Cartridge were then left in a 
non-CO2 incubator at 37°C overnight. The XF24 Analyser was also turned on and left to 
equilibrate overnight. 
Cells were reseeded on the day prior to assay, using the details listed in section 2.2.2. 
and the cell seeding protocol advised by Seahorse Bioscience (Seahorse Bioscience Inc. 
2015a). Unless otherwise stated, the cell density used was 200,000 cells/well. 
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On the day of the assay, all assay media and compound injections were prepared, with 
a pH of 7.40±0.05 at 37°C. For the Glycolysis Stress Test, the medium was always 
supplemented with 2mM L-Glutamine. The microplate media was changed one hour 
prior to assay, with warm XF Assay Media (XFAM). Once again, the recommended 
protocol from Seahorse Bioscience was used (Seahorse Bioscience Inc. 2015b). For 
experiments stated in this report, final microplate media volume, prior to assay, was 
630μl. Injection ports were prepared with compounds at concentrations that were 10-
fold higher than the working concentration, allowing dilution to occur upon injection. 
E.g. 70μl of 100mM compound injected into 630μl, provides a diluted working 
concentration of 10mM. Guidelines for loading compounds into the Sensor Cartridge 
were given by Seahorse Bioscience (Seahorse Bioscience Inc. 2015c). Injection port 
volumes were made up to satisfy the following quantities, allowing appropriate 10-fold 
dilution: Port A 70μl, Port B 77μl, Port C 84μl, Port D 92μl. The Seahorse XF24 command 
protocol timings also varied during optimization stages. However, the final mix, wait, 
measure times used for 2x105 BMDMs/well were 3, 12, 3 minutes respectively. Assay 
results were also normalized, following protein extraction and quantification from all 
microplate wells. 
 
2.4.2. NMR Spectroscopy sample preparation 
BMDMs were reseeded into 6-well plates at 1x106cells/well (unless otherwise stated) 
on the day prior to use, and infected or treated as required. Whole cells, cell 
supernatants and cell extracts were prepared and analyzed using NMR Spectroscopy.  
Whole cell samples were prepared by washing the wells twice with 1ml PBS and scraping 
into a final volume of 460μl PBS containing 10% D2O. Tubes were kept on ice prior to 
NMR Spectrometry, and 5μl of 100mM TSP added to each sample before they were 
loaded into 5mm Shigemi NMR tubes. These tubes have a large susceptibility-matched 
solid glass bottom, which allow sample sedimentation within the sensitive volume of 
the NMR probe coil. This protocol was adapted from Ramm Sander et al (Ramm Sander 
et al. 2013). 
Supernatants were collected directly from the cell culture plate, spun at 2500rpm for 2 
minutes to remove cellular debris, and transferred to fresh tubes to be stored at -80°C 
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until analysis.  On the day of NMR Spectroscopy, 300μl supernatant sample was mixed 
with 300μl D2O Phosphate Buffer and 1μl 100mM Trimethylsilyl propionate (TSP). D2O 
Phosphate Buffer consisted of PBS made with 70% D2O, 30% H2O. 550μl of the sample 
was transferred to a 5mm NMR tube, and a hand-crank centrifuge used to push all 
samples into the lower portion of tube and to remove any air bubbles. In later 
experiments, TSP was added to the main D2O PBS stock to provide a concentration of 
100μM throughout all samples and reduce TSP concentration variability between 
sample preparations. 
To prepare cell extracts, cell culture media was removed and cells were washed with 
1ml/well room temperature PBS. PBS was removed and 1ml ice-cold High Performance 
Liquid Chromatography (HPLC)-grade methanol was added to quench cell metabolism 
and cells were lysed on ice for 5 minutes. Cells were scraped using a cell scraper, to 
further encourage lysing and to harvest intracellular contents. Suspension were 
transferred to clean eppendorf tubes and kept on ice. A further 460μl was used to rinse 
each well and added to the corresponding eppendorf kept on ice. Lysates were dried 
overnight at 45°C using an Eppendorf Concentrator 5301. Once dried, 80% methanol 
extractions were performed twice on the remaining pellets using the following steps: (i) 
resuspend dried lysate in 500μl HPLC-grade methanol and vortex for 30 seconds, (ii) add 
130μl distilled water and vortex again for 30 seconds, (iii) leave tubes on ice for 15 
minutes, (iv) centrifuge samples at 13000rpm for 10 minutes and transfer lysate 
supernatants to fresh eppendorfs kept on ice, (v) repeat methanol extraction stages i-iv 
on remaining pellet. After the two methanol extractions were pooled, they were dried 
again overnight at 45°C using the Eppendorf Concentrator 5301. The following morning, 
samples were transferred to -80°C until analysis. On the day of NMR Spectroscopy, dried 
extracts were resuspended in 600μl D2O Phosphate Buffer, as described for cell 
supernatants, with 1μl TSP. 550μl of the sample was transferred to a 5mm NMR tube 
and a hand-crank centrifuge used to push all samples to the lower portion of tube and 
to remove air bubbles. This protocol was adapted from Lamour et al (Lamour et al. 
2012). 
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2.4.3. NMR Spectroscopy sample acquisition 
Whole cells → Spectra were acquired with a Bruker 600MHz Avance DRX NMR 
spectrometer equipped with a TXI-cryoprobe, at 5°C. The pulse program ‘zgesgp’ was 
used, with 64 scans and processed with a line broadening of 1Hz. 
Cell Supernatants → Spectra were acquired on a Bruker 800MHz Avance I NMR 
spectrometer equipped with a TXI probe, at 25°C. The pulse program ‘ah_robust5.ptg’ 
was used, with 128 scans and processed with a line broadening of 1Hz. The pulse 
program script was written in house by University of Sheffield NMR Facility technician, 
Miss Andrea Hounslow. 
Cell Extracts→ Spectra were acquired with the same method as for supernatants, 
however the number of scans was increased to 512 to increase the signal:noise output. 
Following Fourier transformation, all spectra were phased and baseline-corrected 
manually in TopSpin (Bruker processing software).  
 
2.4.4. Metabolic inhibition 
Metabolic inhibitors were diluted into cell culture media, DMEM with 10% HIFCS. Cells 
were washed twice with 1ml PBS, and 500µl DMEM with 10% HIFCS plus inhibitor added 
to each well. To infect after inhibition, bacteria were added directly into this media at 
an MOI of 10. Adding an equal volume of DMEM with 10%HIFCS to corresponding wells 
stimulated mock-infection. Alternatively, inhibitors were added 4hr post-stimulation, 
after two 1ml PBS washes and in the same media and volumes as above. Concentrations 
of inhibitors used were in accordance with the literature (Haschemi et al. 2012; Tannahill 
et al. 2013), and were as follows: 100mM 2DG, 100μM Iodoacetate and 200μM DHEA. 
 
2.4.5. Measurement of ATP levels 
To measure ATP, the Perkin Elmer ATPlite luminescence assay system was used. Cells 
were reseeded into a 96-well plate at 20,000 cells/well (100μl of 200,000 cells/ml) and 
left to adhere overnight. Wells were washed twice with 100μl PBS and stimulated as 
desired. After 4 hours, wells were again washed twice with 100μl PBS and 100μl media 
returned to each well. After 10 hours, the ATPlite kit was removed from the fridge and 
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allowed to return to room temperature. At 12 hours, media was removed and wells 
washed twice with 100μl PBS. 50μl lysis buffer was added to all wells and the plate was 
shaken for 5 minutes. 50μl substrate solution was added and the plate shaken for a 
further 5 minutes. Finally, 100μl PBS was added and the plate was dark-adapted for 10 
minutes, before reading luminescence on a ThermoScientific VarioSkan plate reader. 
Control wells (containing no cells) provided the assay background. These values were 
subtracted from all conditions. 
 
2.4.6. Measurement of glucose uptake 
To measure glucose uptake, the Promega Glucose Uptake-Glo™ assay kit was used. Cells 
were reseeded into a 96-well plate at 20,000 cells/well (100μl of 200,000 cells/ml) and 
left to adhere overnight. Wells were washed twice with 100μl PBS and stimulated as 
desired. After 4 hours, wells were again washed twice with 100μl PBS and 100μl media 
returned to each well. After 10 hours, the Uptake-Glo™ assay kit was removed from the 
freezer and returned to room temperature. After 11 hours, the 2DG Detection Reagent 
and 2DG solutions were prepared and kept at room temperature. After 12 hours, media 
was removed and wells washed twice with 100μl PBS. 50μl 1mM 2DG solution was 
added to each well (apart from background controls, which were given an equal volume 
of PBS). The plate was shaken and left at room temperature for 10 minutes. 25μl Stop 
Buffer was added and plate shaken briefly, before 25μl Neutralisation Buffer was added 
and shaken briefly again. Finally, 100μl 2DG Detection Reagent was added to all wells, 
the plate was shaken and then dark-adapted for one hour. Luminescence was measured 
using the ThermoScientific VarioSkan plate reader. Control wells, without 2DG 
treatment, provided the assay background and were subtracted from all conditions. 
 
2.5. Functional assays 
2.5.1. Enzyme-linked Immunosorbent Assay (ELISA) 
ELISAs were performed using eBioscience Antibody ELISA kits, targeting mouse TNFα or 
mouse IL-6 following the manufacturer’s instructions. The day prior to assay, 44μl 
capture antibody was diluted in 11ml Coating Buffer, and 100μl of this loaded into wells 
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of a 96-well High-Binding ELISA plate. The plate was sealed and incubated overnight at 
4°C. On the morning of assay, the plate was first washed using the Bio-tek ELX-50 Plate 
Washer. Wash Buffer was made of 0.5M NaCl, 2.5mM NaH2PO4, 7.5mM Na2HPO4 and 
0.1% Tween-20 at pH 7.2. 200μl of Assay Diluent (AD) was added to all wells and left to 
incubate for 1 hour at room temperature, during which Antibody Standards were made, 
providing either 1000pg/ml TNFα or 500pg/ml IL-6. Up to eight serial dilutions of the 
standards were performed, to give standard curves of between 15-1000pg/ml for TNFα 
and 8-500pg/ml for IL-6. The plate was washed again, and 100μl standards and samples 
added in duplicate. The plate was sealed and incubated at room temperature for at least 
2 hours to allow binding. After a further wash, 44μl Detection Antibody was diluted in 
11ml AD, and 100μl of this solution loaded into each well, and left at room temperature 
for one hour. The plate was washed again, and Avidin-HRP Antibody added, in the same 
dilution and volumes as for the Detection Antibody. This was left to incubate for 30 
minutes. After a final plate wash, 100μl TMB Substrate Buffer was added and left for 15 
minutes, and 50μl/well of H2SO4 Stop Buffer added after this time to halt the reaction. 
The plate was then read for absorbance at 450nm, using a Thermoscientific MRX Plate 
Reader with Biolinx S. Cytokine quantification was carried out using standards and 
GraphPad Prism software. 
 
2.5.2. 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate (DAF-FM) staining 
DAF-FM Diacetate is a cell-permeable reagent used to quantify nitric oxide (NO). It is 
non-fluorescent until it becomes de-acetylated in the intracellular environment to give 
DAF-FM. This form is highly fluorescent once reacted with NO and can be measured by 
flow cytometry and other fluorescence readers. 
Cell culture media was discarded and cells washed twice with 1ml PBS. 5μM DAF-FM 
was added to phenol red-free RPMI, supplemented with 2mM L-Glutamine, with 500μl 
pipetted into each well and incubated at 37°C for 30 minutes. Unstained controls were 
incubated in phenol-free RPMI for this same duration. Cells were then washed twice in 
1ml PBS, and 500μl phenol red-free RPMI supplemented with 2mM L-glutamine only, 
was added to all wells before incubation for a further 30 minutes. This allowed time for 
the reaction and fluorescence to develop. Two more 1ml PBS washes were carried out, 
and finally cells were scraped in 300μl PBS, ready for assessment via flow cytometry. 
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Cells were separated by forward scatter and side scatter, with debris excluded and DAF-
FM measures taken in the FLH-1 channel. Geometric means of all conditions were 
recorded, and values for unstained controls subtracted from corresponding stained 
samples. 
 
2.5.3. 2’,7’–dichlorofluorescin diacetate (DCF-DA) staining 
DCF-DA is a cell-permeable reagent used to quantify Reactive Oxygen Species (ROS). It 
is non-fluorescent until it becomes be acetylated in the intracellular environment. This 
form is then highly fluorescent after reacting with ROS and can be measured by flow 
cytometry and other fluorescence readers. 
Cell culture media was discarded and cells washed twice with 1ml PBS. 20μM DCF-DA 
was added to phenol red-free RPMI supplemented with 2mM L-Glutamine, at 500ul per 
well. The plate was incubated for 45 minutes at 37°C. Unstained controls were incubated 
with an equal volume of phenol red-free RPMI with 2mM L-glutamine. Cells were then 
washed in duplicate with 1ml PBS, and scraped in 300ul PBS, ready for flow cytometry. 
Cells were separated by forward scatter and side scatter, with debris excluded and DCF-
DA measures taken in the FLH-1 channel. Geometric means of all conditions were 
recorded, and values for unstained controls subtracted from corresponding stained 
samples. 
 
2.5.4. Latex bead internalisation and calculations 
10μl aqueous red-fluorescent latex bead suspension was diluted into 990μl PBS, to 
provide ~5.7x109beads/ml. Beads were spun at 13,000rpm for 5 minutes, and the final 
pellet resuspended in 225μl DMEM with 25μl mIS. This was incubated with shaking at 
37°C for 30 minutes. During this time, cells on coverslips were washed twice with 1ml 
PBS and 500μl assay media was added. Beads were then spun at 3400rpm for 3 minutes 
and washed twice in 1ml PBS. Opsonised beads were left in 1ml PBS and added to cell 
culture media in a volume that provided ~10 beads per cell. The cell culture plate was 
kept on ice for one hour, then transferred to incubator at 37°C. After a total of 4 hours, 
cells were washed, mounted and counted as stated in section 2.5.6. From each coverslip, 
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the following variables were counted: Total macrophages, total beads, and number of 
macrophages with beads. From these measures, the following calculations were made: 
Calculation Name Calculation Method 
Phagocytic Index  Total beads / Total macrophages 
% Phagocytosis (Number of macrophages with beads / Total macs)*100 
Average Bead Uptake Total beads / Number of macrophages with beads 
 
2.5.6. DAPI staining and microscopy 
Cells cultured on coverslips were fixed, stained, and mounted for microscopy. Media 
was removed and wells washed three times with 1ml PBS. 0.5ml of 2% 
Paraformaldehyde (BDH Ltd.) was added and left at 4°C overnight. The following 
morning, Paraformaldehyde was removed, coverslips washed three times in 1ml PBS, 
then left in 0.5ml PBS ready for mounting, to prevent cells drying out and aid removal 
of coverslip from the well. The DAPI staining reagent used was VECTASHIELD® Mounting 
Medium with DAPI (Vector Laboratories Inc.). Two small drops of this were placed on a 
labeled microscope slide. Coverslips were maneuvered out of wells using a hooked 
needle and tweezers, gently blotted to remove excess PBS, and inverted into the 
VECTASHIELD® solution (i.e. cells in contact with the stain). After mounting, slides were 
blotted to remove excess solution, before being fixed in position using nail varnish 
around the outer edges. The reagent remains liquid during microscopy; therefore 
coverslips must be securely fixed in place. Microscopy was carried out immediately, 
using a Leica DMRB Type 301-371.010 fluorescent microscope, under blue light and 40-
100x magnification, with oil immersion. At least three hundred cells were counted from 
each coverslip. 
 
2.5.7. Protein extraction and quantification 
Cells were lysed at room temperature, and protein was extracted using a trichloroacetic 
acid (TCA) method. Cells were first washed with 1ml PBS three times, then 600μl TBS-
EDTA-SDS lysis buffer (2% 1M Tris pH 7.4, 6% 1M NaCl, 1% 0.5M EDTA, 1% 0.5M EGTA, 
2% SDS (20%) H2O) with complete protease inhibitor added, at a ratio of 1:25, 
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immediately prior to use. DNA was aggregated and protein precipitated using 100% TCA. 
The protein pellet was obtained by centrifugation at 13,000rpm for 5 minutes. This was 
washed in 1ml 2.5% TCA before being dissolved in 40μl 3M Tris base, which was diluted 
to 1.5M Tris base with water after an hour solubilisation at room temperature. Protein 
samples were stored at -20°C. 
Protein was quantified using a colorimetric DC Protein Assay Kit. BSA protein standards 
were dissolved in lysis buffer to a concentration range of 0.5-10mg/ml, allowing the 
construction of a standard curve. 5μl of samples and protein standard were added to a 
96-well plate, with 25μl Reagent A’ (made using 20μl Reagent S in 1ml Reagent A). 200μl 
Reagent B was then added, the plate was shaken and left to incubate at room 
temperature for 15 minutes. Absorbance was measured at 750nm and protein 
concentrations calculated from interpolation of the standard curve, using GraphPad 
Prism. 
 
2.5.8. Western blotting 
Proteins were first separated via sodium dodecyl sulphate polyacrylamide gel 
electrophoresis. Protein samples were denatured by adding equal amounts of protein 
and Lammeli buffer (4% SDS, 20% Glycerol, 0.004% Bromophenol Blue, 10% 2-
mercaptoethanol, 0.125M Tris Hcl), and boiling at 95°C for 5 minutes. Proteins were 
then loaded into lanes of a 1.5mm thick 10% polyacrylamide gel (see Table 2.1) in 
running buffer (0.025M Tris-base, 0.19M glycine, 0.1% SDS). An electrical current of 
100V was applied when passing proteins through the stacking gel, which was increased 
to 140V for passing through the resolving gel. The molecular weight of proteins was 
determined by the addition of 5μl Color Prestained Protein ladder (Broad range, 11-
245kDa). Once the gel had completely run, the resolving gel was cut from the stacking 
gel, and discarded. The resolving gel was placed on top of a nitrocellulose paper 
membrane, with filter paper either side, soaked in transfer buffer (0.047M Tris-base, 
0.038M glycine, 0.04% SDS, 10% methanol, H2O). The sandwiched gel was then 
transferred using the semi-dry Trans-Blot SD transfer cell (Bio-Rad), with an electric 
current of 15V for 45 minutes. 
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After transfer, the nitrocellulose membrane was washed in water and transfer of protein 
was confirmed by Poncheau S staining. The membrane was incubated in Poncheau S for 
2 minutes, and could be removed by washing in TBS (0.1M Tris-HCl, 0.16M NaCl, H2O) 
with agitation. The membrane was then blocked for 1 hour in blocking buffer (TBS with 
5% skimmed milk powder). Membranes were incubated over night at 4°C overnight, in 
TBS-Tween (TBS with 0.05% Tween-20) containing 5% skimmed milk powder and a 
1:1000 dilution of the primary antibody. Primary antibodies used included murine iNOS, 
COX-2 and α-tubulin. After primary incubation, the membrane was washed three times 
in TBS-Tween, each for 10 minutes. Horse radish peroxidase-conjugated polyclonal goat 
anti-mouse antibody was diluted 1:2500 in TBS-Tween with 5% skimmed milk powder, 
and the membrane was incubated in this for 1 hour at room temp. The membrane was 
washed a further three times in TBS-Tween and incubated with Bio-Rad Clarity™ ECL 
substrate for 5 minutes at room temperature. The membrane was then sealed in clear 
film and analysed using the ChemiDoc™ XRS+ System (BioRad). The membrane could 
then be stripped with 0.2M NaCl and water, to be re-probed with α –tubulin as the 
loading control, which was also diluted at 1:1000 in TBS-Tween in 5% skimmed milk 
powder. 
Table 2.1. Ingredients of resolving and stacking gels 
 Resolving Gel (μl) Stacking Gel (μl) 
H2O 7200 3000 
40% Acrylamide 29-1 3800 620 
1.5M Tris, pH 8.8 3800 - 
0.5M Tris, pH 0.8 - 1260 
20% SDS 75 25 
20% Ammonium persulphate 150 50 
T-Med 6 5 
 
2.6. Statistics 
All statistical analyses were performed using GraphPad Prism v.7, with data represented 
as mean ± standard deviation, unless otherwise stated. For comparison between 
multiple groups, a One-Way ANOVA test was used. For multiple comparisons to the 
 78 
mock/unstimulated group, Dunnett’s multiple comparisons were used, and for 
comparisons between all groups, Tukey’s multiple comparisons were used. 
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Chapter 3 – The optimisation and use of Seahorse XF Analysis to study 
BMDM glycolytic responses after S. pneumoniae challenge 
3.1. Introduction 
Immunometabolism is an emerging field that aims to reveal the importance of 
metabolism in immune responses. As described previously, macrophages have been 
shown to shift towards CAM metabolism following stimulation with LPS, with up-
regulated glycolysis and a repressed Krebs cycle both noted as key changes (Tannahill et 
al. 2013; O’Neill et al. 2016). With increased interest in this field, new techniques and 
methods of studying metabolism have emerged – one such technique is the Seahorse 
XF Analyser. The Analyser assesses real-time changes to glycolysis and respiratory 
metabolism in cell cultures, through measuring hydrogen ion and oxygen availability in 
the extracellular environment. These measures are herein referred to as ECAR and OCR 
respectively. This technique provided an ideal candidate for assessing central metabolic 
changes during macrophage stimulation. Therefore, by using the Seahorse XF Analyser 
and the Glycolysis Stress Test, S. pneumoniae-induced changes to macrophage 
metabolism could be assayed, with comparisons made to CAM and AAM metabolic 
changes, as promoted using the singular stimuli, LPS and IL-4, respectively.  
This chapter describes optimisation of the Seahorse XF Analyser, specifically for use with 
murine BMDMs. This includes finding appropriate cell densities, inhibitor concentrations 
and protocol timings to gain robust results. Optimisation was further required when 
considering specific use of the Glycolysis Stress Test, as media composition varied 
between recommended kits and profiling assays. This optimised technique was then 
used to test the effect of S. pneumoniae challenge on BMDM glycolytic metabolism, 
compared to LPS stimulation. The application of this technique was also demonstrated 
for human cells. 
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3.2. Results 
3.2.1. Seahorse XF Optimisation: Cell Density and Command Protocol 
Firstly, an appropriate cell density and timings for mixing, waiting and measuring were 
identified. Figure 3.1 and 3.2 show a representative experiment for simultaneous testing 
of both these factors, with ECAR and OCR responses and changes to oxygen pressure 
shown respectively. Changes to pH are not shown, as fluctuations were negligible. 
BMDMs were seeded in the microplate at the indicated densities, 24 hours prior to XF 
assay. DMEM was substituted for un-supplemented XF assay media (XFAM) one hour 
prior to assay. XFAM is similar to DMEM, however it is non-buffered, to allow accurate 
assessment of pH changes, as required for measuring ECAR. It also lacks sodium 
bicarbonate, glucose, glutamine and sodium pyruvate, allowing users to customise 
XFAM for individual experiments. It is recommended that serum not be added to XFAM, 
unless required to maintain cell viability or phenotype, as it alters XFAM buffer capacity 
(Agilent Technologies 2017a). Upon visual inspection, 300,000 cells/well were most 
confluent, therefore changes to the protocol timings were designed to restore oxygen 
pressure after each cycle, to the baseline seen for this density. A confluent cell 
monolayer was required to measure steady state metabolism, as cell aggregates cause 
false readings and are likely to detach during assays. It was important that the density 
chosen also provided a large and detectable output – raw data measurements for basal 
ECAR were within 2-10mpH/min and were over 100pmol/min for OCR. After measuring, 
baseline ECAR/OCR were restored by mixing and waiting, to avoid acidic or hypoxic 
conditions being formed within the microchamber. Changes to protocol timings were 
made after the injection point, indicated by the black vertical line in Figures 3.1 and 3.2. 
Equilibration of oxygen pressure was achieved, as shown for the final reading in Figure 
3.2B, by an increase in wait time, from 2 to 12 minutes. Table 3.1 lists the changes made 
to the command protocol timings, during the representative assay shown for Figure 3.1 
and 3.2. Amendments were also made to mix timings, however this did not effectively 
improve equilibration of oxygen pressure. The results also suggest that 500,000 
cells/well metabolised too rapidly in this system, and that timings would need to be 
considerably increased to re-equilibrate the baseline oxygen pressure in the media. 
Therefore, to prevent long run times and maintain low costs, the cell densities of 
200,000 and 300,000 cells/well were deemed more suitable.  
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Figure 3.1: Seahorse optimisation - Cell density and command protocol (1) 
A representative OCR (A) and ECAR (B) plot during optimisation of cell density and command 
protocol timings. BMDMs were cultured for 14 days prior to reseeding into the XF 
microplate at the different cell densities indicated. XFAM was injected during the assay, 
either with or without glucose (GLU, 10mM). This experiment aimed to identify the optimal 
cell number for measurements, with the opportunity to find suitable timings for BMDM 
assays. Data represents mean of 3-4 experimental repeats ±SD. Representative of n=3. 
A 
+/- GLU 
B 
+/- GLU 
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Figure 3.2: Seahorse optimisation - Cell density and command protocol (2) 
Representative oxygen pressure changes, during optimisation of cell density and command 
protocol timings. BMDMs were cultured for 14 days prior to reseeding into the XF microplate at 
three cell densities: (A) 200,000 cells/well; (B), 300,000 cells/well; (C) 500,000 cells/well. XF 
media was injected during the assay, with or without glucose (GLU, 10mM). The experiment 
aimed to identify which cell number would give optimal outputs, and to provide an opportunity 
to find suitable timings for a BMDM assay. Changes to protocol timings aimed to restore oxygen 
pressure to the original baseline for 300,000BMDMs/well stimulated with glucose, compared to 
unstimulated cells. This was achieved by the final cycle, as seen in (B). Coloured circles indicate 
measuring points and coloured lines indicate the mixing and waiting periods. The bold black line 
indicates atmospheric oxygen pressure within the XF analyser. Data represent mean summary 
of 3-4 experimental replicates. Representative of n=3.  
 
A 
+/- GLU 
B 
+/- GLU 
C 
+/- GLU 
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Cycle 
(post-injection) 
Mix 
(min) 
Wait 
(min) 
Measure 
(min) 
1 3 6 3 
2 3 6 3 
3 4 8 3 
4 4 10 3 
5 3 12 3 
6 3 12 3 
Table 3.1: Seahorse optimisation – Command protocol timings 
An example of the changes made to the command protocol timings during optimisation 
stages. These timings are taken from the representative data plots shown in Figures 3.1 and 
3.2. Protocol timings are shown for the six cycles following the glucose injection. (min = 
minutes). Representative of n=1.  
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One final test was conducted, to confirm the suitability of 200,000 cells/well and the 
timings stated in Table 3.1. This time, however, XFAM contained 25mM D-glucose in 
solution, as opposed to the 10mM injection. This higher concentration of glucose was 
used to culture BMDMs from initial harvest through to experimental use, therefore it 
was considered a more suitable concentration than the Agilent recommendation of 
10mM. The result is shown in Figure 3.3. The assay verified that 200,000 cells/well was 
enough to provide a measurable reading for both ECAR and OCR. The assay also 
highlighted a slight increase and possible artefact in ECAR, following glucose injection 
into glucose-containing XFAM. This could be due to a variation in pH or temperature in 
the injection port, or alternatively a small increase in glycolysis after addition of more 
glucose. To eliminate potential changes to pH after injection, all compounds were 
injected into blank wells and used for background correction in subsequent assays.  
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Figure 3.3: Seahorse optimisation - Protocol confirmation 
BMDMs were cultured for 14 days and reseeded at either 200,000 or 300,000 cells/well, 
with metabolic responses to a single glucose stimulus assessed using the XF Analyser. A 
representative OCR plot (A), ECAR plot (B) and oxygen pressure changes (C) are shown. XF 
media contained 25mM D-Glucose and the vertical line on all graphs indicates the glucose 
injection (GLU, 25mM). Data in (A) and (B) represent mean ±SD of up to ten experimental 
replicates. Data in (C) represent measuring points (coloured circles), linked by mixing and 
waiting times (coloured lines). Representative of n=1 
A 
+/- GLU 
B 
+/- GLU 
C 
+/- GLU 
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3.2.2. Seahorse XF Optimisation: Inhibitor Concentrations 
Prior to using the XF Analyser with BMDMs, suitable concentrations were identified for 
inhibitors used in the XF assay kits. Inhibitors were tested at a range of concentrations, 
to achieve a maximal change in metabolic output, with the explicit ECAR and OCR 
changes for each inhibitor noted. The Glycolysis Stress Test recommends sequential 
injection of glucose, followed by Oligomycin A (Oligo) and then 2-Deoxyglucose (2DG). 
The first injection is a concentration of glucose, which saturates the cells, prompting 
them to utilise glucose and begin glycolysis at a basal metabolic rate. Oligo is an ATP 
Synthase inhibitor that prevents mitochondrial ATP production, causing a backlog stress 
on the electron transport chain, and shifting energy production from respiration to 
glycolysis. The inhibitor therefore causes a maximal increase in glycolysis, to indicate the 
glycolytic capacity of the cells. This inhibitor is also used in the Mito Stress Test to cause 
maximal inhibition of respiration. Lastly, 2DG is an analogue of glucose, which enters 
cells and competitively inhibits both Hexokinase and Phosphoglucose Isomerase, the 
first two enzymes of glycolysis. This halts glycolytic activity, allowing indication of non-
glycolytic acidifications. By using this combination of inhibitors, the assay measures 
glycolytic activity under stress, allowing basal glycolysis, glycolytic capacity, the 
glycolytic reserve, and non-glycolytic acidification of cells to be calculated from ECAR 
results  - as previously shown in Figure 1.5. 
To identify a suitable concentration of Oligo, for use with 200,000 cells/well and the 
corresponding protocol timings, concentrations ranging between 0.5-2.5μM were 
tested, as shown in Figure 3.4. XFAM was supplemented with 25mM D-Glucose, to 
reduce the running time of the Analyser whilst mimicking the glucose-containing 
environment into which Oligo would be injected. Results were not normalised to cell 
number or protein content during these inhibitor optimisation assays, which could 
indicate why error bars remain quite large for the ‘Oligo NIL’ group. Here, the most 
appropriate inhibitor concentration was selected after repeat assays and by identifying 
the lowest concentration to induce the greatest increase in ECAR – also associated with 
a reciprocally large decrease in OCR. A working concentration of 1μM was chosen, which 
correlated with concentrations previously seen for similar cells in the literature and also 
recommended by Agilent Technologies (Covarrubias et al. 2016; Seahorse Bioscience & 
Agilent Technologies 2016)  
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Figure 3.4: Seahorse optimisation – Oligomycin A (Oligo) concentration 
A representative OCR plot (A) and representative ECAR plot (B) of BMDMs, following 
injection with Oligo concentration range of 0.5-2.5μM. BMDMs were grown for 14 days 
prior to reseeding for XF Analysis, at 2x105cells/well. Assessment of ECAR and OCR 
responses of BMDMs, at a range of concentrations, helped to identify the optimal Oligo 
concentration. The ideal concentration should induce the greatest increase in ECAR, 
associated with a major decrease in OCR. Assay media used was XF DMEM supplemented 
with 25mM D-Glucose. The optimal, lowest Oligo concentration was 1.0μM. Data represent 
mean ±SD for 3-4 experimental replicates. Representative of n=3 
A 
Oligo 
B 
Oligo 
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To identify a suitable concentration of 2DG, concentrations ranging between 50-200mM 
were tested, as shown in Figure 3.5. XFAM was supplemented with 25mM D-Glucose, 
and the 2DG injection preceded by an Oligo injection - as would be the case during a 
Glycolysis Stress Test. Once again, the results here were not normalised to protein 
content and the optimal concentration was chosen by inspecting the data after repeat 
experiments, to identify the lowest concentration to produce the largest decrease in 
ECAR. The chosen working concentration for 2DG was 100mM. Seahorse specialists and 
colleagues, who had previously used the XF Analyser to study immune cells, also 
recommended this concentration at the time, and it had been used at this concentration 
in the literature (Na et al. 2015). However, Agilent have since recommended 50mM 
working concentration for 2DG rather than 100mM (Seahorse Bioscience Inc. 2012; 
Seahorse Bioscience & Agilent Technologies 2016). 
The optimal conditions for XF Analysis of BMDMs are listed in Table 3.2. 
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Figure 3.5: Seahorse optimisation – 2-Deoxyglucose (2DG) concentration 
A representative OCR plot (A) and representative ECAR plot (B) of BMDMs, following 
injection with 2DG concentration range of 50-200mM. BMDMs were grown for 14 days prior 
to reseeding for XF analysis, at 2x105cells/well. The ideal concentration would dramatically 
reduce ECAR after Oligo stimulation (1μM). Assay media was supplemented with 25mM D-
Glucose. The optimal, lowest 2DG concentration was identified as 100mM. Data represent 
mean ±SD for 3-4 experimental replicates. Representative of n=3 
 
A 
Oligo 2DG 
B 
Oligo 2DG 
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 Glycolysis Stress Test Mito Stress Test 
Inhibitors: 
(Working concentrations - must 
be made up 10-fold higher for 
injection ports): 
*Glucose (25mM) 
Oligomycin (1μM) 
2DG (100mM) 
Oligomycin (1μM) 
FCCP (2μM) 
Rotenone (1μM) and 
Antimycin A (1μM) 
XFAM  
supplemented with: 
*Glucose (25mM) 
L-Glutamine (2mM) 
**Penicillin (50U/ml) 
**Streptomycin (50μg/ml) 
Glucose (25mM) 
L-Glutamine (2mM) 
Sodium Pyruvate (1mM) 
**Penicillin (50U/ml) 
**Streptomycin (50μg/ml) 
Injection port volumes: A – 70μl 
B – 77μl 
C – 85μl 
D – 94μl 
Timings Mix – 3 minutes 
Wait – 12 minutes 
Measure – 3 minutes 
Cell Density 200,000 cells/well 
(Detach and re-suspend cells 2x106/ml, then use 100μl/well 
for optimal coverage without clumping) 
Table 3.2: Summary of optimal Seahorse XF analyser conditions for BMDMs 
Table summarises optimal conditions, required for using BMDM cell cultures in the Seahorse 
XF Analyer. *Glucose injection can be omitted and replaced with glucose supplemented in 
XFAM (NB. Do not require both); **Antibiotics can be added; to ensure no extracellular 
bacteria are present after live bacterial challenge. Alternatively antibiotic treatment can 
occur prior to assay, and remain omitted from XFAM. 
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3.2.3. Real-time effect of heat-killed S. pneumoniae on glycolytic metabolism of 
BMDMs 
After optimising the XF protocol, BMDMs were assessed for their responses to different 
stimuli, using the Glycolysis Stress Test. This experiment aimed to see whether cells 
responded to S. pneumoniae by increasing their glycolytic rate after a one hour 
stimulation, compared to responses induced by LPS and IL-4 – stimuli that induce CAM 
and AAM phenotypes respectively (Van den Bossche et al. 2015).  
Heat-killed (HK)-S. pneumoniae was used as this would interact with cells, without 
contributing to metabolic outputs. The experiment was set-up using injection ports in 
the sensor cartridge plate, with stimulants and inhibitors injected within the machine 
and changes assessed directly over the experimental time course. The injection ports 
followed the sequence: Port A: stimulus (see Figure 3.6 legend and graph key for details), 
Port B: glucose (25mM working concentration), Port C: Oligo (1μM working 
concentration) and Port D: 2DG (100mM working concentration). Figure 3.6 shows a 
representative ECAR plot of this set-up, with post-stimulation and glycolytic basal rates 
calculated from measurements immediately before the glucose, and immediately 
before the Oligo injections respectively. From this, it appears that LPS increased 
glycolytic metabolism within just one hour of stimulation, compared to mock-stimulated 
BMDMs, although this was not found to be statistically significant. HK-S. pneumoniae 
also did not induce any significant changes. Additionally, Oligo is used to provoke 
increased glycolytic capacity of cells and help metabolic profiling of cells, as 
demonstrated in Figure 1.5B. However, in these experiments it did not produce the 
desired effect on ECAR, after glucose injection.  
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Figure 3.6: Glycolysis Stress Test – Real-time (1hr) BMDM stimulation 
BMDMs were cultured for 14 days prior to seeding for XF Analysis at 2x105cells/well. Media 
was replaced with XFAM, and stimuli injected using the XF Analyser apparatus. A 
representative and normalised ECAR plot (A) is shown, with a reciprocal key. Injection points 
are indicated by the dotted lines, and in the following order: 1=Stimulus (as shown in key: HK-
SPN, D39 at MOI 10, LPS at 100ng/ml, IL-4 at 10ng/ml), 2=Glucose (25mM), 3=Oligomycin A 
(1μM), 4=2DG (100mM); Post-stimulation basal ECAR (B) and glycolytic basal ECAR (C) are 
shown, as taken from the 76th and 131st minutes of the experiment, to correlate with 
immediately before the glucose and oligomycin injections respectively. A one-way ANOVA 
with Dunnett’s multiple comparisons calculated no significance (ns) compared to the mock 
condition. Each donor is indicated by a different shape and is the mean value of 4-5 
experimental replicates; Representative of biological n=3. (HK-SPN = heat-killed D39 S. 
pneumoniae) 
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3.2.4. Re-optimisation of Oligo and Glucose for Glycolysis Stress Test 
To test for discrepancies after Oligo stimulation, different concentrations of Oligo and 
glucose were tested, to see if these concentrations and/or stocks were still appropriate. 
The results of these experiments can be found in Figures 3.7 and 3.8. First, 
concentrations of Oligo between 1-10μM, after a preliminary 25mM glucose injection, 
were trialled to see if this would help stimulate an increased shift from respiration to 
glycolysis. Regardless of the Oligo concentration used, ECAR was not increased further 
than the original 1μM concentration. Secondly, lower concentrations of glucose, 
between 5-25mM, were trialled to prevent overwhelming the cells with glucose and to 
test whether this could reduce their basal glycolytic rates, leaving greater opportunity 
to increase the subsequent capacity with Oligo. There appeared to be a small 
concentration-dependent change in the glycolytic rate, with decreased glycolysis seen 
for lower glucose concentrations; however, this same pattern remained after Oligo 
injection, with low glucose availability diminishing the total measurable metabolic shift. 
The original Oligo concentration of 1μM was therefore still deemed suitable. 
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Figure 3.7: Glycolysis Stress Test – Re-optimisation of Oligo usage 
(A) BMDMs were cultured for 14 days prior to seeding for XF Analysis at 2x105cells/well. 
Media was replaced with XFAM supplemented with 2mM L-glutamine. Glucose (G; 
25mM) and oligomycin (O; 1-10μM, see key) were added using the injection ports, 
indicated by the dotted lines respectively. Figures represent raw data, as protein 
normalisation was not used. n=1 
(B) BMDMs were cultured for 14 days prior to seeding for XF Analysis at 2x105cells/well. 
Media was replaced with XFAM supplemented with 2mM L-glutamine. Glucose (G; 5-
25mM, see key) and Oligo (O; 1μM) were added using the injection ports, as indicated by 
the dotted lines respectively. Figures represent raw data, as protein normalisation was 
not used. n=1 
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Following this, an alternative Oligo stock was tested to see: 1) if this new stock would 
consistently increase glycolytic capacity after glucose injection and 2) whether there 
were differences in sensor cartridge port loading for Oligo or solubility in XFAM. Figure 
3.8A shows the changes seen across the plate, as separated by plate row and Oligo 
loading order (rows loaded chronologically, 1→4). This secondary Oligo stock did work 
effectively, although there were slight differences after Oligo stimulation, depending on 
how this was loaded in the cartridge plate. That said, as there was no normalisation to 
protein content after this experiment, these variances could primarily be due to 
differences in cell number rather than the effect of the compound. From this experiment 
onwards, the secondary Oligo stock was used. The final experiment shown in Figure 3.8B 
shows a test run of the new stock, used to measure the glycolytic capacities of cells 
following mock-stimulation, S. pneumoniae-challenge, or stimulation with IL-4 or LPS for 
4 hours. Despite attempts to re-optimise this protocol, the Oligo did not induce the 
desired effect. It was hypothesised here that cells had metabolised maximally after the 
glucose injection and that this could not be pushed further with Oligo treatment; 
therefore from here on, the glucose was no longer injected as a stimulus, but was 
instead added to the XFAM, to improve output measures and further reduce time on 
the analyser. 
  
 96 
 
  
A 
0 5 0 1 0 0 1 5 0
0
2 5
5 0
7 5
1 0 0
T im e  (m in u te s )
E
C
A
R
 (
m
p
H
/m
in
)
E C A R  D a ta  -  L o a d in g  T e s t
R O W  1
R O W  2
R O W  3
R O W  4
G O 
B 
0 5 0 1 0 0 1 5 0 2 0 0
0
5
1 0
1 5
E C A R  D a ta  -  T e s t R u n
T im e  (m in u te s )
E
C
A
R
 (
m
p
H
/m
in
/m
g
 p
r
o
te
in
)
M O C K
IL -4
S P N
L P S
G O 2DG 
Figure 3.8: Glycolysis Stress Test – Re-optimisation of Oligo usage, with new stock 
(A) Experimental set-up was as described for Figures 3.7A-B, with glucose (25mM) and 
oligomycin (1μM) injected by the dotted lines respectively. However, a different oligo stock was 
used and groups here indicate the rows of the cell microplate, to reveal any differences caused 
by loading order. Figures represent raw data, as protein normalisation was not used. n=1 
(B) BMDMs were cultured for 14 days prior to seeding for XF Analysis at 2x105cells/well. Cells 
were infected/stimulated for 4hrs (as per key: IL-4 =interleukin-4 (10ng/ml); SPN = D39 S. 
pneumoniae MOI 10; LPS = 100ng/ml), treated with penicillin and gentamycin to kill extracellular 
bacteria, washed with PBS, and XFAM supplemented with 2mM L-glutamine was added. 
Injection ports are indicated by the dotted line, containing glucose (25mM), oligomycin (1μM, 
new stock) and 2DG (100mM) in this order. Data was normalised to protein content. n=1 (G = 
glucose; O = oligomycin; 2DG = 2-deoxyglucose) 
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3.2.5. Glycolysis Stress Test – Glycolytic changes after 4 hour bacterial challenge 
Using the amended Glycolysis Stress Test, with glucose in the XFAM as opposed to the 
first injection port, BMDMs were assessed for differences in basal and maximal glycolytic 
rates, following 4 hours mock-stimulation, live S. pneumoniae challenge, IL-4- or LPS-
stimulation. The results of these experiments are displayed in Figure 3.9. Upon initial 
inspection of the ECAR data plots, it seemed that LPS and S. pneumoniae increased 
glycolysis in BMDMs, compared to mock-stimulation; however, the results in Figure 3.9 
suggest there were no statistically significant changes between these groups after 4 
hours stimulation. Interestingly, this contradicts findings previously shown in Figure 3.6, 
which suggest that LPS induces an increase in glycolytic metabolism after one hour. One 
cause of this discrepancy could be in the experimental design: in previous assays, LPS 
was injected, without any media changes or disruptions; however, assays involving live 
bacterial infections were treated with antibiotics prior to performing the XF assay and 
therefore required prior preparation. Additionally, there were differences in the XFAM, 
as glucose was supplemented during these experiments with live bacteria. Additionally, 
macrophage metabolism is very plastic, and any induced changes in glycolytic 
metabolism by these stimuli could have been reversed – or overwritten – by the 
subsequent media changes and delay in assaying this model.  
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Figure 3.9: Glycolytic Stress Test – 4 hour bacterial challenge of BMDMs 
A) A representative ECAR profile of four experiments. BMDMs were cultured for 14 days 
prior to seeding for XF Analysis at 2x105cells/well. Cells were infected/stimulated for 4hrs 
(as per key: IL-4 = interleukin-4 (10ng/ml); SPN = D39 S. pneumoniae MOI 10; LPS = 
100ng/ml), treated with penicillin (40U/ml) and gentamycin (20ug/ml) to kill extracellular 
bacteria, washed with PBS, and XFAM supplemented with 2mM L-glutamine and 25mM 
D-glucose was added. Injection ports are indicated by the dotted lines, containing 
oligomycin (Oligo; 1μM) and 2DG (2DG; 100mM) respectively. Results were normalised to 
total protein content, which was collected for every well and assayed for after XF analysis. 
B) - G) Calculated values from four independent biological repeats, as follows (* indicate 
points represented in 3.8A):  
Basal Glycolysis = Basal ECAR (*1) – Non-Glycolytic Acidifications (*3) 
Glycolytic Capacity = Maximal ECAR (*2) – Non-Glycolytic Acidifications (*3) 
Glycolytic Reserve = Glycolytic Capacity (*2 - *3) – Basal Glycolysis (*1 - *3) 
Glycolytic Reserve % = ((Glycolytic Capacity – Basal Glycolysis)/Basal Glycolysis)*100 
Non-Glycolytic Acidifications = Immediately after 2DG (*3) 
Basal OCR = Immediately before Oligo (*1) 
Statistics calculated using One-way ANOVA with Tukey’s multiple comparisons. Data 
represent mean summary of 5 experimental replicates. Representative of biological n=4; 
different shapes indicate different donors. 
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3.2.6. Glycolysis Stress Test – Glycolytic changes after 12 hour bacterial challenge 
To further study the glycolytic responses exhibited by BMDMs during live S. pneumoniae 
challenge, a later 12 hour time point was assayed. These results are shown in Figure 
3.10. The representative ECAR plot in Figure 3.10A shows a distinction between the 
basal glycolysis of LPS-stimulated and S. pneumoniae-challenged cells, compared to the 
mock-infected group. However, no statistical significance was found for basal glycolysis 
of S. pneumoniae-challenged cells, compared to the mock. Furthermore, the percentage 
glycolytic reserve - the difference between basal and maximal glycolytic rates - was 
reduced in both LPS-stimulated and S. pneumoniae-challenged cells, suggesting that 
BMDMs may only have a finite inducible capacity for glycolysis. Another interesting 
observation is shown in Figure 3.10F, whereby 12 hours LPS-stimulation or bacterial 
challenge increased non-glycolytic acidifications – that being acidic pH changes not 
contributed by increased glycolysis, and the production of lactate and H+. It is difficult 
to stipulate what might have caused this, but it indicates that an acidic environment 
and/or intracellular change could influence BMDM metabolism. Finally, basal OCR was 
assessed and there were no significant differences between groups, suggesting that 
respiration remains unchanged after this time. 
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Figure 3.10: Glycolysis Stress Test – 12 hour bacterial challenge of BMDMs 
A) A representative ECAR profile of four experiments. BMDMs were cultured for 14 days 
prior to seeding for XF Analysis at 2x105cells/well. Cells were infected/stimulated for 4hrs 
(as per key: IL-4 =interleukin-4 (10ng/ml); SPN = D39 S. pneumoniae MOI 10; LPS = 
100ng/ml). Cells were then treated with penicillin (40U/ml) and gentamycin (20ug/ml) to 
kill extracellular bacteria, washed with PBS and culture media +/- LPS/IL-4 was replaced until 
12hr post-stimulation. Cells were washed in PBS and XFAM supplemented with 2mM L-
glutamine added and 25mM D-glucose. Injection ports are indicated by the dotted lines, 
containing oligomycin (Oligo; 1μM) and 2DG (2DG; 100mM) respectively. Results were 
normalised to total protein content, which was collected and assayed for every well. 
B) - G) Calculated values from four independent biological repeats, as follows (* indicate 
points represented in 3.8A):  
Basal Glycolysis = Basal ECAR (*1) – Non-Glycolytic Acidifications (*3) 
Glycolytic Capacity = Maximal ECAR (*2) – Non-Glycolytic Acidifications (*3) 
Glycolytic Reserve = Glycolytic Capacity (*2 - *3) – Basal Glycolysis (*1 - *3) 
Glycolytic Reserve % = ((Glycolytic Capacity – Basal Glycolysis)/Basal Glycolysis)*100 
Non-Glycolytic Acidifications = Immediately after 2DG (*3) 
Basal OCR = Immediately before Oligo (*1) 
Statistics calculated using One-way ANOVA with Tukey’s multiple comparisons. Data 
represent mean summary of 5 experimental replicates. Representative of biological n=4; 
different shapes indicate different donors. 
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3.2.7. Mito Stress Test to study human monocyte-derived macrophage metabolic 
responses to pneumococcal challenge 
Following earlier work in this chapter on murine BMDMs, the XF procedure was used to 
consider a human cell model of infection. For this, collaboration was made with PhD 
student Joby Cole, who was also part of the Dockrell research group. The research 
question addressed ‘tolerisation’ of human monocyte-derived macrophages (MDMs) 
and how this could affect respiratory metabolism during S. pneumoniae challenge. Here, 
the Mito Stress Test was used, which had been optimised for use with human cells, in 
collaboration with a third Dockrell PhD student, MD Mohasin.  
The aim of this experiment was to address the respiratory modifications in MDMs, 
following 24 hour pre-treatment, or ‘tolerisation’, with either LPS or heat-killed S. 
pneumoniae, and to assess how this influenced MDM respiratory metabolism when 
followed by a live 4 hour S. pneumoniae challenge. The results of these experiments are 
shown in Figure 3.11. Whilst no statistically significant differences are seen for any of 
the calculated measures shown, there are still some interesting trends in this data. For 
example, the basal and maximal respiration rates of MDMs are lower after encountering 
bacteria, regardless of whether their exposure involved heat-killed or live S. 
pneumoniae. This may suggest that MDMs shift their mitochondrial functioning away 
from respiration, upon contact with bacteria, and potentially towards other functions, 
for example the production of ROS (Liemburg-Apers et al. 2015). The results of Figure 
3.11G are also very interesting: whilst MDM contact with bacteria produced a trend of 
increased Basal ECAR, a 24 hour tolerisation with LPS did not. This contrasts with the 
published literature and results shown previously in Figure 3.10. Despite this, it could be 
proposed that increases in ECAR after bacterial challenge are sustained for longer 
periods, compared to stimulation with LPS. There was also no difference in ECAR or OCR 
for tolerised cells with S. pneumoniae challenge, suggesting that these different stimuli 
do not induce a lasting influence on metabolism that could be observed after bacterial 
infection. 
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Figure 3.11: Mito Stress Test in tolerised MDMs 
A) Representative OCR profile of four MDM Mito Stress experiments. MDMs were cultured 
for fourteen days, prior to reseeding at 200,000 cells/well for XF analysis. Cells were 
tolerised as per the key for 24hrs (MOCK = no stimulus; LPS = 100ng/ml; HK-SPN = heat-
killed D39 S. pneumoniae MOI 10), then either S. pneumoniae-challenged (D39, MOI 10) or 
mock-infected for 4 hours. At this time, cells were washed 2x with XFAM, supplemented 
here with 25mM D-glucose, 2mM L-glutamine, 1mM Na-pyruvate, 50U/ml penicillin, 
50ug/ml streptomycin and pH adjusted to 7.4 at 37°C. A final volume of 630μl XFAM was 
added to the plate, ready for XF assay. The injection ports, indicated by the dotted lines, 
contained oligomycin (O = 10μM), FCCP (F = 20μM) and Rotenone + Antimycin (R+A, both 
10μM) respectively. Results were normalised to total protein content, which was collected 
for every well and assayed for after XF analysis. 
B) - G) calculated values from four independent repeats as follows: 
Basal Respiration = Basal OCR (*1)  
Maximal Respiration = Maximal OCR (*2)   
Non-mitochondrial OCR = Immediately after Rotenone + Antimycin A (*3) 
Spare Respiratory Capacity = Max OCR (*2)  – Basal OCR (*1)   
Spare Respiratory Capacity % = ((Spare Respiratory Capacity – Basal OCR)/Basal OCR)*100 
Basal ECAR = Immediately before Oligo (*1) 
No statistically significant differences were found for any measures, after One-way ANOVA 
with Tukey’s multiple comparisons; Data represent mean summary of 3-4 experimental 
replicates. Representative of biological n=4; 
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3.3. Discussion 
3.3.1. Chapter Summary 
In this chapter, optimisation of the Seahorse XF Analyser has been shown, with the 
adjusted technique used to study glycolytic metabolism of BMDMs after S. pneumoniae-
challenge. XF analysis has been used to study a wide range of disease models, including 
neurodegenerative disorders, cancer, obesity and inflammation, however, few studies 
have used it to look at the metabolic effects of cell cultures challenged with whole, live 
bacteria (Agilent Technologies 2017b). The optimisation of this technique aimed to suit 
the specific cell type, however many users and publications do not detail these stages, 
as it has been overlooked for the convenience of using standard protocols 
recommended by the manufacturer. This optimisation can be critical, to avoid false 
metabolic measurements, particularly concerning oxygen pressure and OCR readings.  
The optimal cell density and protocol timings were first identified: 200,000 cells/well 
were shown to be effective, in combination with mix, wait, measure timings of 3, 12, 3 
minutes respectively. Suitable concentrations of inhibitors for the Glucose Stress Test, 
Oligo and 2DG, were then identified as 1μM and 100mM respectively. Concentrations 
for inhibitors used in the Mito Stress Test kit, including Carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP), Antimycin A and Rotenone were also 
identified, using the same experimental set-up as that seen of Oligo and 2DG. 
Establishing an appropriate concentration for FCCP can be critical, as it can cause loss of 
inner mitochondrial transmembrane potential, leading to toxicity and cell death 
(Gottlieb et al. 2003; Held et al. 2010). However, the Mito Stress assay was not relevant 
to the research aims of this thesis; therefore these have been omitted. Table 3.2 
provides a summary of all the optimal conditions required for both the Glycolysis and 
Mito Stress Tests with BMDMs. 
Optimisation of the technique was further continued after Oligo did not induce the 
desired effect. This could have been because cells were already working maximally after 
glucose injection, and it was not feasible to increase this further. A second plausible 
theory could be that macrophages were starved of glucose prior to the injection, during 
both XFAM equilibration and initial XF analysis; therefore cutting off the glucose supply 
for prolonged periods and suddenly returning it could affect the outcome of this assay, 
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as macrophages are highly reliant on glycolysis when differentiating or converting to a 
CAM phenotype (Suzuki et al. 2016; Kelly & O’Neill 2015). Furthermore, preliminary 
Oligo optimisations were carried out with glucose present in the XFAM, as opposed to 
being injected, which may also change the expected outcome. Finally, there could have 
been technical problems with the Oligo stock itself. Oligo solubility might have 
influenced the assay, with loading of this compound varying between injection ports. 
This could be caused by the compound dropping out of solution upon dilution into a 
different solute, or by inadequate mixing of the central stock prior to aliquoting for 
storage. Therefore, further optimisations and checks were required to continue using 
this glycolytic profiling experiment effectively. 
Once optimisations were finalised, metabolic responses of BMDM were assessed. After 
both 4 and 12 hours stimulation, no significant differences were observed between 
mock-stimulated, LPS-stimulated or S. pneumoniae-challenged macrophages. However, 
there was a notable trend of increased non-glycolytic acidification and decreased 
glycolytic reserve with both LPS and S. pneumoniae stimulation. Lastly, XF analysis was 
used to dissect the importance of mitochondrial respiration in human macrophages, 
following stimulation with LPS or S. pneumoniae. This also revealed no significant 
differences between these stimulatory groups regarding oxidative metabolism.  
 
3.3.2. Chapter Discussion 
Seahorse XF analysis was used to measure glycolytic metabolism of S. pneumoniae-
challenged BMDMs, and to compare this with BMDMs stimulated with LPS – a prototypic 
bacterial and inflammatory stimulus that induces distinct metabolic changes and a CAM 
phenotype (Haschemi et al. 2012; Freemerman et al. 2014). There were no significant 
differences seen between different stimulations of BMDMs at a 4 hour time point; that 
said, notable differences were seen at a later 12 hour time point, as bacterial challenge 
stimulated an increase in glycolysis. Interestingly, LPS stimulation did not produce a 
statistically significant change in basal glycolysis, in either murine BMDMs or human 
MDMs. This contradicts what was expected following LPS stimulation and does not align 
with the current literature (Van den Bossche et al. 2015; Tannahill et al. 2013). This could 
be due to the type or concentration of LPS used here, or could potentially have been 
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influenced by macrophage plasticity, with the cells adapting to the different media 
changes required both prior to and during the assay. That said, an interesting 
observation was the significant increase in non-glycolytic acidifications by LPS 
stimulation of BMDMs, as this has not been widely reported on. This may suggest that 
media acidifications, usually indicative of glycolysis, were being produced by an 
alternative mechanism. One plausible suggestion could be CO2 release during Krebs 
Cycle metabolism – this pathway has also been reported as broken following LPS 
stimulation (O’Neill et al. 2016).  
Since these assays were carried out, Lachmandas et al published a similar experimental 
set-up, using Seahorse XF analysis but with bacterial isolates and lysates to demonstrate 
changes in ECAR and OCR of human monocytes, comparing microbial stimulation to LPS 
(Lachmandas et al. 2016). Intriguingly, they too indicate distinct differences between 
different bacterial stimuli, with the Gram-positive bacterium, Staphylococcus aureus, 
inducing the smallest changes in both measures, compared to the mock. This work is 
particularly provocative as it suggests that changes seen after LPS stimulation are not 
necessarily mirrored by complex bacterial stimulation. It could be proposed that the 
complex stimulation seen during microbial infection, by multiple ligands and diverse 
host receptors, are causing changeable levels of downstream pathway activation, 
resulting in pathway convergence and/or receptor redundancy. For example, whilst LPS 
is known to activate TLR4 in isolation, it could be that TLRs and other surface receptors 
are synergising upon contact with further bacterial stimuli. This is shown to be the case 
for the recognition of LPS and lipoteichoic acid, which can both co-ordinate activation 
of TLR4 with CD14 (Kusunoki et al. 1995). It is also seen in the cooperation of TLR2 and 
TLR6 in detecting bacterial lipoproteins (Takeuchi et al. 2001). Further literature, 
describing the use of Seahorse XF analysis to uncover the effects of live bacterial 
infection on host immune cells, is quite limited. However, it has been briefly used to 
highlight an increased glycolytic metabolism during M. tuberculosis infection of alveolar 
macrophages (Gleeson et al. 2016), a role for S. aureus metabolic stress during infection 
of keratinocytes (Wickersham et al. 2017) and a proposed role for the P. aeruginosa 
toxin Pyocyanin in mediating bioenergetic changes to neutrophils (Managò et al. 2015). 
To date, no further publications have been shown to use the Seahorse XF Analyser to 
make comparisons between the metabolism of cells stimulated with extracellular 
bacteria, versus others stimulated with PAMPS or bacterial components such as LPS. 
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Instead, research has focused on using this technique to study bacterial metabolism 
independent of mammalian host cells, which has been demonstrated for S. aureus, M. 
tuberculosis and E. coli (Lamprecht et al. 2016; Lobritz et al. 2015). Further work is 
required in this area, to truly understand the unique detection and responses induced 
by different bacteria, and what this means for downstream responses – including the 
typical antimicrobial responses such as cytokine release, but also for immunometabolic 
responses and their importance in tackling specific bacterial infections. 
The Seahorse XF Analyser is beneficial for monitoring live cell culture metabolism in real 
time, without the need for labelled substrates or complex data analysis. The technique 
requires relatively few cells, compared to traditional radiolabelling methods, and does 
not require any further specialist equipment or training to analyse the resulting data. 
However there are some limitations to this technique. The analyser used here was 
housed in a neurobiology lab, and as S. pneumoniae is a hazard Category II pathogen, 
any live bacterial work was limited. Care was taken to ensure only heat-killed or 
intracellular bacteria were present, with extracellular antibiotics used as required, to 
limit the effects of extracellular bacterial metabolism on XF analyser measurements. 
This therefore increased the preparation time and media changes prior to assessment, 
which could have influenced subsequent metabolism, in both murine BMDMs and 
human MDMs. Additionally, XF Analysis can only be presented as an indirect measure 
of glycolysis, as media acidification could occur through other means. It provides limited 
pathway information; therefore, additional techniques should be implemented to 
confirm these findings.  
Assays that complement XF Analysis could involve the quantification of metabolites. 
Simple assays include direct quantification using commercially available assay kits, for 
example measuring glucose or lactate in the cell culture media, or ATP inside the cell. 
Glucose uptake can also be measured with a fluorescent glucose analog, such as 2-[N-
(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-d-glucose, or 2NBDG (Zou et al. 
2005). Alternatively, more detailed and complex assay designs can be used. The ‘gold 
standard’ in this case would be heavy or radioactive labelling of glucose, which can be 
traced through glycolysis and subsequent pathways, and separated for high-resolution 
analysis via NMR Spectroscopy or tandem Mass Spectrometry techniques, such as gas 
or liquid chromatography. This provides extensive information on metabolic pathway 
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engagement, but also requires extensive experience in data handling and analysis 
methods, compared to XF Analysis (Everts et al. 2012; Dupuy et al. 2013). 
 
3.3.2. Future work 
The XF Analyser has been used here to consider glycolytic changes at distinct intervals 
post-infection; however, Agilent have opened this technique up to greater 
opportunities, as they now supply a wider range of profiling kits, including assays for 
fatty acid oxidation and the dependency of mitochondria for different fuel sources. 
Therefore, these assays could be used to further understand other metabolic changes 
that occur during infection. Alternatively, the injection ports could be used to inject 
metabolites of interest, to examine their importance in macrophage health or their 
utilisation during macrophage responses to bacterial challenge. An example here could 
be using XFAM free from glucose, glutamine and/or galactose, and injecting these into 
the system, observing their importance during metabolic switches, such as those seen 
in the literature after LPS stimulation. 
For these experiments, the use of live S. pneumoniae was not permitted and antibiotics 
were used to prevent extracellular bacteria from influencing XF readings; however, it 
would be interesting to follow real-time metabolic changes during bacterial challenge, 
to observe how rapidly this occurs and if they compare to responses seen with LPS. That 
said, Lachmandas et al used bacterial lysates, which could be alternative method to take 
forward (Lachmandas et al. 2016). A modification of this bacterial experiment would be 
to use extracellular bacterial components, such as the pneumococcal capsule 
polysaccharide, peptidoglycan or pneumolysin toxin, rather than whole bacteria, and to 
see how the responses to these stimuli compare to those seen for LPS. 
Finally, as noted earlier in this discussion, XF Analysis should be accompanied by other 
metabolic measures where possible. It would have been favourable to assay metabolic 
enzymes and transporters, such as Hexokinase and GLUT1 – either at a transcriptional, 
protein or enzymatic level – to supplement this data further. 
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Chapter 4 – The optimisation and use of NMR Spectroscopy to study 
global metabolic changes of BMDMs after S. pneumoniae challenge 
4.1. Introduction 
Metabolomic researchers employ NMR Spectroscopy, to analyse changes to metabolite 
profiles in a wide range of samples. It has been particularly valuable for researchers 
considering the metabolome as a potential diagnostic tool for disease, and it has been 
heavily applied to analysis of clinical samples such as bloods, urines, and tissues. By 
analysing these biological samples, NMR Spectroscopy may aid identification of 
metabolomic phenotypes or biomarkers that distinguish healthy patients from those 
with disease, aiding patient diagnosis or in evaluating the effectiveness of treatments 
(Emwas et al. 2013). NMR approaches have also been used to consider metabolic 
changes in cell cultures, as seen with drug testing in cancer cells (Lauri et al. 2016), and 
in microbiological studies, for example, in studying metabolic changes seen in biofilm 
formation (Zhang & Powers 2012). 
Different sample preparations and NMR approaches for cell culture systems are found 
across the literature. Two specific papers provided opposing approaches to this: Ramm 
Sander et al. described the use of whole cell suspensions, to assess live, real-time 
metabolism with minimal preparation and in the absence of culture media, whereas 
Lamour et al. compared the extracellular supernatant and intracellular extracts of cells, 
which required more processing prior to running on the NMR spectrometer (Lamour et 
al. 2012; Ramm Sander et al. 2013). Both approaches are considered in this chapter, as 
1H-NMR can be used to measure metabolite levels, making it an appropriate method to 
study the metabolic changes correlated with CAM activation. 
This chapter demonstrates the optimisation and use of 1H-NMR Spectroscopy to identify 
metabolomic changes that occur during the host-pathogen interaction, between murine 
BMDM cell cultures exposed to S. pneumoniae. This research aimed to optimise a novel 
NMR Spectroscopy protocol and to compare the metabolic changes observed during 
bacterial infection, with spectra acquired from BMDMs stimulated with LPS - a stimulus 
shown to induce a CAM phenotype with distinct metabolic changes, including changes 
to glycolysis, arginine and TCA cycle metabolisms.   
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4.2. Results 
4.2.1. Initial NMR Spectroscopy protocols 
Firstly, the Ramm Sander and Lamour protocols were tested, to assess which provided 
the most effective output for BMDM analysis. To identify significant differences in 
BMDM metabolite profiles, a comparison was made between healthy, unstimulated 
cells, and cells stimulated with INFy+LPS for 24 hours; this stimulation is shown to 
convert macrophages into a classically-activated, inflammatory phenotype, which 
increases their glycolytic metabolism and lactate release (Van den Bossche et al. 2015).  
For the Ramm Sander protocol, samples were run in 5mm Shigemi NMR tubes. These 
tubes are engineered like a standard NMR tube, but with a large, solid base and small 
inner tube. This allows for smaller volumes and more concentrated samples to be 
assessed within the optimal sampling region of the magnet, but without compromising 
data acquisition quality. Figure 4.1 shows an example Shigemi tube and the spectra 
observed from whole BMDMs, using the protocol adapted from Ramm Sander et al. on 
a 600MHz magnet. Some compounds have been tentatively assigned in the comparative 
spectral view in Figure 4.1C, identified using spectral tables and open access databases, 
such as the Human Metabolome Database (HMDB). The spectra achieved were 
relatively reproducible between the two conditions, with small increases seen for, what 
was tentatively assigned as, lactate, succinate and potentially a choline-related product.  
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Figure 4.1: NMR Spectroscopy protocol test – Ramm Sander whole cells 
Cells were reseeded at a density of 600,000 cells/well, and left overnight to adhere, before 
being mock-stimulated or stimulated with IFNγ +LPS (both at 10ng/ml). After 24 hours, cells 
were washed, scraped in 10% D2O PBS with 1μM of 100mM Trimethylsilylpropanoic acid (TSP), 
and assessed via NMR spectroscopy on a 600MHz magnet with 5mm Shigemi NMR tubes; n=1. 
A) A diagram and representative image of a Shigemi tube. Images taken with permission from 
http://www.shigeminmr.com/  
B) The full spectral acquisition window, from 0-10ppm, is shown from an IFNγ+LPS stimulated 
cell sample. The TSP reference peak is shown at 0ppm, water peak at 5ppm and the central 
region of interest indicated by the hashed square. 
C) An enlarged and tentatively labelled region of Figure 4.1B, showing a comparative view 
between mock-stimulated (red) and IFNγ+LPS stimulated (blue) cells. Compounds were 
assigned using open access spectral tables and databases, such as HMDB. 
Inner 
Outer 
Sample 
A 
Lactate 
Alanine 
Ethanol 
Ethanol 
Glutamate 
Succinate 
and Pyruvate 
Glutamine 
unknown 
G3P/Choline 
C 
C 
B 
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Following this, the Lamour et al. protocols for intracellular versus extracellular 
metabolomic components were tested. This required more preparation of samples prior 
to NMR acquisition. Supernatant samples only were first used to trial the Lamour et al. 
protocol for extracellular spectral acquisition and were loaded into standard 5mm NMR 
tubes. Using this protocol, comparable spectra were achieved, to those shown in 
Lamour et al., with the addition of a few extra peaks, which could result from 
components of the specific culture media. These spectra are shown in Figure 4.2. The 
supernatants required minimal preparation and only had a short acquisition time of 8-
10 minutes. Therefore, the Lamour protocol was deemed suitable, and optimised for 
metabolic assessment of S. pneumoniae-challenged BMDM cell cultures. 
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Figure 4.2: NMR Spectroscopy protocol test – Lamour cell supernatants 
Cells were reseeded using accutase, to a density of 600,000 cells/well, left overnight, then 
mock-stimulated or stimulated with IFNγ+LPS (both at 10ng/ml) for 24 hours. At this time, 
supernatants were frozen at -80°C, whilst whole cells were prepared for analysis seen in 
Figure 4.1. Supernatants we diluted 300μl:300μl in 70% D2O PBS, with 1μM of 100mM 
Trimethylsilylpropanoic acid (TSP), and assessed on a 800Hz magnet; n=1. 
A) 1H-NMR spectra of culture media are shown, from the absence of cells (BLANK - green), 
for supernatants from unstimulated BMDMs (UNS - red) and from IFNγ+LPS stimulated 
BMDMs (IFNγ+LPS - blue) after 24 hours. Lactate has been tentatively labelled, the TSP 
reference peak is shown at 0ppm and water peak at 5ppm. 
B) – C) Enlarged versions of the IFNγ+LPS supernatant 1H-NMR spectra, as indicated in 
Figure 4.2A, with annotations of suggested metabolic identifications, identified using 
open-access spectral tables and databases, such as HMDB;(AA=Amino Acid). 
Lactate 
A 
B 
C 
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Following this, both supernatants and cell extracts were prepared from three biological 
BMDM donors, using the adapted Lamour et al. protocol. BMDMs were reseeded and 
left unstimulated for 24 hours. Supernatants were collected directly and intracellular 
metabolites extracted using an 80% methanol extraction procedure. The results of these 
experiments are shown in Figure 4.3, with the comparison between supernatants from 
cell-free conditions (i.e. blank) and supernatants from healthy BMDMs. This provided an 
insight into the profiles expected in repeat supernatant samples from unchallenged, 
healthy cells – for example, increases in the lactate peak only happened when cells were 
present. It also indicated that there could be differences in media prepared on different 
days, as this was different for each donor preparation. Despite this, spectra here could 
still be closely compared to those found in Figure 4.2. With regards to the cell extracts, 
these spectra are far less concentrated than the supernatants, requiring an increased 
number of scans and longer acquisition time within the spectrometer. This resulted in 
an increased level of noise and distortion to the baseline. These spectra also suggest 
there could be carry-through of media components, altering the cell extract spectra; for 
example, as seen for the peak present at ~1.5ppm. From these trial experiments, the 
Lamour protocols were deemed suitable to take forward, to assess metabolic changes 
in the extracellular versus intracellular environments, as the protocol provided clear 
peaks for analysis and acquisition times that were reasonable for the quality of spectra 
achieved. 
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Figure 4.3: NMR Spectroscopy protocol test – Lamour cell supernatants and extracts  
Cells were reseeded at 1x106 cells/well via accutase and haemocytometer counting, and left 
to adhere for 24 hours. Supernatants were stored at -80°C and cell extracts prepared using 
80% methanol extraction. 70% D2O PBS with 167μM TSP was used in both supernatant and 
cell extract acquisitions, in an 800Hz NMR magnet. The TSP reference peak is shown at 0ppm 
and water peak at 4.8ppm. Biological n=3, experimental n=1. 
A) Triplicate supernatant spectra each from cell-free, blank samples (top) and BMDM-
containing samples (bottom). Metabolites are tentatively assigned using references tables 
and HMDB.  
B) Triplicate cell extract preparations from healthy, unstimulated BMDMs only. Metabolites 
are tentatively assigned using references tables and HMDB.  
A 
lactate 
branched chain 
AAs glutamine     ---
- glutamate 
pyruvate 
glucose 
alanine 
B 
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methanol 
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4.2.2. NMR Spectroscopy preliminary screen  
The metabolism of S. pneumoniae-challenged BMDMs had not previously been 
examined; therefore, a preliminary screen, sampling at intervals over a 24 hour time 
course was first used. The effect of bacterial metabolism was minimised by using 
external antibiotics for all samples after 4 hours, and with utilisation of a bacteria-only 
supernatant control (shown in the Appendix). This initial assessment also provided a 
data set with which to trial some preliminary analysis methods. Both supernatants and 
cell extracts were prepared, with representative spectra shown in Figures 4.4 and 4.5.  
The supernatant spectra of healthy, unstimulated BMDMs are shown in Figure 4.4A. 
There are no visually distinct or obvious changes upon overlaying the spectra, apart from 
peaks at 1.3 and 4.1ppm, which correlated with lactate production. In comparison, there 
were several peaks following infection that appeared to change in pneumococcal-
challenge samples, particularly at 16 hours, as indicated in Figure 4.4B. Analysis against 
known spectral patterns suggested these could potentially correlate with changes in the 
peaks of acetate and glutamate. The supernatant spectra after 24 hours also had greatly 
decreased glucose peaks, between 3.2-4.9ppm, which associated with a large increase 
in lactate peaks at 1.3 and 4.1ppm.  
With regards to cell extract profiles, most changes were notable between the 8-16 hour 
timeframe, as indicated by the small black arrows in Figure 4.5. These were tentatively 
identified as changes to lactate, acetate, glutamate, choline and glucose. The 8 hour 
spectrum in Figure 4.5B also demonstrates how difficult spectral analysis can be if the 
baseline is warped – i.e. if it is not flat.  
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Figure 4.4: Preliminary 1H-NMR screen -BMDM cell supernatants  
Supernatants taken from cells seeded at 600,000 cells and either mock-infected or challenged 
with S. pneumoniae (D39, MOI 10), and sampled over a 24 hour period. For NMR spectroscopy, 
supernatants were diluted 300μl:300μl in 70% D2O PBS with 167μM TSP. Black arrows indicate 
noted differences between spectra. Supernatant control samples (no cells with/without S. 
pneumoniae) were used, as shown in the Appendix. 
A) Spectra of between 0-6ppm from supernatants of mock-infected cells. The only clear 
differences were increases to peaks at 1.3 and 4.1ppm, correlating with lactate production. 
B) Spectra of supernatants from S. pneumoniae-challenged cells. Differences in peak intensity 
identified by black arrows at 1.9, 2.4, 2.7, 3.7 and 4.1ppm. These correlated with increases to 
lactate, and tentative increases in acetate, glutamate and glucose. 
A 
B 
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Figure 4.5: Preliminary 1H-NMR screen – BMDM cell extracts  
Cell extract samples prepared from cells seeded at 600,000 cells, and either mock-infected or 
challenged with S. pneumoniae (D39, MOI 10), and sampled over 24 hours. Cell extract 
preparation performed using 80% methanol-water extraction. For NMR spectroscopy, cell 
extract pellets were re-suspended in 600μl 70% D2O PBS with 167μM TSP. Black arrows indicate 
noted differences. 
A) Spectra of between 0-6ppm from cell extracts of mock-infected cells. Differences observed at 
3.2-3.7ppm, correlating with glucose and other unidentifiable compounds. 
B) Spectra of between 0-6ppm from cell extracts of S. pneumoniae-challenged cells. Differences 
observed at 1.3, 1.9, 2.7, 3.1-3.7ppm, correlating with lactate and tentative changes in acetate, 
glutamate, choline and glucose. The 8hr sample also has a distorted baseline and poor phasing. 
A 
B 
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4.2.2.1. Preliminary screen data handling – metabolite identification 
When viewing supernatant spectra, they were dominated by components found within 
the cell culture media. Whilst this may have masked smaller metabolite peaks, it also 
provided a starting point for metabolite identification, as the media components were 
listed by the manufacturer. Therefore, an initial identification method involved 
correlating the components of Lonza’s DMEM, with spectral references and peak 
information from the Human Metabolome Database (HMDB). The HMDB has an 
extensive collection of metabolites and provides information on expected ppm shifts 
and peak shapes. Therefore, preliminary analyses were carried out by eye, comparing 
the HMDM expected spectra, to those shown in Figures 4.4 and 4.5.  
A second metabolite identification method involved using a trial-version of Chenomx, a 
software that allows manual fitting of reference compounds to experimental spectra, 
aiding metabolite identification and with the potential for automated quantification. A 
screenshot and example of this process is shown in Figure 4.6. In this figure, an example 
supernatant spectrum is shown, with a glucose reference spectrum used to 
demonstrate the automated fitting of compounds. Here you can see that only 338 
compound spectra are available in this trial version, and that appropriate alignment to 
these reference spectra can be quite difficult. Using these preliminary methods, a 
reference table was produced, listing potential compounds of interest and their 
expected spectral information. Table 4.1 provides this list of metabolites and their 
expected ppm shifts, which were predominantly identified in DMEM and supernatant 
samples. 
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Figure 4.6: Chenomx Profiler 
A) Screenshot of Chenomx Profiler Suite, showing an experimental spectrum. Here the cell 
supernatant of S. pneumoniae-challenged cells at 6 hours is shown. The table in the lower half 
of the image lists the 338 compounds available in the free trial version of this software. 
B) Example spectral fitting of 6 named compounds, with a focused view on the glucose peaks. 
The red line shows summary fit (ie of all ‘fitted compounds’ listed in table) and blue shading 
shows expected shape of a chosen compound, here showing the peaks produced by glucose. 
The numbers in the top left corner indicate mid-point ppm of the expected peaks. 
A 
B 
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Metabolite ppm (in H20, +/-0.03, 
pH7.0) and peak shape 
Amino Acids 
L-Alanine • 1.460 (doublet) 
• 3.760 (quadruplet) 
L-Arginine • 1.68 (multiplet ~11) 
• 1.90 (multiple ~6) 
• 3.23 (triplet) 
• 3.76 (triplet) 
L-Aspartate • 2.66 (quadruplet, 
steep) 
• 2.80 (quadruplet, 
split) 
• 3.89 (quadruplet) 
L-Cysteine 
 
• 3.06 (quadruplet) 
• 3.97 (multiplet ~8, 
split) 
L-Glutamate • 2.040 (multiplet ~5) 
• 2.119 (?) 
• 2.341 (multiplet ~7) 
• 3.748(quadruplet) 
L-Glutamine • 2.125 (multiplet ~8) 
• 2.446 (multiplet ~11) 
• 3.766 (triplet) 
L-Glycine • 3.54 (singlet) 
•  
L-Histidine • 3.16 (quadruplet) 
• 3.23 (doublet) 
• 3.98 (quadruplet) 
• 7.09 (singlet) 
• 7.90 (singlet) 
L-Isoleucine • 0.926 (triplet) 
• 0.997 (doublet) 
• 1.248 (multiplet ~6) 
• 1.457 (multiplet ~6) 
• 1.968 (multiplet ~8) 
• 3.661 (doublet) 
L-Leucine • 0.948 (triplet) 
• 1.700 (multiplet ~12)  
• 3.722 (quadruplet)  
L-Lysine • 1.46 (multiplet ~10) 
• 1.71 (quadruplet) 
• 1.89 (multiplet ~12) 
• 3.02 (triplet) 
• 3.74 (triplet) 
L-Methionine 
 
• 2.157 (multiplet ~10, 
1 long) 
• 2.631 (triplet) 
• 3.851 (quadruplet) 
L-
Phenylalanine 
• 3.19 (wide/split 
multiplet) 
• 3.98 (quadruplet) 
• 7.32 (doublet) 
• 7.36 (singlet/doublet) 
• 7.42 (doublet) 
L-Proline • 1.99 (multiplet ~7) 
• 2.06 (quadruplet) 
• 2.34 (multiplet ~5) 
• 3.33 (quadruplet) 
• 3.41 (quadruplet) 
• 4.12 (quadruplet) 
L-Serine • 3.832 (quadruplet) 
• 3.958 (multiplet ~8) 
L-Threonine • 1.316 (doublet) 
• 3.575 (doublet) 
• 4.244 (multiplet ~6) 
L-Tryptophan • 3.292 (quadruplet) 
• 3.472 (quadruplet) 
• 4.046 (quadruplet) 
• 7.194 (quadruplet) 
• 7.274 (multiplet ~5) 
• 7.310 (singlet) 
• 7.531 (doublet) 
• 7.723 (doublet) 
L-Tyrosine • 3.024 (quadruplet) 
• 3.170 (triplet) 
• 3.921 (quadruplet) 
• 6.877 (quadruplet) 
• 7.170 (triplet?) 
L-Valine • 0.976 (doublet) 
• 1.029 (doublet) 
• 2.261 (multiplet ~9) 
• 3.601 (doublet) 
Carbohydrate metabolism and 
intermediates 
D-Glucose • 3.233 (quadruplet) 
• 3.398 (multiplet ~6) 
• 3.458 (multiplet ~9) 
• 3.524 (quadruplet) 
• 3.728 (multiplet ~10) 
• 3.824 (multiplet ~7 
• 3.889 (quadruplet) 
• 4.634 (doublet) 
• 5.223 (doublet) 
Glucose-6-
phosphate 
• 3.27 (quadruplet) 
• 3.50 (multiplet ~7) 
• 3.56 (mutliplet ~10) 
• 3.71 (triplet) 
• 3.87 (triplet) 
• 3.92 (mutliplet ~8) 
• 3.99 (quadruplet) 
• 4.03 (multiplet ~7) 
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• 4.64 (doublet) 
• 5.22 (doublet) 
Ribose-5-
phosphate 
• 3.85 (multiplet ~5) 
• 3.93 (quadruplet) 
• 4.06 (quadruplet) 
• 4.20 (multiplet ~5) 
• 4.30 (triplet) 
• 5.22 (doublet) 
• 5.39 (multiplet ~9) 
6-
Phosphogluco
nate 
• 3.84 (singlet) 
• 3.96 (multiplet ~9) 
• 4.09 (doublet) 
• 4.19 (doublet) 
Glyceraldehyd
e-3-phosphate 
• Not in HMDB 
Glycerol-3-
phosphate 
• 3.61 (multiplet ~6) 
• 3.67 (multiplet ~6) 
• 3.82 (multiplet ~20) 
Fructose-2,6-
bisphosphate 
• 1.17 (triplet) 
• 3.34 (singlet) 
• 3.64 (quadruplet) 
• 3.81 (singlet) 
• 3.84 (singlet) 
• 3.93 (quadruplet) 
• 3.98 (quadruplet) 
• 4.03 (doublet) 
• 4.05 (doublet) 
• 4.18 (triplet) 
Fructose-6-
phosphate 
• 3.55 (quadruplet) 
• 3.65 (multiplet ~7) 
• 3.92 (multiplet ~18) 
• 4.11 (triplet) 
• 4.23 (triplet) 
Pyruvic Acid/ 
Pyruvate 
• 2.46 (singlet) 
cis-Aconitic 
Acid/ 
Aconitate 
• 3.43 (doublet) 
• 6.58 (singlet) 
Citric Acid/  
Citrate 
• 2.65 (doublet) 
• 2.53 (doublet) 
Isocitric acid/  
Isocitrate 
• 2.46 (mutliplet ~8) 
• 2.97 (mutliplet ~6) 
• 3.98 (doublet) 
Oxoglutaric 
acid/  
alpha-
ketoglutarate 
• 2.43 (triplet) 
• 2.97 (triplet) 
Oxaloacetate • 2.377 (singlet) 
Succinic Acid/ 
Succinate 
• 2.393 (singlet) 
Fumaric Acid/ 
Fumarate 
• 6.51 (singlet) 
L-Malic acid/ 
Malate 
• 2.35 (quadruplet) 
• 2.66 (doublet) 
• 4.29 (doublet) 
L-Lactic acid • 1.324 (doublet) 
• 4.101 (quadruplet) 
Itaconic Acid/ 
Itaconate 
• 3.40 (singlet) 
• 5.85 (singlet) 
• 6.33 (singlet) 
2-
Ketobutyrate 
• 1.07 (triplet) 
• 2.76 (quadruplet) 
Miscellaneous  
Choline • 3.189 (singlet) 
• 3.507 (doublet) 
• 4.056 (quadruplet) 
Citrulline 
 
• 1.56 (multiplet ~12) 
• 1.87 (multiplet ~11) 
• 3.14 (multiplet ~6) 
• 3.74 (quadruplet) 
Ornithine • 1.727 (multplet ~5) 
• 1.826 (multiplet ~5) 
• 1.933 (multiplet ~7) 
• 3.046 (triplet) 
• 3.774 (triplet) 
Acetic Acid/ 
Acetate 
• 1.91 (singlet) 
L-Cystine 
 
• 3.18 (quadruplet) 
• 3.38 (quadruplet) 
• 4.10 (quadruplet) 
Glycerophosp
hocholine 
• 3.20 (singlet) 
• 3.63 (quadruplet) 
• 3.90 (multiplet ~13) 
• 4.30 (multiplet ~9) 
Phosphoenolp
yruvate 
• 5.18 (singlet) 
• 5.36 (singlet) 
Phosphocholi
ne 
• 3.21 (singlet) 
• 3.59 (singlet) 
• 4.17 (singlet) 
3-
Hydroxybutyra
te 
• 1.204 (doublet) 
• 2.314 (quadruplet) 
• 2.414 (quadruplet) 
• 4.160 (multiplet ~6) 
Hydroxyaceto
ne 
• 2.172 (singlet) 
• 3.257 (singlet) 
• 4.260 (singlet) 
Creatine 
Phosphate/ 
Phosphocreati
ne 
• 3.03 (singlet) 
• 3.93 (singlet) 
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Creatine • 3.02 (singlet) 
• 3.92 (singlet) 
Creatinine • 3.03 (singlet) 
• 4.05 (singlet) 
Glycolate • 3.94 (singlet) 
Urea • 5.78 (singlet 
Malonate • 3.11 (singlet) 
Formic Acid/ 
Formate 
• 8.44 (singlet) 
Fumarate • 6.51 (singlet) 
Pantothenate 
(Vit B5?) 
• 0.88 (singlet) 
• 0.92 (singlet) 
• 2.41 (triplet) 
• 3.39 (singlet) 
• 3.43 (quadruplet) 
• 3.51 (doublet) 
• 3.98 (singlet) 
Folate/Folic 
Acid 
• 2.11 (mutliplet ~10) 
• 2.33 (mutliplet ~6) 
• 4.20 (quadruplet) 
• 4.30 (triplet) 
• 6.42 (doublet) 
• 7.50 (doublet) 
• 8.01 (doublet) 
• 8.49 (singlet) 
Niacinamide 
(Nicotinamide) 
• 7.58 (quadruplet) 
• 8.24 (quadruplet) 
• 8.70 (quadruplet) 
• 8.92 (singlet) 
Inosinic Acid • 4.02 (quadruplet) 
• 4.36 (doublet) 
• 4.50 (triplet) 
• 6.13 (doublet) 
• 8.21 (singlet) 
• 8.55 (singlet) 
Glutathione • 2.15 (multiplet ~6) 
• 2.54 (multiplet ~10) 
• 2.97 (quadruplet) 
• 3.78 (multiplet ~5) 
• 4.20 (quadruplet) 
Purine/Pyrimidine metabolism 
AMP • 4.01 (doublet) 
• 4.36 (doublet) 
• 4.50 (doublet) 
• 6.12 (doublet) 
• 8.23 (singlet) 
• 8.58 (singlet) 
ATP • 4.211 (multiplet ~5) 
• 4.284 (quadruplet) 
• 4.394 (triplet) 
• 4.507 (singlet) 
• 4.619 (triplet) 
• 6.127 (doublet) 
• 8.239 (singlet) 
• 8.526 (singlet) 
Allantoin/ 
Allantoic Acid 
• 5.38 (singlet) OR 
• 5.34 (triplet) 
Cytosine • 5.96 (doublet) 
• 7.49 (doublet 
Cyclic AMP • 4.34 (doublet) 
• 4.53 (doublet)  
• 6.16 (singlet) 
• 8.22 (singlet) 
NAD(H) • 4.225 (multiplet ~5) 
• 4.353 (doublet) 
• 4.373 (multiplet ~3) 
• 4.434 (multiplet ~4) 
• 4.499 (triplet) 
• 6.027 (doublet) 
• 6.088 (doublet) 
• 6.122 (doublet) 
• 8.142 (singlet) 
• 8.207 (multiplet ~4) 
• 8.406 (singlet) 
• 8.839 (doublet) 
• 9.152 (doublet) 
• 9.332 (singlet) 
NADP(H) • 4.23 (multiplet ~5) 
• 4.29 (multiplet ~5) 
• 4.37 (triplet) 
• 4.45 (triplet) 
• 4.52 (triplet) 
• 4.56 (multiplet ~5) 
• 4.65 (triplet) 
• 5.10 (triplet) 
• 6.12 (doublet) 
• 6.21 (doublet) 
• 8.21 (singlet) 
• 8.24 (quadruplet) 
• 8.49 (singlet) 
• 8.88 (doublet) 
• 9.19 (doublet) 
• 9.36 (singlet) 
Table 4.1: 1H-NMR identifiable 
compounds  
A list of metabolites and their expected 
ppm, according to the HMDB, Chenomx 
and NMR reference tables. Each 
compound will produce all peaks indicated 
in the table, if it is truly present in samples. 
This served as a metabolite ID resource 
and a personal reference during 
subsequent work. 
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4.2.2.2. Preliminary screen data handling – integral analysis 
To compare changes between conditions and over time, spectra were ‘binned’ into 
specific ppm segments and integrals were calculated from these defined regions. For 
this preliminary data set, variable size integral regions were chosen, rather than uniform 
and regular regions that spanned the full ppm scale. This aimed to reduce the data load 
for analysis and allowed selection of whole peaks within individual integrals. Integral 
bins were selected as one bin per spectral peak, with ppm regions as listed in Table 4.2. 
These integrals were then plotted as stimulatory conditions versus time. Representative 
and tentatively assigned graphs are shown in Figures 4.7 and 4.8 for supernatant and 
cell extract integrals respectively. From these graphs, it is clear there was considerable 
variability between spectra, and that further data processing is required prior to 
analysing in this way. This screening experiment was not repeated as further technical 
optimisations were identified. 
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Integral Number Integral Region (ppm)  Integral Number Integral Region (ppm) 
1 8.511 8.432  45 3.585 3.571 
2 8.291 8.136  46 3.57 3.553 
3 8.125 7.981  47 3.553 3.519 
4 7.905 7.842  48 3.518 3.477 
5 7.823 7.780  49 3.477 3.445 
6 7.772 7.725  50 3.444 3.381 
7 7.722 7.676  51 3.372 3.344 
8 7.668 7.643  52 3.344 3.308 
9 7.642 7.572  53 3.307 3.278 
10 7.569 7.532  54 3.276 3.223 
11 7.456 7.408  55 3.218 3.195 
12 7.408 7.357  56 3.195 3.177 
13 7.357 7.309  57 3.17 3.084 
14 7.309 7.272  58 3.081 2.998 
15 7.219 7.168  59 2.794 2.737 
16 7.168 7.095  60 2.714 2.661 
17 7.095 7.024  61 2.661 2.621 
18 7.024 6.970  62 2.583 2.530 
19 6.97 6.835  63 2.529 2.491 
20 6.835 6.716  64 2.491 2.471 
21 6.716 6.572  65 2.471 2.429 
22 6.076 5.952  66 2.428 2.390 
23 5.952 5.591  67 2.389 2.368 
24 5.282 5.186  68 2.366 2.331 
25 4.28 4.211  69 2.33 2.234 
26 4.206 4.161  70 2.226 2.171 
27 4.161 4.094  71 2.147 2.100 
28 4.094 4.055  72 2.075 2.012 
29 4.048 4.030  73 2.011 1.950 
30 4.03 4.014  74 1.953 1.858 
31 4.014 3.993  75 1.858 1.775 
32 3.993 3.958  76 1.767 1.711 
33 3.958 3.931  77 1.711 1.625 
34 3.925 3.876  78 1.583 1.500 
35 3.872 3.812  79 1.494 1.467 
36 3.811 3.791  80 1.359 1.305 
37 3.79 3.770  81 1.303 1.217 
38 3.77 3.755  82 1.217 1.164 
39 3.755 3.748  83 1.064 1.028 
40 3.748 3.697  84 1.028 1.000 
41 3.687 3.649  85 1 0.980 
42 3.644 3.620  86 0.98 0.946 
43 3.618 3.598  87 0.946 0.909 
44 3.598 3.586  88 0.06 -0.054 
  
Table 4.2: Integral regions for preliminary 1H-NMR screen data handling 
Cells seeded at 600,000 cells and either mock-infected or challenged with S. pneumoniae (D39, 
MOI 10), then sampled over a 24 hour period. Supernatants and cell extract spectra were 
acquired via the Lamour protocol on a 800Hz magnet. Spectra were binned and integrals 
calculated from these regions in Bruker TopSpin software, using raw NMR spectra data. Integral 
regions were selected as one peak per bin. Binned ppm regions and Integral numbers are 
indicated above with corresponding ppm regions shown for each; n=1.  
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Figure 4.7: NMR spectroscopy preliminary data handling – supernatant integrals 
Cells seeded at 600,000 cells and either mock-infected or challenged with S. pneumoniae 
(D39, MOI 10), then sampled over a 24 hour period. Supernatant spectra were acquired via 
the Lamour protocol on a 800Hz magnet. Spectra were binned and integrals calculated from 
raw NMR spectral data, using Bruker TopSpin software. Integrals were plotted using 
GraphPad, to show specific changes within that integral region, both over time and 
between the four supernatant conditions. Here just eight representative integral regions 
are shown, with tentative assignments; n=1. 
Blank = no cells, no bacteria; spn = no cells with S. pneumoniae; MI = mock-infected 
BMDMs; Inf = S. pneumoniae-challenged BMDMs. (BCAAs = Branched-chain amino acids, 
TSP = Trimethylsilylpropanoic acid,) 
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Figure 4.8: NMR spectroscopy preliminary data handling – cell extract integrals 
Cells seeded at 600,000 cells and either mock-infected or challenged with S. 
pneumoniae (D39, MOI 10), then sampled over a 24 hour period. Cell extract spectra 
were acquired via the Lamour protocol on a 800Hz magnet. Spectra were binned and 
integrals calculated from raw NMR spectral data, using Bruker TopSpin software. 
Integrals were plotted using GraphPad, to show specific changes within that integral 
region, both over time and with comparison made between the two cell extract 
conditions. Here just eight representative integral regions are shown, with tentative 
assignments; n=1. 
MI = mock-infected BMDMs; Inf = S. pneumoniae-challenged BMDMs. (BCAAs = 
Branched-chain amino acids, TSP = Trimethylsilylpropanoic acid,) 
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4.2.3. NMR Spectroscopy method optimisation  
Following the preliminary screen, there were aspects of the technique and experimental 
design that required further optimisation. This included optimising the number of cells 
used in preparations, understanding the influence of culture media and the bacterial 
challenge protocol on the resulting spectra, and characterising the expected spectral 
profiles after BMDM CAM and AAM stimulation, as potential controls for macrophage 
activation status. 
 
4.2.3.1. Method optimisation – The influence of cell number 
Increasing the cell number in sample preparations aimed to improve both spectral 
resolution and intensity, for supernatant and cell extract profiles. BMDMs were seeded 
at either a low (5x105cells) or high (2x106cells) density. Samples were taken from both 
an early 4 hour and late 12 hour time point, following mock-infection or S. pneumoniae 
challenge. The resulting spectra are shown in Figures 4.9 and 4.10. By overlaying the 
supernatant spectra, there were no identifiable differences between the 4 hour profiles. 
The most discernible difference after 12 hours was the increased lactate peak at 
~1.3ppm. This increase correlated with increased cell number, and with the presence of 
bacteria. Additionally, the peak corresponding to acetate at ~1.9ppm was very distinct 
when bacteria were grown independently but was also detectable in S. pneumoniae-
challenged cells, particularly those at a higher cell density. The minimal differences seen 
between supernatant samples could be due to the overwhelming metabolite content of 
DMEM, and the low sensitivity of NMR spectroscopy, thus making analysis of these 
spectra quite challenging. When examining the cell extract spectra in the same way, an 
increased cell number produced more prominent and defined peaks, allowing 
comparative analysis of spectra to be much easier. However, due to the limited cell 
numbers available from each murine bone marrow preparation, the use of 2x106cells 
per condition was not feasible for future studies; therefore an intermediate density of 
1x106cells was chosen as a suitable compromise for further work. 
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Figure 4.9: NMR spectroscopy optimisation: different cell densities – cell supernatants 
Cells were seeded at either a low (5x105cells) or high (2x106cells) density, before being mock-
infected or challenged with S. pneumoniae (D39 MOI 10). Supernatants were collected directly, 
and NMR spectra acquired on a 800Hz magnet. Figures are annotated to indicate sample 
condition: blank = no cells, no bacteria; spn = no cells with S. pneumoniae; MI = mock-infected 
BMDMs; INF = S. pneumoniae-challenged BMDMs. n=1 
A) Supernatant samples collected after 4 hour stimulation. No discernible differences seen. 
B) Supernatant samples collected after 12 hour stimulation, following 4 hour PBS wash and 
media replacement. Increases at 1.3ppm (lactate) and 1.9ppm (acetate) with bacterial challenge. 
A 
B 
 132 
  
A 
B 
Figure 4.10: NMR spectroscopy optimisation: different cell densities – cell extracts 
Cells were seeded at either a low (5x105cells) or high (2x106cells) density, before being mock-
infected or challenged with S. pneumoniae (D39 MOI 10). Cell extracts were prepared via 
methanol extraction and NMR spectra acquired on a 800Hz magnet. Figures are annotated to 
indicate sample condition: MI = mock-infected BMDMs; INF = S. pneumoniae challenged 
BMDMs (5x105cells). n=1 
A) Cell extract samples after 4 hour stimulation. Spectra definition improved with increased cell 
number. 
B) Cell extract samples prepared after 12 hour stimulation, following 4 hour PBS wash and media 
replacement. Spectra definition improved with increased cell number. 
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4.2.3.2. Method optimisation – The influence of culture media on spectral profiles 
To understand how cell culture media contributed to the spectra of supernatants, the 
influence of HIFCS was specifically assessed. There are no definable lists for what can be 
found in calf serum, and it can be subject to batch variation from suppliers, hence it 
incurs unwanted variation between spectra. To investigate this, DMEM and HIFCS were 
sampled both independently and in combination, as shown in Figure 4.11. This 
confirmed the technical challenges that HIFCS may present for analysis; it is rich in 
protein, which distorts the 1H-NMR baseline, making phasing and peak definition very 
poor. It was also difficult to scale the TSP in the HIFCS-only spectra to align with the two 
other spectra shown, without getting incredibly high background noise. However, as 
HIFCS was only used at 10% in DMEM during experiments, these issues are lessened, as 
shown in the red spectra of Figure 4.11. The two compounds that look like they were 
dominant in HIFCS are at ~1.33 and ~2.04ppm, which may correlate with metabolite 
chemical shifts of lactate and/or threonine, and glutamate respectively. HIFCS is used as 
an essential supplement in the BMDM culture system, therefore it was not omitted, but 
precaution was taken from this point to use the same batch for all comparable 
experiments, where physically possible. 
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Figure 4.11: NMR spectroscopy optimisation: HIFCS 
1H-NMR spectra are shown for HIFCS only (top, green), DMEM+10% HIFCS (middle, red) and 
DMEM only (bottom, blue). Samples were diluted 300μl:300μl in 70% D2O PBS with 167μM 
TSP and measured on a 800Hz magnet. Black arrows indicate regions of interest as follows: 
0ppm indicates TSP, 1.3ppm indicates lactate and/or threonine, and 2.04ppm correlates 
with glutamate. n=1 
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Metabolite spiking of DMEM was also trialled, as an aid to metabolite identification (ID). 
Figure 4.12 shows the resulting spectra of DMEM spiked with saturated solutions of 
glucose, glycine, glutamine and glutamate. Each of the indicated compounds produce a 
clear and distinct chemical shift. That said, some compounds, for example glutamate, 
produced a more acidic pH and could therefore cause an undesirable pH shift, making 
spectra harder to align and ID. Additionally, the concentrated spike of glycine dominated 
the spectrum intensity, making it difficult to reliably scale and align to TSP. This spiking 
technique is ideally used for identifying compounds in clustered regions, compounds at 
low concentrations or for confirming tentative metabolite IDs. 
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Figure 4.12: NMR spectroscopy optimisation: metabolite spiking 
DMEM was spiked with powdered D-glucose, L-glycine, L-glutamine or L-glutamate, then 
diluted 300μl:300μl in 70% D2O PBS with 167μM TSP. Spectra were obtained on a 800Hz 
magnet. Spectra are annotated to indicate compound name and suspected resulting 
peaks: DMEM only (bottom, blue), DMEM with glutamate (red), DMEM with glutamine 
(green), DMEM with glycine (purple), DMEM with glucose (top, yellow). Black arrows 
indicate the proposed peaks for the metabolites used. Spectra have been aligned to a TSP 
reference but have been scaled to aid the visualisation of spiked compound peaks. 
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4.2.3.3. Method optimisation – A comparison between CAM and AAM stimuli to S. 
pneumoniae challenge in BMDMs 
To study the effects of S. pneumoniae challenge on BMDM metabolism, and to compare 
to responses reported in the literature, LPS and IL-4 were used as stimuli associated with 
the CAM and AAM phenotypes respectively. After 4 hours, all cells were washed, treated 
with antibiotics to remove extracellular bacteria, and media replaced until samples were 
collected at either 8 hours or 20 hours post-stimulation. Spectral comparisons were 
conducted via manual inspection in TopSpin software, with spectra from supernatants 
and cell extracts shown in Figures 4.13 and 4.14 respectively.  
In Figure 4.13, apart from changes to lactate and acetate peaks at ~1.3 and ~1.9ppm 
respectively, there were no visually discernible differences between the supernatant 
spectra of mock-stimulated or S. pneumoniae-stimulated cells, at either time point. Both 
S. pneumoniae challenge and LPS stimulation increased lactate in the supernatant. 
Likewise, in cell extract samples, one of the most distinct changes was the increase to 
lactate after both LPS and S. pneumoniae stimulation. Furthermore, the cell extract 
spectra were not dominated by high levels of glucose or DMEM components, making it 
much easier to identify changes and ID metabolites; for example, differences can be 
seen in Figure 4.14A at 2.42ppm for S. pneumoniae-challenged and LPS-stimulated 
spectra compared to the rest, and in Figure 4.14B, differences can be seen at 1.17ppm 
for IL-4, at 3.06 and 3.72ppm for mock-infected, and at 3.24ppm for both IL-4- and S. 
pneumoniae-challenged conditions. While these could be genuine differences induced 
by the conditions, it must be considered that carry through of external metabolites or 
contaminates could be present – this is likely to be the case for the large singlet peak at 
3.72ppm for the mock-infected spectrum of Figure 4.14B. These results advocate the 
use of cell extract profiles, to provide more detailed changes to metabolite levels, than 
those seen for supernatant spectra. Fewer regions of these spectra overlap and are not 
dominated by components of the cell culture media. It also demonstrated that LPS can 
induce a CAM status, making it a useful pro-inflammatory control stimulus, whilst IL-4 
would be less valuable in this study. 
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A 
Figure 4.13: NMR spectroscopy optimisation: comparison of BMDM supernatant 
profiles after S. pneumoniae challenge, CAM or AAM stimulation after 8 and 20 hours 
Cells were seeded at 1x106cells, treated as per key, with 1 hour on ice and 3 hours incubation. At 
4 hours, all cells were treated with 20ug/ml Gentamycin and 40U/ml Penicillin, before media was 
replaced and cells returned to incubator. Supernatants were collected directly, and spectra 
acquired on a 800Hz magnet. Images are annotated as follows: Blank = no cells, no bacteria; spn 
= no cells with S. pneumoniae; MI = mock-infected BMDMs; Inf = S. pneumoniae-challenged 
BMDMs (D39, MOI 10); IL-4 = BMDMs with 10ng/ml IL-4; LPS = BMDMs with 100ng/ml LPS. n=1 
A) Supernatant profiles from 8 hours post-stimulation 
B) Supernatant profiles from 20 hours post-stimulation. Glucose, lactate and acetate are labelled. 
B 
Acetate 
Lactate 
Lactate 
Glucose 
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Figure 4.14: NMR spectroscopy optimisation: comparison of BMDM cell extract 
profiles after S. pneumoniae challenge, CAM or AAM stimulation after 8 and 20 hours 
Cells were seeded at 1x106cells, treated as per key, with 1 hour on ice and 3 hours incubation. 
At 4 hours, all cells were treated with 20ug/ml Gentamycin and 40U/ml Penicillin, before 
media was replaced and cells returned to incubator. Cell extracts were prepared by methanol 
extraction, and spectra acquired on a 800Hz magnet. Images are annotated as follows: MI = 
mock-infected BMDMs; Inf = S.pneumoniae-challenged BMDMs (D39, MOI 10); IL-4 = BMDMs 
with 10ng/ml IL-4; LPS = BMDMs with 100ng/ml LPS. n=1 
A) Cell extract profiles from 8 hours post-stimulation 
B) Cell extract profiles from 20 hours post-stimulation. Lactate and peaks of unknown origin 
are labelled. Unknowns were contaminants or metabolites not identified by spectral tables. 
A 
B 
Lactate 
Lactate 
unknown 
unknown 
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4.2.3.4. Method optimisation - The influence of temperature on early metabolite 
profiles 
The use of a 4°C incubation immediately after bacterial stimulation was questioned. It 
was hypothesised to affect the immediate responses of macrophages to bacteria, and 
that cellular responses could be different if cells were instead able to immediately 
respond at 37°C. Therefore, an alternative protocol was tested, whereby cells were 
stimulated, and the culture plate centrifuged briefly, before immediately transferring to 
a 37°C incubator. This aimed to increase adherence of bacteria to macrophage surfaces, 
without needing a reduced temperature. It also assessed whether early metabolite 
changes could be detected within four hours post-stimulation. Supernatant and cell 
extract samples were collected at 1, 2, 3, and 4 hours post-stimulation, both with and 
without the initial hour at 4°C. Once again, visual comparisons of spectra were carried 
out in TopSpin software.  
Gradual differences could be seen over this time, with the most significant comparisons 
between the 1 hour and 4 hour post-stimulation groups. After one hour, the main 
noticeable difference in supernatant spectra was the emergent singlet peak at 
~1.92ppm, in S. pneumoniae-only and BMDM S. pneumoniae-challenged groups. This 
correlated with acetate production by the bacterium, and was not previously observed 
in supernatant spectra until after 2 hours, when cells were first cooled upon addition of 
bacteria. Figure 14.15 specifically shows the 4 hour supernatant spectra from the six 
conditions sampled, with overlaid regions of interest indicated. After 4 hours 
stimulation, changes in the supernatant spectra were seen at: 1.33ppm (lactate), 
whereby presence of cells and/or bacteria increased this peak and the largest increase 
seen for S. pneumoniae-challenged BMDMs and LPS-stimulated BMDMs; 1.92ppm 
(acetate), which only increased in S. pneumoniae-only or S. pneumoniae-challenged 
BMDMs; 2.38ppm (oxaloacetate, not confirmed by spiking but displayed similar ppm 
shift), which only decreased in S. pneumoniae-only or S. pneumoniae-challenged 
BMDMs and could be associated with the emergent peak at 1.92ppm, as a product of 
streptococcal metabolism. The rest of the supernatant spectra could be overlaid without 
any other discrepancies or misalignments; hence this further supported the idea that 
supernatant samples were not going to be as valuable in revealing metabolic changes 
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between these conditions, due to dominance of media components in these samples. 
The focus of future work from here on was therefore on the analysis of cell extracts.  
Upon analysing the cell extracts, no differences between spectra or conditions could be 
identified after 1 hour stimulation, but small changes became visible after 2 hours, for 
example, at 3.56ppm (choline/phosphocholine, not confirmed by spiking but displayed 
expected ppm shift), which increased in IL-4 stimulated cells. The most distinct changes 
were seen after 4 hours, suggesting that this should be the earliest time point sampled. 
Figure 14.16 shows an overview of regions 0-5ppm of cell extracts after 4 hours 
stimulation, with overlaid regions of interest highlighted. After 4 hours S. pneumoniae-
challenge, the intensity of the spectrum had lowered compared to other conditions, 
with only a few regions remaining consistent between all groups – such as at 1.40ppm, 
2.31ppm and 3.36ppm, each of which cannot accurately be correlated with a specific 
metabolite. Despite this, it was suggested that LPS and S. pneumoniae stimulation could 
induce different metabolic changes. These results suggest that the preliminary hour at 
4°C, as part of the infection protocol, does not make a difference to cell extract spectra, 
if sampling at or after a 4 hour period. 
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Figure 4.15: NMR spectroscopy optimisation: the effect of immediate incubation 
on supernatant metabolite profiles  
Cells were seeded at 1x106cells, treated as per key, centrifuged at 9000rpm for 3 minutes 
and immediately incubated for 4 hours. Supernatants were collected directly and spectra 
obtained on a 800Hz magnet. Images annotated as follows: Blank = no cells, no bacteria; 
spn = no cells with S. pneumoniae; MI = mock-infected BMDMs; Inf = S. pneumoniae-
challenged BMDMs (D39, MOI 10); IL-4 = BMDMs with 10ng/ml IL-4; LPS = BMDMs with 
100ng/ml LPS. 
A) Supernatant spectra from 4 hour post-stimulation samples only. 
B) Regions of interest from all 4 hour post-stimulation groups, showing overlaid spectra 
from Figure 4.15A. Lactate, oxaloacetate (tentative assignment) and acetate and have 
labelled. 
B 
A 
Acetate 
Oxaloacetate 
Lactate 
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Figure 4.16: NMR spectroscopy optimisation: the effect of immediate incubation 
on cell extract metabolite profiles 
Cells were seeded at 1x106cells, treated as per key, centrifuged at 9000rpm for 3 minutes 
and immediately incubated for 4 hours. Cell extracts were obtained by methanol extraction 
and spectra obtained on a 800Hz magnet. Images annotated as follows: MI = mock-infected 
BMDMs; Inf = S.pneumoniae challenged BMDMs (D39, MOI 10); IL-4 = BMDMs with 10ng/ml 
IL-4; LPS = BMDMs with 100ng/ml LPS. 
A) Cell extract spectra from 4 hours post-stimulation samples only. 
B) Regions of interest from all 4 hour post-stimulation groups, showing overlaid 4 hour 
spectra from Figure 4.16A. Glucose, choline (tentative assignment) and peaks of unknown 
origin are labelled. Unknowns are contaminants or not metabolites not identified by 
spectral tables. 
A 
B 
unknown 
Glucose 
Choline 
unknown 
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To verify any effect of cooling versus centrifugation on BMDM metabolism, three 
biological preparations were collected from mock-stimulated BMDMs, with one 
triplicate set from each donor exposed to a temperature shift from ~4°C to 37°C, and a 
second triplicate set centrifuged and immediately transferred to 37°C. All samples were 
prepared after a total of 4 hours. In Figure 4.17, representative spectra are shown from 
just one donor. Interestingly, cells exposed to an hour at 4°C produced more consistent 
and reproducible cell extract preparations, with fewer variations both between donors 
and experimental replicates. Therefore this method was continued with, and time points 
were restricted to no earlier than 4 hours, to allow plenty of time for cells to respond at 
37°C, prior to sampling. 
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Figure 4.17: NMR spectroscopy optimisation: The effect of varying temperature on 
unstimulated BMDM cell extracts 
Cells were seeded from three biological donors at 1x106cells. One triplicate set from each 
donor was sampled after 1 hour at 4°C (on ice) followed by 3 hours incubation at 37°C. A 
second triplicate set was sampled after centrifugation at 9000rpm for 3 minutes and 
immediate incubation for 4 hours at 37°C. Cell extracts were obtained via methanol 
extraction and spectra obtained on a 800Hz magnet. Biological n=3, experimental n=2. 
A) Spectra from cells left at 4°C for 1 hour followed by 3 hours incubation (1) or after 
centrifugation and immediate incubation at 37°C for 4 hours (2). Only the 4.1-0.7ppm region 
is shown, for clear visualisation of spectra. Representative cell extract spectra shown from 
one biological donor.  
B) Higher resolution image of overlaid spectra from Figure 4.16A, showing between 3.10-
1.85ppm, indicating the reproducibility of these preparations. Spectra from cells left on ice 
for 1 hour followed by 3 hours incubation are shown at the top of the figure (1). Spectra 
from cells provided centrifugation and immediate incubation for 4 hours are shown at 
bottom of figure (2). Spectra are more defined and consistent for group (1). 
A 
B 
(1) 
(2) 
(1) 
(2) 
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4.2.9. Using 1H-NMR Spectroscopy to assess metabolic changes in BMDMs, following 
stimulation with LPS or S. pneumoniae 
One-dimensional 1H-NMR Spectroscopy was used to consider the metabolic changes of 
murine BMDMs during S. pneumoniae challenge or LPS stimulation. To complement 
work shown previously using the Seahorse Extracellular Flux Analyser in Chapter 3, an 
early 4 hour and late 12 hour time point were both assessed. Following optimisation of 
this technique, only cell extract spectra were acquired and analysed, as they offered a 
more robust strategy for identifying changes to metabolic profiles after BMDM 
stimulation. 
As described previously, the cell extracts of samples were prepared using an 80% 
methanol:water extraction method and acquired on a 800MHz spectrometer, via the 
pulse sequence ‘ah_robust5.ptg’. A total of four murine donors were used, with 
duplicate extractions for each condition. To process the raw NMR data, a MATLAB 
algorithm was used to align, normalise, and calculate integral regions. An external 
collaborator, Dr. Stephen Reynolds from the University of Sheffield Jessop Fertility 
Research Centre, developed and ran this MATLAB script. The script processed all 
spectra, aligning to the average spectral position, replacing the water region (4.5-
5.2ppm) with random integral values, binning the whole spectral region in equal 
0.04ppm segments (-0.5-11ppm), and normalising to the area under each spectrum, 
before exporting the integral values of the processed data in plain text files. A copy of 
the MATLAB script can be found in the Appendix. The data produced from this script 
was used for the subsequent statistical analysis.  
One of the most accessible resources in the field of metabolomics is the free online tool 
MetaboAnalyst. This is an online R-based server, currently maintained by the Jianguo 
Xia lab at McGill University in Québec, Canada. It provides different methods of 
processing and analysing metabolomic data, from both Mass Spectrometry (MS) and 
NMR Spectroscopy sources (Xia Lab 2017). Using this program, a ‘Time series/Two-
factor Design’ analysis was performed on the integral bins calculated from the MATLAB 
algorithm, with a Two-factor independent sample study design, and using the data 
format shown in Figure 4.18. In this model, statistical functions were calculated, 
including an interactive Principal Component Analysis (iPCA), Heatmap visualisation, 
Two-way ANOVA and ANOVA Simultaneous Component Analysis (ASCA). Initially, all 
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samples and all binned integrals were used, to assess for variability and overall trends 
in the data. However, three samples varied significantly from the rest, and were 
identified as outliers via interactive PCA and heatmap analysis. These spectra were 
affected by either carry-through of supernatant metabolites or ineffective spectral 
alignment, therefore they were eliminated from further analysis. Regions of spectra 
known to be noise were also unwantedly flagged up as regions of interest. With this in 
mind, the data used for subsequent analysis was modified, to eliminate the problematic 
samples (MI4.2.1502, INF4.1.0203 and INF4.1.1403) and the following spectral regions: 
Bins1-50 (11-9ppm, spectral noise), Bins73-92 (8-7.3ppm, spectral noise), Bins147-164 
(5.1-4.4ppm, water region) and Bins262-287 (0.5--0.5ppm, TSP region). This aimed to 
provide a more directed analysis, on robust samples and using only the regions of 
spectra containing peaks. 
The revised data set was analysed, with the resultant heatmap and iPCA plot shown in 
Figures 4.19 and 4.20 respectively. From the heatmap, it could be stated that S. 
pneumoniae challenge induces a very different intracellular metabolic profile, compared 
to mock-stimulated or LPS-stimulated cells, after 12 hours. From this figure, regions of 
interest were selected, which increased either during S. pneumoniae or LPS challenge of 
BMDMs, compared to the mock condition. This provided specific spectral regions to 
identify, rather than identifying the whole spectrum. To identify the metabolites found 
in these spectral regions, Table 4.1, the HMDB, Bruker TopSpin and Chenomx software 
were used. When considering the interactive PCA plot, 12 hours S. pneumoniae-
challenge caused the largest inherent sample variation compared to other sample 
groups, demonstrated by their group separation and high PC1 values. This further 
demonstrated that cells challenged with S. pneumoniae present a very different NMR 
spectra and metabolic phenotype compared to unstimulated or LPS-stimulated cells.  
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Figure 4.18: Format of processed 1H-NMR integrals for MetaboAnalyst analysis 
Data inputted to MetaboAnalyst must be formatted appropriately. Here shown is the format 
required for a ‘Time Series or Two-factor Design’ module, where data used are ‘spectral bins’, 
separated as ‘samples in rows’. Cell extract integrals are shown, and normalised against the 
sum of all 287 integrals, from -0.5-11ppm. The columns are titled: Sample (ID code for each 
sample spectra), Time (4 or 12), Subject (stimulatory condition) and Bin numbers (1-287). 
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Figure 4.19: 1H-NMR MetaboAnalyst Results - Heatmap 
Cells were seeded at 1x106cells, treated as per key, with one hour on ice and 4 hours incubation. 
Cell extracts were obtained by methanol extraction, after either 4 hour stimulation, or 12 hour 
stimulation, following antibiotic treatment and media replacement at 4 hours. Spectra were 
obtained on a 800Hz magnet. Image annotated as follows: MI = mock-infected; Inf = S. pneumoniae 
challenge (D39, MOI 10); LPS = 100ng/ml LPS. Heatmap generated using MetaboAnalyst, after data 
was processed via MATLAB. Data was sum normalised and auto-scaled. Three samples were 
excluded as outliers due to contamination, and ppm regions containing noise were eliminated 
from analysis. The most significant bins are shown, as calculated via Two-way ANOVA with 
Bonferroni multiple testing correction (p<0.05). Rows represent spectral bins, and columns 
indicate stimulation groups. Colours specify a relative increase (red) or decrease (blue) in this area 
of the spectrum, as shown by the key. 
 150 
 
  
Figure 4.20: 1H-NMR MetaboAnalyst Results – PCA plot 
Cells were seeded at 1x106cells, treated as per key, with one hour on ice and 4 hours 
incubation. Cell extracts were obtained by methanol extraction, after either 4 hour 
stimulation, or 12 hour stimulation, following antibiotic treatment and media replacement 
at 4 hours. Spectra were obtained on a 800Hz magnet. Image annotated as follows: MI = 
mock-infected; Inf = S.pneumoniae challenge (D39, MOI 10); LPS = 100ng/ml LPS. The 
interactive PCA plot generated using MetaboAnalyst online software. Data was sum 
normalised and auto-scaled prior to analysis. Three samples have been excluded as outliers, 
and ppm regions containing noise eliminated from analysis. Here, it is shown that 12 hour 
S. pneumoniae-challenged samples have a higher variation compared to all other samples, 
as separated by three principal component analyses. (NB. PCA analysis of original data set 
was used to distinguish outliers for subsequent analyses) 
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From the MetaboAnalyst results, integral regions of interest were further investigated. 
Once again, the HMDB, Chenomx Profiler and Table 4.1 were used to ID metabolites that 
corresponded to these integrals. The proposed metabolite IDs are shown in Table 4.2, 
and are listed as tentative/partial similarity, or high similarity. The partial similarity 
group present similar but weak spectral alignments and chemical shifts between this 
data set and compounds in spectral databases, whilst the high similarity demonstrate 
stronger correlations and more confident matches. These integral regions, or ‘bins’, 
have also been plotted separately in Figure 4.21, to show the changes between 
conditions. That said, further metabolite ID confirmation was needed, as these integral 
regions could result from multiple metabolite signals.  
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Bin no. Metabolite ID – tentative/partial similarity Metabolite ID – high similarity 
Bin128 - Itaconic Acid 
Bin140 Allantoin, Phosphoenolpyruvate,  - 
Bin170 Phophocholine, 6-Phosphogluconate, Fruc-
2,6-bis-P,  
- 
Bin173 Creatinine, Lactate, Rib-5-P, Isocitrate  Choline 
Bin174 Fruc-2,6-bis-P, Inosinic Acid, Glu-6-P, - 
Bin177 Betaine, Glycerophosphocholine Creatine/Creatine-P 
Bin178 Aspartate, Methionine, Serine, Glucose - 
Bin179 Glucose, 6-Phosphogluconate, Glycerol-3-P - 
Bin182 Dimethylglycine, Leucine, Glucose, Glu-6-P - 
Bin215 Oxaloacetate, Succinic acid, Pyruvate Glutamate, Glutamine 
Bin216 Proline, Malate Glutamate 
Bin221 Glutathione, Methionine, Acetylcholine Glutamine, Glutamate 
Bin223 Proline Glutamate 
Bin 227 - Acetate 
Bin 241 Threonine Lactate 
  
Table 4.3: 1H-NMR spectral regions of interest following MetaboAnalyst 
assessment: metabolite IDs 
Binned regions of interest identified from the data displayed in Figures 4.18, 4.19 and 4.20. 
Metabolite IDs have either been assigned to these regions, as tentative/partial similarity or 
as high similarity, compared to the expected chemical shifts and peak shapes of metabolites, 
as seen in spectral data tables and online databases. 
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Figure 4.21: 1H-NMR spectral regions of interest – processed integrals 
Cells were seeded at 1x106cells, treated as per key, with one hour on ice and 4 hours incubation. 
Cell extracts were obtained by methanol extraction, after either 4 hour stimulation, or 12 hour 
stimulation, following antibiotic treatment and media replacement at 4 hours. Spectra were 
obtained on a 800Hz magnet. Image annotated as follows: MI = mock-infected; Inf = 
S.pneumoniae challenge (D39, MOI 10); LPS = 100ng/ml LPS. Integral regions are plotted to 
show proposed changes to metabolite levels, following stimulation with either S. pneumoniae 
or LPS. Integrals were processed via MATLAB and plotted via GraphPad. Metabolites tentatively 
assigned using Table 4.1, 4.2 and online databases. Statistics were calculated via One-Way 
ANOVA with Dunnett’s multiple comparisons to the MI group from the same time point. 
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To ascertain whether these metabolite IDs were both correct and present in cell extract 
samples, individual compounds were used to spike D2O-PBS. This opportunity was also 
taken to test the detection of other compounds of interest, including arginine and 
succinic acid (succinate). Powdered metabolites were added to separate aliquots of 
buffer and pH adjusted to 7.8, to avoid ppm shift changes caused by strong acid or alkali 
solutions. This pH adjustment also correlated with standards seen for spectral libraries. 
An unstimulated cell extract was used for alignment and comparison, with the resultant 
and appropriate spectral regions shown for these spiked compounds in Figure 4.22. It 
was clear that arginine was not detectable in the cell extracts; therefore its utilisation in 
CAM metabolism could not be traced using this NMR Spectroscopy methodology. The 
same was also true of glutamine: some but not all its peaks are detected, which could 
be due to the high structural similarity with glutamate - which was detectable in the cell 
extract samples.  Metabolite spiking also confirmed itaconic acid and glycine presence 
in cell extract samples, and a tentative confirmation of choline and succinic acid, both 
potentially present at low concentrations. Itaconic acid, a distinguishable marker of the 
broken TCA cycle during CAM metabolism, was shown to be produced by BMDMs within 
12 hours LPS stimulation. Contrastingly, the same response was not seen for S. 
pneumoniae-challenged cells, indicating that the reported metabolic changes seen after 
LPS-stimulation, may not occur during live infection with this pathogen.  
To identify further metabolites in Figure 4.20, crosschecks were made using Table 4.1, 
the HMDB, Bruker TopSpin and Chenomx software. Other distinguishable compounds 
were acetate (Bin227) and lactate (Bin240-243), both of which increased during a 12 
hour challenge with S. pneumoniae and correlated with earlier findings. 
.  
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Figure 4.22: 1H-NMR spectral regions of interest – spiked compounds 
Powdered metabolites of interest were added to 70% D2O PBS with 167μM TSP, and pH adjusted 
to 7.8. Cells were seeded at 1x106cells, and cell extracts were obtained by methanol extraction. 
Spectra were obtained on a 800Hz magnet. The spectra of an unstimulated cell extract (blue) is 
shown, overlaid with spectra from spiked metabolites (red) - *cell extract of a previous 12hr LPS-
stimulated sample is shown here, as itaconic acid is not produced by unstimulated cells; n=1. 
L-Arginine 
Choline Itaconic acid* 
  L-Glutamic acid 
L-Glutamine 
Glycine 
Succinic acid 
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4.3. Discussion 
4.3.1. Chapter Summary 
This chapter outlines the attempted optimisation of NMR Spectroscopy to study murine 
BMDM metabolites, and the processes required for metabolomic analysis of spectra. 
Attention was made to ensure appropriate cell numbers were used for preparations, 
and to consider the influence of culture media and temperature changes of this model 
on the resultant spectra. The technique was then used to consider the metabolome of 
unstimulated BMDMs, compared to LPS-stimulated and S. pneumoniae-challenged cells. 
The overarching, novel conclusion of this chapter is that S. pneumoniae does not induce 
the same global metabolic changes as seen for LPS.  
Optimisation of NMR Spectroscopy, for the analysis of metabolic changes in cell culture 
samples, was initially discussed. Firstly, appropriate protocols were identified in the 
literature, with Ramm Sander and Lamour providing the two principal methods tested 
(Ramm Sander et al. 2013; Lamour et al. 2012). With the Ramm Sander whole cell 
approach, the preparation and run time for each sample was approximately half an 
hour, during which the cells settled and adhered to the bottom of the Shigemi tubes. 
This was problematic as samples were not homogenous during acquisition time, which 
could affect the resulting spectra. Additionally, the adherence of cells made it difficult 
to clean the tubes, which hindered upscaling this experiment to a larger sample set. 
Finally, the cells were still viable, metabolising and reacting to the environment inside 
the spectrometer, which was below 5°C and absent of nutrients. Therefore, it was 
considered that this protocol was not suitable to take forward. Contrastingly, the 
Lamour method was more labour-intensive, but provided a simple way of measuring 
changes between the intracellular and extracellular environment. Cell preparation 
required destruction of samples, therefore real-time analysis was not possible, but the 
Lamour protocols were used in favour of the shorter acquisition times and spectral 
quality. 
A preliminary screen of S. pneumoniae-challenged BMDMs was carried out, to assess 
visible metabolic changes over a 24 hour period. This data set was used to test 
preliminary analysis techniques, such as Chenomx and integral calculations. No distinct 
differences were seen for supernatants, apart from an overall decrease in the intensity 
of glucose peaks with pneumococcal challenge, which amplified over time. This could 
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have been due to an increased metabolic demand and elevated glycolysis; however, it 
was also considered that increased cell death typically occurs 16-24 hours after S. 
pneumoniae challenge (Dockrell et al. 2003b), therefore fewer viable cells may have 
contributed to these spectra. BMDMs could also have been overwhelmed and shifted 
towards increased apoptosis by excess bacterial growth at these later time points. This 
idea of reduced cell numbers was supported upon viewing the 16-24 hour spectra from 
corresponding cell extracts, as the intensity of the spectra also decreased with time. 
Another noted problem in this data set concerned warping of spectral baselines. These 
warped spectra could have been a result of poor manual phasing and baseline 
correction, or the presence of contaminants such as excess protein in the culture media. 
When plotting integrals with this data set, mis-alignments and potential contamination 
were identified. Prior to calculating or comparing integrals, spectra should be 
normalised and aligned appropriately. According to the literature, metabolomic NMR 
data processing and analysis is typically performed using numerical programming; for 
example with the use of programs such as R or MATLAB, many of which are written in-
house (Lamour et al. 2012; Ellinger et al. 2013). From here, technical optimisation was 
needed, particularly regarding sample extraction, metabolite ID and data handling 
methods. 
Initial optimisations included assessing the impact of cell number, culture media and the 
infection protocol on resulting spectra. An intermediate cell number was found to give 
clear and visible spectral readouts, and the undesirable effect of HIFCS in supernatant 
spectra was highlighted. The expected spectral profiles from CAM and AAM stimuli were 
assessed, for both supernatants and cell extracts. This demonstrated that LPS would be 
a worthwhile control for CAM activation, whilst IL-4 was not of primary interest, as this 
work focused instead on pro-inflammatory and CAM-type activation patterns rather 
than AAM-type. Upon reflection of these results, the appropriateness of a cell extract 
after 20 hour pneumococcal-challenge could be questioned. It has been documented by 
the Dockrell group that BMDMs undergo apoptosis from 16hr post-infection with S. 
pneumoniae (Marriott et al. 2005). Therefore sampling should occur prior to this to 
avoid cell loss, to provide more cells for NMR preparation and therefore increase the 
signal:noise ratio in cell extract spectra.  
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The influence of temperature changes in the infection protocol were also evaluated. 
Within the typical infection procedure, cells were first kept at 4°C (on ice) for one hour 
immediately after stimulation, before being transferred to a 37°C incubator for a further 
3 hours. This initial cooling correlates with previous studies carried out by the Dockrell 
group, and aims to increase bacterial adhesion to the BMDM cell surfaces, promoting 
synchronous phagocytosis across the whole cell population, once cells are transferred 
to 37°C (Gordon et al. 2000; Ali et al. 2003). It was considered that this temperature 
shock could hinder the immediate cellular responses to bacteria or hamper bacterial 
growth and virulence in this system. However, upon comparison between cooled and 
non-cooled conditions, no undesirable differences were observed in the spectrum. The 
original infection procedure was therefore continued with, to remain in-line with 
current practice by the Dockrell-Marriott group. 
Following these optimisation stages, NMR Spectroscopy was used to analyse the cell 
extract samples of BMDMs, after stimulation with LPS or S. pneumoniae, compared to 
the mock condition. Duplicate samples from four biological donors were used, and data 
was aligned and normalised via a collaboration with the University of Sheffield Jessop 
Fertility Research Centre. The subsequent data was analysed and visualised via 
MetaboAnalyst. Regions of interest were identified by assessing for 
increased/decreased integral values after pneumococcal or LPS challenge compared to 
the mock. Compounds such as glucose, glutamate, choline, succinate and itaconic acid 
were identified as key changes during these experiments. However, parts of the spectral 
regions of interest were in overlapped metabolite regions, making identification quite 
restricted. One of the largest issues here regarded glucose, which has seven major peaks 
between 3.1-3.9ppm. This could therefore mask changes to other low concentration 
compounds that produce similar chemical shifts. An analogous situation to this was also 
seen regarding the multiple ppm shifts for glutamate. Due to this, a limited number of 
metabolite IDs were confirmed. That said, a major finding here was the production of 
itaconic acid by LPS-stimulated macrophages, which was not seen during mock-
stimulation or pneumococcal challenge of BMDMs. 
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4.3.2. Chapter Discussion 
LPS is well documented as being a strong pro-inflammatory stimulus, known to cause 
distinct metabolic changes including increases to glycolysis, elevated succinate 
production and a shift in arginine metabolism towards NO production (Tannahill et al. 
2013; Rath et al. 2014). Here, 1H-NMR was used to identify metabolites in central carbon 
metabolism of BMDMs, including lactate, itaconic acid and glutamic acid, to propose 
that S. pneumoniae does not induce a strong change to CAM metabolism, like LPS does. 
A key finding here is the identification and confirmation of itaconic acid, specifically at 
5.68ppm, following LPS stimulation. This is interesting and noteworthy because this did 
not occur during S. pneumoniae challenge of BMDMs. The production of itaconic acid 
during LPS stimulation is thought to occur during arrest of the Krebs cycle, and is 
considered to play a part in antimicrobial activity of macrophages (O’Neill et al. 2016). 
This is a hallmark of pro-inflammatory macrophage activation, further supporting the 
idea that S. pneumoniae does not induce the same, strong CAM phenotype or metabolic 
changes. In addition to this, S. pneumoniae induced increases in lactate and acetate, 
which are likely due to increases in glycolysis and from pneumococcal metabolism 
respectively. Furthermore, it was considered that glutamate levels decreased during 
bacterial challenge, which could be due to an increased need to feed glutamate into the 
Krebs cycle, through conversion to α-ketoglutarate. Finally, with noted changes to 
arginine metabolism during pro-inflammatory stimulation, it was discouraging not to be 
able to identify this compound in our samples, particularly following LPS stimulation. 
This could be due to the low sensitivity of this technique, particularly in comparison to 
MS strategies. 
An explanation for the difference between LPS- and S. pneumoniae-stimulation could 
involve the strength of the initial host-pathogen interaction and subsequent activation 
of receptor pathways. LPS has been characterised as a TLR4 agonist, with well-defined 
intracellular pathway activation, via factors such as MyD88, which ultimately lead to NF-
kB activation (Koppe et al. 2012; Opitz et al. 2010); however S. pneumoniae presents an 
assorted range of surface proteins and PAMPs, as opposed to just one, with many 
antigens also hidden beneath the thick polysaccharide capsule of the bacteria. This could 
mean they remain undetected, perhaps until the capsule is degraded in the 
phagolysosome. This would therefore make it hard for the macrophage to bind, 
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recognise and respond to the pathogen in a swift manner. Wolf et al. previously 
discussed a related theory. They showed that intracellular degradation of lysozyme-
sensitive S. aureus – a pathogen normally capable of resisting lysosomal degradation – 
produced an elevated IFNβ cytokine response following activation of intracellular PRRs, 
compared to the wild-type strain. They describe how inflammation appeared in two 
waves: an initial activation after surface receptor engagement, followed by a second 
wave that correlated with bacterial phagosomal breakdown (Wolf et al. 2011). Further 
to this, macrophage responses to bacteria have been shown to be case-dependent, with 
cellular polarisation often variable in each instance. For example, Goldmann et al. 
described an unusual phenomenon following S. pyogenes infection of murine 
macrophages, whereby typical pro-inflammatory responses, such as cytokine release, 
were induced but were observed in association with up-regulation of Arginase, an AAM 
phenotypical marker, instead of the CAM-associated marker iNOS (Goldmann et al. 
2007). This could suggest that macrophage responses are unique to each pathogen, 
and/or that bacteria are able to subvert and/or manipulate some CAM-associated host 
responses, to sustain their own survival. The latter is thought to be the case for M. 
tuberculosis, which avoids lysosomal killing and persists in the intracellular environment 
through promoting macrophages into a more AAM phenotype (Lugo-villarino & 
Neyrolles 2014).   
 
4.3.3. Future work 
NMR Spectroscopy for metabolomic assessment of cell cultures had not previously been 
assessed at the University of Sheffield. This work provided a novel methodology both in 
the field and at this University. However, the lack of initial expertise resulted in a slow-
going experimental process, compared to well-established centres such as those found 
in London, Liverpool and Birmingham. Therefore in order to progress this work and 
verify findings at an increased pace, collaboration with external NMR metabolomic 
facilities would be desirable. This would allow access to informed workflows that have 
continuously evolved with the field – from initial NMR acquisition through to statistical 
and pathway analyses. This would also provide potential for high sample throughput, 
with the use of automated samplers and in-house spectral processing methods, all of 
which contribute to high quality and reproducible spectra that provide more informative 
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outcomes (Aranı´bar et al. 2006). Many publications in this field increasingly use tandem 
techniques, to achieve superior metabolite coverage, separation and sensitivity - for 
example by using chromatography with MS and NMR (Zhang et al. 2012); therefore 
working with metabolic centres would allow these set-ups to be accessed. A further 
benefit to this collaboration would also be the experience in data analysis, particularly 
concerning multivariate statistical analysis with reciprocal metabolite and pathway 
identification.  
One of the biggest challenges of this chapter concerned confirmation of metabolite ID, 
therefore this would be a major theme to continue with. A method that was not trialled 
here was 2D-NMR. This allows metabolites to be identified simultaneously via both 1H 
and 13C NMR, providing a way of cross-referencing the two spectra to aid metabolite 
ID. However, analysing this 2D-spectra requires specialist understanding and 
interpretation of J-coupling patterns, therefore it was not utilised here. Additionally, 
metabolite spiking was used to aid metabolite ID, however this can be a limitless activity 
– hence it was only performed with a select batch of compounds. That said, this targeted 
identification method could be continued, and accompanied using databases and 
software with wider metabolite ranges, to identify more compounds across the spectral 
region. Finally, a further method that could be used to aid metabolite ID is Statistical 
Total Correlation Spectroscopy (STOCSY), which looks for correlations in changes to peak 
intensities, which are statistically likely to be contributed by the same molecule. This 
only works on compounds with multiple peaks, but has been previously shown to aid 
metabolite ID of complex mixtures (Cloarec et al. 2005). 
NMR Spectroscopy could alternatively be used to trace isotope-labelled metabolic 
precursors through predetermined metabolic pathways using 13C-labelled compounds - 
glucose and glutamine are two of the most commonly used (Walther et al. 2012; Metallo 
et al. 2009). This allows the user to trace metabolism, through chasing an isotope label 
in metabolic compounds. However, this technique has a few drawbacks: a priori 
knowledge is required for the metabolic pathway of choice, making it difficult to use 
during extensive pathway discovery or screening; labelled compounds must be taken up 
by cells, so often central carbon metabolism is the focus of experimentation as this is 
typically rate-limiting for growth and survival in mammalian cells; the technique is very 
costly, as expensive labelled compounds, long acquisition times and a high demand for 
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computational or mathematical modelling are required (Cascante & Marin 2008; Malloy 
et al. 2013). Therefore this may not be suitable in the immediate future but would be 
ideal for longer term future studies. 
The field of NMR metabolomics is still progressing, and the use of NMR to study 
metabolomics has been largely overshadowed by MS techniques. However, it is 
developing to assess a wide range of samples, from bacteria and cell cultures, through 
to samples obtained directly from patients, such as blood, urine and tissue. This 
therefore brings with it a complex and varied methodology, with different preparations, 
extraction and acquisition steps required in each case. Here, only cell cultures were 
used. This allowed an experimental design that considered metabolites in both the 
extracellular and intracellular environments, using simple 1H-NMR. The Lamour et al. 
protocol was chosen, as it provided a convenient method for BMDM model analysis, 
using unprocessed supernatants and a methanol-water extraction of cell extracts. That 
said, extraction methods are extremely variable across the field, with different 
combinations of solvents used including water, chloroform, acetonitrile and/or 
perchloric acid, and also different variations in quenching, including ice-cold PBS, liquid 
nitrogen and sonication (Lin et al. 2007; Kostidis et al. 2017). Therefore, it could be worth 
assessing the benefits of these processes to aid sample extraction and analysis. For 
example, a two-phase extraction using methanol, water and chloroform, could be used 
to produce two separate fractions, consisting of aqueous water-soluble metabolites and 
organic non-polar molecules respectively. This could also allow greater precipitation of 
proteins and other large macromolecules prior to NMR acquisition, which would further 
improve baseline correction and phasing of spectra (Lauri et al. 2016; Teng et al. 2009).  
Looking to the future, it would be interesting to apply metabolomic NMR Spectroscopy 
to samples obtained from patients or animal models infected with S. pneumoniae 
and/or other respiratory pathogens. This has already been touched upon by Slupsky et 
al. with their analysis of urine from patients of pneumococcal pneumonia (Slupsky et al. 
2009) and also by McClay et al. who looked for metabolic biomarkers of lung disease, in 
the blood and urine of chronic obstructive pulmonary disease patients (McClay et al. 
2010). Whilst ex vivo and patient sample analysis has focused on blood and urine, it 
would be interesting to observe metabolic signatures in sputum, to consider metabolite 
biomarkers that may arise during different types of respiratory infection. These 
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applications, however, focus mainly on potential diagnostic applications while my work 
has been focused more upstream on understanding key steps in the host-pathogen 
interaction, whose application could be therapeutic, prognostic or diagnostic.  
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Chapter 5 – The importance of glucose metabolism during BMDM 
challenge with S. pneumoniae  
5.1. Introduction 
It is shown that LPS increases glycolytic metabolism in macrophages and that this is 
important in priming the cell to fight infection (Tannahill et al. 2013). To test whether 
this was also true for BMDM responses to S. pneumoniae, three inhibitors were used to 
interrupt glycolysis and the PPP, mirroring work that had previously been done with LPS 
and macrophages (Haschemi et al. 2012; Tannahill et al. 2013). The glucose analogue 2-
deoxyglucose (2DG) competitively inhibits Hexokinase and leads to intracellular 
accumulation of 2DG-phosphate, which cannot be used by Phosphoglucose Isomerase. 
It has been used in the literature as a method of halting glycolysis and depleting cellular 
ATP (Pelicano et al. 2006). Dehydroepiandrosterone (DHEA) is an androgen precursor, 
which inhibits Glucose-6-phosphate Dehydrogenase, the rate-limiting enzyme of the 
pentose phosphate pathway (PPP), and Iodoacetate (Iodo) inhibits Glyceraldehyde-3-
phosphate Dehydrogenase, an enzyme at the branch-point of glycolysis, by irreversibly 
binding cysteine residues in the enzyme active site and preventing substrate interaction 
(Haschemi et al. 2012). The chosen compounds were tested simultaneously to dissect 
the role of glucose in these responses, as they acted at different stages of the glucose 
pathway: 2DG restricted glucose entry and glycolysis entirely, Iodo allowed glucose 
entry and the PPP, but blocked glycolysis halfway through the pathway, whilst DHEA 
allowed glycolysis but inhibited PPP metabolism. Figure 5.1 highlights the action of the 
inhibitors in these pathways. The inhibitors were used in the context of macrophage 
effector functions assays, to establish the importance of glucose metabolism in these 
processes during S. pneumoniae challenge.  
Further to this, supporting functional and metabolic experiments were performed, to 
compare BMDM responses induced by LPS with those seen after S. pneumoniae 
challenge. These experiments aimed to understand the role of glucose metabolism in 
macrophage activation and innate immune functions, comparing bacterial challenge to 
LPS-induced responses, as a stimulus of the CAM phenotype. These experiments also 
complemented the work shown in Chapters 3 and 4.  
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Figure 5.1: Glycolysis and PPP metabolism indicating glycolytic inhibitor activities 
Details of the pathways for glycolysis (green) and the PPP (orange) are shown, highlighting 
enzymes, intermediates, and key interlinking regions in both. The inhibitory action of the 
compounds used in this chapter are shown in bold red. 
(ATP = adenosine triphosphate, PFK = phosphofructokinase, PFK2 = phosphofructokinase-2, G3P 
= glyceraldeyde-3-phosphate, NADH = nicotinamide adenine dinucleotide, NADPH = 
nicotinamide adenine dinucleotide phosphate, PEP = phosphoenolpyruvate) 
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5.2. Results 
5.2.1. The role of glycolysis in BMDM bacterial internalisation and TNFα release during 
S. pneumoniae challenge 
The inhibitors - 2DG, Iodoacetate and DHEA - were used to consider the impact of 
glucose metabolism on TNFα cytokine release, following S. pneumoniae challenge of 
BMDMs. BMDMs were inhibited for one hour, followed by addition of S. pneumoniae 
for 4 hours. This is referred to here as the inhibit-then-infect strategy, with results shown 
in Figure 5.2. In the absence of bacteria, 2DG induced a trend of increased TNFα release; 
however this change was not statistically significant. All other conditions induced 
cytokine changes narrowly within the detection limit of this ELISA kit (~5pg/ml). During 
pneumococcal challenge, unstimulated cells (UNS - cells with no metabolic inhibition) 
demonstrated the anticipated increased release of TNFα. A similar level was also seen 
during Iodo treatment. However, both 2DG and DHEA significantly reduced TNFα release 
during bacterial challenge. The effect of DHEA could be suggested to be partly caused 
by it’s solvent, as the DHEA vehicle control also caused a drop in TNFα after 
pneumococcal challenge, although this was not found to be statistically significant. That 
said, the large reduction in cytokine release, following 2DG treatment and S. 
pneumoniae challenge, could suggest here that glucose uptake and/or glycolysis play a 
role in early macrophage cytokine responses to pneumococci. 
In Figure 5.2, bacterial growth curves of S. pneumoniae in the presence of the glycolytic 
inhibitors are shown. These inhibitors were not specific to murine macrophage 
metabolism, so were tested for their effects against bacterial growth and metabolism. 
It was hypothesised that if the inhibitors affected bacterial growth, this could impact on 
the virulence of the bacteria and therefore the host-pathogen interaction (Peterson 
1996). Here, 2DG slowed bacterial replication, as measured by OD, whilst DHEA seemed 
to halt it completely. This inhibition of viable bacterial growth could have been the cause 
of the low cytokine release in Figure 5.2B. From these findings, an alternative 
experimental method was proposed, whereby simultaneous use of the inhibitors and 
bacteria were avoided, to avoid undesirable inhibition of bacterial metabolism or 
growth in the extracellular environment.  
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Figure 5.2: TNFα release of BMDMs following inhibit-then-infect model, and 
pneumococcal growth in the presence of glycolytic inhibitors 
A) BMDMs were seeded at 2x105cells/ml, and treated as per x-axis for one hour, followed by 
4 hours mock-infection (-Spn). Supernatants were collected and assayed for TNFα release. 
(2DG = 100mM, Iodo = 100μM, DHEA = 200μM, DHEA Vehicle = methanol). Biological n=4, in 
duplicate. Analysed using Kruskal-Wallis test, with Dunn’s multiple comparisons, using the 
unstimulated group (UNS) as the control in each data set. Data shows mean ±SD. 
B) BMDMs were seeded at 2x105cells/ml, and treated as per x-axis for one hour, followed by 
4 hours S. pneumoniae challenge (+Spn; D39, MOI 10). Supernatants were collected and 
assayed for TNFα release. (2DG = 100mM, Iodo = 100μM, DHEA = 200μM, DHEA Vehicle = 
methanol). Biological n=4, in duplicate. Analysed using Kruskal-Wallis test, with Dunn’s 
multiple comparisons, using the unstimulated group (UNS) as the control in each data set; 
*p=0.011, ****p<0.0001. Data shows mean ±SD. 
C) Growth curves of S. pneumoniae (Spn) with glycolytic inhibitors, assayed in 5ml Brain-
Heart-Infusion (BHI) broth with 20% HIFCS, and 100μl D39 bacterial stock. n=4. 
(UNS=unstimulated/no inhibitors, 2DG = 100mM, Iodo = 100μM, DHEA = 200μM, DHEA 
Vehicle = methanol). Data shows mean ±SD. 
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5.2.3. The role of glycolysis on BMDM internalisation of latex beads 
With the glycolytic inhibitors shown to manipulate bacterial growth, the importance of 
glucose metabolism during BMDM phagocytosis was instead evaluated using 
fluorescent latex beads. The beads were opsonised using murine immune serum and 
internalisation quantified via fluorescence microscopy after 4 hours. BMDMs were pre-
treated with the inhibitors for one hour prior to adding the beads, allowing metabolic 
changes to occur before this interaction. LPS was also used here as an additional 
condition, to compare responses to a CAM-inducing stimulant. The results of these 
counts are shown in Figure 5.3. Three different calculations were used, to ascertain the 
phagocytic index, the percentage of macrophages demonstrating active phagocytosis 
and average bead uptake per macrophage, for each condition. The results suggest that 
LPS significantly increased phagocytosis, whilst DHEA significantly reduced it. No further 
trends were found to be significant after 2DG or Iodo treatment compared to the 
unstimulated condition, suggesting that glucose metabolism is not essential for 
phagocytosis of opsonised beads by murine BMDMs. 
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Figure 5.3: The effect of glycolytic inhibition on BMDM phagocytosis of latex beads 
BMDMs were seeded at 2x105cells/ml, and challenged with red-fluorescent latex beads 
opsonised with mouse immune serum. After 4 hours, cells were washed and fixed in 
paraformaldehyde before DAPI staining and counting via fluorescent microscopy. 300 cells 
were counted per condition. 
A) Phagocytic Index = (Total beads/Total macrophages) 
B) % Phagocytosis = (Macrophages with internalised beads/Total macrophages) 
C) Average Bead Uptake = (Total beads/Macrophages with internalised beads) 
Statistics were calculated via One-way ANOVA with Dunnett’s multiple comparisons to the 
unstimulated (UNS) group (*= p<0.05; **= p<0.01; ***= p<0.001; ****= p<0.0001); n=5, in 
duplicate. Data shows mean ±SD. 
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5.2.4. The role of glycolysis in BMDM killing of intracellular S. pneumoniae by reactive 
nitrogen species. 
A different experimental approach was taken to establish the role of glycolysis in early 
macrophage responses – specifically the production of nitric oxide (NO). Here, BMDMs 
were first mock infected or S. pneumoniae challenged for 4 hours, washed to remove 
extracellular bacteria, and then given glycolytic inhibitors or left unstimulated for a 
further 4 hours. This will be referred to as the infect-then-inhibit model. This allowed 
bacterial internalisation to occur uniformly for all conditions, prior to adding the 
inhibitors. Once again, LPS was added as an extra condition, to allow comparison of S. 
pneumoniae-induced responses to a CAM phenotype that should also induce NO 
release. To measure NO production, DAF-FM diacetate was used. This is a non-
fluorescent, cell-permeable dye that emits high levels of fluorescence upon reaction 
with NO in the intracellular space. The dye was measured via flow cytometry, with 
unstained controls subtracted from all conditions. These results are shown in Figure 5.4. 
For NO production in the absence of infection, DHEA increased release compared to 
unstimulated cells, although this was not statistically significant. 2DG also induced a 
trend of increased NO, however this was also not found to be statistically significant, 
whilst LPS did not induce detectable increases in NO. After S. pneumoniae challenge NO 
production was very similar and not significantly different between all groups. This could 
suggest that pneumococcal stimulation induces NO production, that this is not 
dependent on glycolytic metabolism. 
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Figure 5.4: The effect of glycolytic inhibition on BMDM NO production 
BMDMs were seeded at 2x105cells/ml, and mock-infected (-Spn) or S. pneumoniae 
challenged (+Spn) for 4 hours. Cells were then washed with PBS and treated with 
compounds for 4 hours, as per key. After a total of 8 hours, cells were stained with DAF-
FM and Median Fluorescence Intensity (FI) measured via flow cytometry in the FLH-1 
channel, and analysed with FlowJo software. Median FI values from unstained controls 
were subtracted from DAF-FM stained values for each condition. Experimental duplicates 
used, and data represents mean of biological n=5. 
Statistics calculated via Two-Way ANOVA indicate a statistical difference between the 
mock-infected and S. pneumoniae-challenged group (p=0.001); however there were no 
statistical differences found within each of these two groups, after Sidak’s multiple 
comparisons. 
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5.2.5. The role of glycolysis in BMDM cytokine release during S. pneumoniae infection  
In parallel with measuring NO, TNFα and IL-6 inflammatory cytokine release was 
assessed, using the same infect-then-inhibit format. Supernatants were collected from 
both mock-infected and S. pneumoniae challenged cells, with glycolytic inhibitors used 
as presented in Figure 5.5.  
In the absence of bacteria, cytokine release was barely within the limit of detection for 
the ELISA kits used. S. pneumoniae exposure alone stimulated a significant 5-fold and 
15-fold increase in IL-6 and TNFα release respectively, compared to unchallenged cells.  
However, S. pneumoniae-induced release was much lower than LPS stimulation - almost 
10-fold less than LPS for both IL-6 and TNFα. No significant differences were found 
between unstimulated and inhibitor groups in the absence of bacteria. The release 
detected for pneumococcal-challenged cells was not significantly altered in the 
presence of 2DG and Iodoacetate. 2DG produced a trend of lower cytokine release after 
pneumococcal challenge, but DHEA and its vehicle control significantly reduced IL-6 
release during bacterial exposure. 
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Figure 5.5: The effect of glycolytic inhibition on BMDM cytokine production 
BMDMs were seeded at 2x105cells/ml, and mock-infected (-Spn) or S. pneumoniae 
challenged (+Spn) for 4 hours. Cells were then washed with PBS and treated with compounds 
for 4 hours, as per key. Supernatants were collected and ELISAs performed to measure IL-6 
release (A) and TNFα release (B). Statistical differences calculated via One-Way ANOVA with 
Dunnett’s multiple comparisons, excluding the LPS group and comparing all conditions to 
the unstimulated group in each data set (i.e. either with or without bacterial exposure) 
(p<0.005; *=0.02, **=0.009); Biological n=3, with duplicates. Data shows mean ±SD. Dotted 
line indicates lower assay detection limit. 
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5.2.6. Verifying the effects of glycolytic inhibition on key macrophage effector 
functions 
A combination of methods were used to study the effects of glycolytic inhibition on key 
macrophage effector functions; however it was difficult to draw conclusions from some 
of these results. Therefore, repeats of key assays were conducted to assess the influence 
specifically of 2DG and Iodoacetate on macrophage effector functions. DHEA was 
excluded here due to its proposed negative influence on bacterial growth and cell 
viability. A comparison was also made between the D39 encapsulated pneumococcal 
strain, obtained from Professor Tim Mitchell at the University of Birmingham, and an R6 
unencapsulated pneumococcal strain, obtained from Dr Andrew Fenton at the 
University of Sheffield. 
In Figures 5.6 and 5.7, TNFα cytokine release, reactive oxygen species (ROS) detection 
and bacterial phagocytosis are shown, after stimulation with either the D39 or R6 strain 
respectively. TNFα was detected after D39 stimulation but was not detectable within 
the limits of the ELISA kit following mock-stimulation. Interestingly, 2DG appeared to 
increase cytokine release during D39 challenge, which contrasted to previous results. In 
comparison, cytokine levels were much higher during challenge with the R6 
unencapsulated strain. That said, no significant differences were identified for cytokine 
release, following R6 stimulation with glycolytic inhibition. This supports the conclusion 
from prior experiments, whereby no effect of glycolytic inhibition was observed, that 
was not explicable by confounding effects on bacterial replication or macrophage 
viability.  
There was no evidence of ROS generation after bacterial challenge, with no further 
effect induced by the inhibitors, when measured via DCF-DA staining. IFNγ was used as 
a positive control during D39 stimulation, whilst IFNγ and Antimycin A were used during 
R6 stimulation. The efficacy of these controls could be challenged and is discussed later 
in this chapter. 
Lastly, internalisation of the two strains was assessed. Colony forming units (CFU) were 
measured from both the extracellular supernatant, and the intracellular cell lysate after 
antimicrobial treatment. 2DG inhibited detectable growth of D39 in the extracellular 
media during this assay, as shown in the pre-treatment CFU counts. This confirmed the 
confounding effect of altered bacterial replication on results with this inhibitor. 
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Internalisation of D39 was very low for all conditions. Contrastingly, higher levels of 
internalisation were achieved for the R6 strain. There appeared to be no difference in 
internalisation following Iodoacetate treatment but there was a significant reduction in 
intracellular CFU counts with 2DG treatment. Consistent with this, there were 
significantly fewer bacteria in the extracellular environment following 2DG treatment; 
this therefore supports the idea that 2DG impacts extracellular bacterial replication, 
with knock-on consequences for intracellular bacterial burden and stimulation of innate 
immune effector responses, which would otherwise hamper interpretation of results.  
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Figure 5.6: The effects of glycolytic inhibition on BMDM cytokine release, ROS 
production and bacterial phagocytosis, using D39 S. pneumoniae 
A) BMDMs were seeded at 2x105cells/ml and challenged with S. pneumoniae (D39, MOI 10) 
for 4 hours, followed by a PBS wash and 4 hours treatment with compounds 2DG or 
Iodoacetate (Iodo), or left unstimulated (UNS), as indicated on x-axis; Supernatants were 
collected and used to measure TNFα release via ELISA. Biological n=3, with duplicates. 
B) BMDMs were seeded at 2x105cells/ml, treated with the indicated inhibitors or left 
unstimulated (UNS) for 1 hour, prior to being mock-challenged (MI) or S. pneumoniae-
challenged (+D39, MOI 10) for 4 hours. Cells were stained with DCF-DA, scraped in PBS and 
assessed by flow cytometry. Figure indicates negative control and positive controls used (no 
DCF and 24 hour stimulation with 20μg/ml IFNγ, respectively). Biological n=2, with duplicates.  
C) BMDMs were seeded at 2x105cells/ml, treated with the indicated inhibitors or left 
unstimulated (UNS) for 1 hour, prior to being challenged with S. pneumoniae (D39, MOI 10) 
for 4 hours. CFU counts were calculated from extracellular supernatants. Biological n=3, with 
duplicates. 
D) BMDMs were seeded at 2x105cells/ml, treated with the indicated inhibitors or left 
unstimulated (UNS) for 1 hour, prior to being challenged with or S. pneumoniae (D39, MOI 
10) for 4 hours. CFU counts were calculated from lysed cells, with extracellular bacteria 
removed via antimicrobial treatment. Biological n=3, with duplicates.  
 
Statistical differences identified via One-Way ANOVA with Dunnett’s multiple comparisons to 
the unstimulated (UNS) group; (p<0.05, * = <0.03.) Data shows mean ±SD. 
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Figure 5.7: The effects of glycolytic inhibition on BMDM cytokine release, ROS 
production and bacterial phagocytosis, using R6 S. pneumoniae 
A) BMDMs were seeded at 2x105cells/ml and challenged with S. pneumoniae (R6, MOI 10) 
for 4 hours, followed by a PBS wash and 4 hours treatment with compounds 2DG or 
Iodoacetate (Iodo), or left unstimulated (UNS), as indicated on x-axis; Supernatants were 
collected and used to measure TNFα release via ELISA. Biological n=3, with duplicates. 
B) BMDMs were seeded at 2x105cells/ml, treated with the indicated inhibitors or left 
unstimulated (UNS) for 1 hour, prior to being mock-challenged (MI) or S. pneumoniae-
challenged (+R6, MOI 10) for 4 hours. Cells were stained with DCF-DA, scraped in PBS and 
assessed by flow cytometry. Figure indicates negative control and positive controls used (no 
DCF and 24 hour stimulation with 20μg/ml IFNγ or 4 hour 10μM Antimycin A (Ant A) 
treatment, respectively). Biological n=2, with duplicates.  
C) BMDMs were seeded at 2x105cells/ml, treated with the indicated inhibitors or left 
unstimulated (UNS) for 1 hour, prior to being challenged with S. pneumoniae (R6, MOI 10) 
for 4 hours. CFU counts were calculated from extracellular supernatants. Biological n=3, with 
duplicates. 
D) BMDMs were seeded at 2x105cells/ml, treated with the indicated inhibitors or left 
unstimulated (UNS) for 1 hour, prior to being challenged with or S. pneumoniae (R6, MOI 10) 
for 4 hours. CFU counts were calculated from lysed cells, with extracellular bacteria removed 
via antimicrobial treatment. Biological n=3, with duplicates.  
 
Statistical differences found via One-Way ANOVA, with Dunnett’s multiple comparisons to 
the unstimulated (UNS) condition (p<0.05; ***  = 0.001). Data shows mean ±SD. 
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5.2.7. A comparison of polarisation status between LPS-stimulated and S. pneumoniae 
challenged BMDMs 
The use of glycolytic inhibitors during S. pneumoniae challenge was shown to be 
problematic, after experiments showed reduced numbers of BMDMs and increased 
numbers of trypan blue positive cells after exposure to DHEA (data not shown). DHEA 
also reduced bacterial viability, and therefore altered the nature of the host-pathogen 
interaction. 2DG was still used with relative confidence as it was shown to be effective 
in Chapter 3 of this thesis; however, this inhibitor also affected bacterial growth (Figure 
5.2C) and could have impacted bacterial interaction with host cells. In parallel with these 
observations, it became apparent that the responses of BMDMs after LPS stimulation 
versus S. pneumoniae were different, as shown for the metabolic profiles shown in 
Figures 4.19 and 4.21. Therefore subsequent experiments examined the differences 
between LPS-stimulated and S. pneumoniae-challenged cells, rather than utilising the 
metabolic inhibitors further. These remaining experiments were performed using D39 
pneumococci only. 
To appropriately respond to bacterial infection, macrophages develop a CAM 
phenotype, with LPS stimulation often used to induce this (Mosser & Edwards 2008). 
However, whether activation of BMDMs occurs on a similar scale or timeframe after S. 
pneumoniae challenge is yet to be shown.  To consider this, two markers of theCAM 
phenotype were examined: inducible nitric oxide synthase (iNOS), as a marker of CAM 
metabolism, and cyclooxygenase-2 (COX2), as a marker of CAM pro-inflammatory 
activation (Rodriguez-Prados et al. 2010). These proteins were assayed via western blot, 
after BMDMs were stimulated for 12 hours. The representative gel images are shown in 
Figure 5.8. The amount of loading control protein, α-tubulin, was low after bacterial 
challenge, which is a common finding in cells at later time points, as proteases become 
activated (Schmeck & Gross 2004). The upregulation of iNOS following LPS stimulation 
was evident, especially when compared to the mock condition. Contrastingly, iNOS was 
not present after bacterial challenge with S. pneumoniae. Prior findings have shown 
iNOS induction in macrophages after S. pneumoniae challenge (Marriott et al. 2004), but 
the absence of comparable upregulation here suggested that any induction levels were 
lower than with LPS. On the other hand, COX2 expression was upregulated after S. 
pneumoniae-challenge, but was not detectable after mock- or LPS-stimulation.  
 179 
  
Figure 5.8: Expression of CAM protein markers, following 12 hour stimulation 
with LPS versus 12 hour S. pneumoniae bacterial challenge  
BMDMs were seeded at 2x105cells/ml, and mock-infected (MI), treated with LPS 
(100ng/ml) or S. pneumoniae challenged (SPN, D39 MOI 10) for 4 hours. Cells were 
washed with PBS and media replaced until 12 hours post-infection. Cells were washed 
and protein extracted via trichloroacetic acid, before separation on a 1.5mm 10% 
polyacrylamide gel. Protein samples were either loaded with equal volumes (A) or 
equal estimated protein, after total protein calculation using a Bradford assay (B). 
Lysates from 4 biological donors were used. (iNOS = inducible nitric oxide synthase; 
COX2 = cyclooxygenase-2; α-tub = α-tubulin.) 
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5.2.8. A comparison of glucose uptake and ATP production between LPS-stimulated 
and S. pneumoniae challenged BMDMs 
To complement Chapters 3 and 4 of this thesis, ATP production and glucose uptake were 
compared between mock-infected, LPS-stimulated and S. pneumoniae-challenged 
BMDMs after 12 hours. To do this, the Perkin Elmer ATPlite and Promega Glucose 
Uptake-Glo™ assay kits were used, with the results shown in Figure 5.9. ATP levels were 
significantly decreased following S. pneumoniae challenge, whilst both mock-infected 
and LPS-stimulated cells were not significantly different. On the other hand, there was 
a trend of increased glucose uptake following LPS stimulation, although no statistical 
differences were found. This trend correlates with the literature, regarding increased 
glycolysis with LPS stimulation, which could be significant with increased experimental 
repeats. That said, there was no concurrent increase in glucose uptake after 
pneumococcal challenge.  
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Figure 5.9: A comparison of ATP levels and glucose uptake after 12 hours mock-
infection, LPS stimulation or S. pneumoniae challenge  
A) BMDMs were seeded at 2x105cells/ml, and mock-infected (MI), treated with LPS 
(100ng/ml) or S. pneumoniae-challenged (SPN, D39 MOI 10) for 4 hours. Cells were washed 
with PBS and media replaced until 12 hours post-infection. ATP uptake was measured using 
a Perkin Elmer ATPlite assay kit. Statistical analysis via One-Way ANOVA with Tukey’s 
multiple comparisons, comparing all conditions with each other (p<0.005); Biological n=4, 
with duplicates. Data shows mean ±SD. 
B) BMDMs were seeded at 2x105cells/ml, and mock-infected (MI), treated with LPS 
(100ng/ml) or S. pneumoniae-challenged (SPN, D39 MOI 10) for 4 hours. Cells were washed 
with PBS and media replaced until 12 hours post-infection. Glucose uptake measured using 
Promega Glucose Uptake-Glo™ assay kit. No statistical differences were found after One-
Way ANOVA with Tukey’s multiple comparisons; Biological n=3, with duplicates. Data shows 
mean ±SD. 
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5.3. Discussion 
5.3.1. Chapter Summary 
In this chapter, methods to study macrophage effector functions, following bacterial 
challenge and metabolic inhibition, have been shown. Glycolytic inhibitors were chosen, 
as they offered a simple method for testing the influence of glycolysis and the PPP, on 
BMDM responses to S. pneumoniae challenge. Glucose metabolism has previously been 
shown to be important in the conversion to a CAM phenotype (Rodriguez-Prados et al. 
2010), therefore it was hypothesised to play an important role during live bacterial 
challenge of macrophages, prompting activation of functional responses against 
bacteria. The difficulties in using glycolytic inhibitors with live bacteria are described, 
with experiments shown utilising metabolic inhibitors after bacterial internalisation, to 
limit adverse effects of the inhibitors on the initial bacterial replication, prior to 
internalisation. Additionally, an interesting contrast was once again shown between 
macrophage responses to S. pneumoniae compared to LPS stimulation, specifically 
regarding changes to protein expression, ATP levels and glucose uptake. This could 
suggest that the metabolic and immunological phenotype of BMDMs following S. 
pneumoniae challenge, differs from that seen after stimulation with LPS. 
 
5.3.2. Chapter Discussion 
To use the inhibitors in conjunction with live bacteria, their effects on bacterial 
replication were first assayed. DHEA and 2DG both hindered bacterial growth, as 
measured via CFU counts. It was hypothesised that inhibition of metabolism or 
metabolite availability could impact on the virulence of S. pneumoniae (Paixao et al. 
2015; Somerville & Proctor 2009). Therefore assays were designed to only use the 
inhibitors after bacteria were internalised, and to focus on the effects of metabolic 
inhibition on later, downstream responses. 
To study the effect of metabolic inhibition on BMDM internalisation, phagocytosis of 
fluorescent latex beads was measured. The results suggest that LPS stimulation 
increased phagocytic index and the percentage of cells ingesting; however, the average 
number of internalised beads in those BMDMs ingesting remained consistent, compared 
to unstimulated cells. This implied that LPS stimulated more cells within the population 
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to actively phagocytose beads, inducing BMDMs towards a pro-inflammatory CAM 
phenotype. This is in line with previous reports demonstrating increased phagocytosis 
during LPS stimulation of both murine and human macrophages (Patel et al. 2012; 
Scheraga et al. 2016). 2DG and Iodoacetate did not affect bead phagocytosis. On the 
other hand, DHEA caused a highly significant decrease in all phagocytic measures. This 
could suggest a role for the PPP in controlling phagocytosis. That said, cell densities of 
DHEA-stimulated cells appeared lower and were not fully comparable with unstimulated 
cells, when inspected via microscopy; this implied that DHEA caused adverse effects 
regarding cell adhesion or viability. DHEA has previously been shown as a compound 
that can induce apoptosis in murine cells (Tian et al. 1999), further supporting this idea. 
Metabolic inhibitors were used to test the role of glucose metabolism in generation of 
NO. Elevated NO was detected in the absence of bacteria, after both DHEA and 2DG 
treatments. Increased NO after DHEA treatment could have lead to cell cytotoxicity, 
since NO production causes mitochondrial dysfunction (Beltrán et al. 2002). The small 
increase in NO detected after 2DG stimulation could also suggest that inhibition of 
glucose metabolism induces oxidative stress, consequent upon upregulation of 
oxidative phosphorylation. This could further alter viability and function in this model. 
Additionally, the MFI measured after S. pneumoniae exposure was lower than expected, 
which could reflect the early time point studied. It has been shown that NO production 
in response to S. pneumoniae is a delayed response, that is more marked at later times 
(Marriott et al. 2004). However, studying later time points would have been problematic 
due to prolonged exposure of cells to the inhibitors, with potential for adverse effects 
on both bacterial survival and macrophage viability. 
The effect of metabolic inhibition on cytokine release by BMDMs was assayed, 
specifically for TNFα and IL-6. No significant differences were observed in the absence 
of infection. An increase in both cytokines was detected after bacterial stimulation, but 
only DHEA and the DHEA vehicle control altered cytokine release. While this might 
suggest that PPP metabolism influences cytokine production and/or release, the results 
cannot be interpreted with confidence, in view of the effects of DHEA on bacterial 
replication, the potential impact on macrophage viability and a reciprocal response by 
the DHEA vehicle control. Further to this, LPS induced elevated release of both 
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cytokines. This difference between LPS stimulation and bacterial challenge suggested 
that S. pneumoniae stimulated a reduced and/or slower response by BMDMs.  
Further functional experiments were continued, comparing responses seen after either 
D39 S. pneumoniae or R6 S. pneumoniae stimulation of BMDMs. It was hypothesised 
that an R6 strain would elicit stronger responses from BMDMs compared to the D39, 
due to its lack of capsule and subsequently easier internalisation by BMDMs (Hyams et 
al. 2010). TNFα release was indeed higher after R6 challenge, suggesting that BMDMs 
were able to phagocytose and respond to this strain much quicker – as was expected 
from a strain that lacks capsule and is more easily phagocytosed (Ali et al. 2003). 
Additionally, 2DG seemed to increase cytokine release after D39 challenge. This 
contrasts with earlier findings but could largely be due to one hyper-responsive donor 
skewing the data set – the influence of which could be reduced with increased 
replicates. The effect of metabolic inhibition on ROS generation was also tested after 
both D39 and R6 challenge. Two controls, IFNγ and Antimycin A, were included to 
confirm that the DCF-DA dye effectively measured ROS, as has been previously shown 
(Jubrail et al. 2016). IFNγ stimulation causes upregulation of gp91phox in macrophages, 
a component of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 
which generates ROS immediately after bacterial internalisation (Cassatella et al. 1990). 
During D39 experiments, IFNγ resulted in a very modest increase in DCF signal. When 
challenging with the R6 bacterial strain, Antimycin A was also used. This is an inhibitor 
of Complex III of the electron transport chain in mitochondrial respiration, and causes 
mitochondrial ROS generation (Liu et al. 2002). During R6 experiments, Antimycin A 
demonstrated a significant shift in DCF-DA fluorescence, but there was no shift in DCF-
DA signal for IFNγ. It is not clear why macrophages in these experiments were unable to 
generate a DCF-DA signal with either IFNγ or bacteria, as there is extensive evidence in 
the literature of NADPH oxidase-dependent production of ROS in BMDMs, activated by 
bacteria and other CAM-inducing stimuli (Zhao et al. 2013). This absence of ROS 
induction with bacterial stimulation was also unexpected - despite the known anti-
oxidant defence systems of pneumococci, which partially neutralise ROS (Aberdein et 
al. 2013). It is possible that induction occurred earlier or later than assessed, although 
the time point used here has previously been shown to be sufficient to detect NADPH 
oxidase activation in macrophages (Jubrail et al. 2016). The absence of ROS induction 
meant the effect of these inhibitors could not appropriately be examined here. Lastly, 
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internalisation of the two strains was compared. Similar CFU counts were observed in 
the extracellular supernatants, however internalisation of R6 was far greater than for 
D39. The low level internalisation for D39 demonstrates the challenge for BMDMs 
internalising this pathogen, due to its complex capsular coating and other bacterial 
factors that inhibit internalisation (Kadioglu et al. 2008).  
On the whole, DHEA was seen to hinder BMDM responses, including cytokine release 
and phagocytosis; however it is debatable whether this was due to inhibition of the PPP 
in mediating these responses, or adverse effects of the inhibitors. DHEA has previously 
been shown to increase mitochondrial permeability and obstruct cellular redox (Tian et 
al. 1999), which may have induced early apoptosis and undesired cell loss in this model. 
Contrastingly 2DG and Iodoacetate did not induce significant differences during 
pneumococcal challenge, compared to unstimulated cells. In summary, it could be 
suggested that glucose metabolism is not critical for macrophage effector responses to 
S. pneumoniae; however, confounding effects on bacterial replication and macrophage 
viability impede interpretation of the impact of these glycolytic inhibitors on 
macrophage function.  
Protein markers of the CAM phenotype, COX2 and iNOS, were assayed, as a comparison 
of activated cell status after S. pneumoniae- or LPS-stimulation of BMDMs. COX2 
transcription and activity has been shown to be upregulated in BMDMs following just 2 
hours incubation with LPS (Eliopoulos et al. 2002). However, this was not shown to be 
the case as COX2 was undetected after LPS stimulation. The difference here could be 
contributed by LPS concentration, cell culture conditions or different timings of analysis 
between these studies. The data here demonstrate increased COX2 but lesser induction 
of iNOS after pneumococcal challenge, compared to LPS stimulation. LPS is a specific 
TLR4 agonist, whilst S. pneumoniae activates a variety of pattern recognition receptors 
(PRRs) and might induce lower levels of TLR4 activation than other PRRs, with 
subsequently less induction of iNOS. These findings may suggest a role for COX2, during 
the specific interaction between BMDMs and S. pneumoniae. COX2 is a key enzyme that 
converts arachidonic acid into prostaglandins, autocrine mediators of inflammation and 
cytokine release, which could suggest a role in both acute inflammation and 
inflammation resolution, during bacterial challenge with S. pneumoniae (Ricciotti & 
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Fitzgerald 2011).  That said, further verification and testing would be required to 
understand this more.  
Finally, ATP levels and glucose uptake were measured after either stimulation with LPS 
or D39 S. pneumoniae. ATP levels were significantly decreased with bacterial challenge 
but were unchanged after LPS stimulation. This could indicate that cells struggle to 
maintain ATP production during bacterial challenge and following bioenergetically 
demanding processes such as phagocytosis. Rates of phagocytosis of bacteria have 
previously been linked to reductions of ATP in monocytes (Webster et al. 2010). The 
reduction in ATP also could be because cells switch mitochondrial function away from 
producing ATP and towards ROS generation (Mills & O’Neill 2016; West et al. 2011), 
which facilitates bacterial killing (Garaude et al. 2016). ATP levels could then drop, as 
the rate at which glycolysis produces ATP does not match that given by uninterrupted 
mitochondrial respiration (O’Neill et al. 2016). Contrastingly, glucose uptake 
measurements contradicted the findings of earlier chapters, as it was not significantly 
increased after LPS stimulation or pneumococcal challenge. It could be proposed that 
this anomaly was an artefact of the assay kit used; here, glucose uptake was measured 
through using a labelled glucose analogue that inhibits glycolysis. Therefore, this could 
cause false positive read outs from metabolically plastic cells, as inhibition of this 
pathway would cause a back-log stress and prevent typical uptake in this system. 
Therefore, further verification would be required to confirm this finding. 
 
5.3.3. Future work 
The lower than expected readouts – particularly for RNS and ROS production during S. 
pneumoniae challenge – could have been because the time points studied were too 
early, or because the emergence of oxidative and nitrogenous species is very transient. 
It is possible that internalisation, degradation, signalling and killing of the pneumococcus 
occurs slower than anticipated, and that different cell types, host species or bacterial 
serotypes also influence these interactions. Therefore, it could be valuable to study 
different combinations of host species, cells and/or S. pneumoniae serotypes over a full 
24 hour time course, to identify peak readouts in effector function measures. Jonczyk et 
al have previously shown there are distinctions in the responses of mice to different 
pneumococcal serotypes, with disparities in readouts such as cytokine release (Jonczyk 
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et al. 2016). These differences are thought to be influenced both by host genetics and 
bacterial serotypes. Within the Dockrell research group, both murine and human cell 
cultures are used, from primary and cell line systems, and with different serotypes and 
bacterial species used between studies. Therefore not all experimental protocols or 
results are fully comparable, and a better understanding of each unique case could 
provide an interesting perspective on these experimental variations. This would also 
enable verified and optimal time points to be used in subsequent research, when 
measuring fundamental macrophage effector functions. 
In this work, glycolytic inhibitors were used to manipulate host metabolism, however 
due to the non-specific nature of their chemistry, they proved more challenging to use 
than predicted. If this work were to be carried on, alternative methods for inhibiting 
such enzymes could include the use of gene knockdown. This could be achieved by using 
techniques such as RNA interference (eg. siRNA) or CRISPR (clustered regularly 
interspaced short palindromic repeats). Tan et al. recently demonstrated this concept, 
using siRNAs to knockdown pyruvate dehydrogenase kinase to expose its role in 
macrophage polarisation (Tan, Xie, Cui, et al. 2015). That said, this could be a timely 
process, as confirmation of a successful enzyme knockdown and of its activity would 
require evidence, before application in host-pathogen interaction experiments. 
Therefore a quicker, albeit more expensive, option could be to use the bone marrow or 
cells of established knockout mice instead. Contrastingly, the metabolic gene 
transcription, protein expression and enzymatic activity of BMDM cell cultures could be 
measured during S. pneumoniae challenge, with comparisons made to LPS, and 
potentially also other pathogens or stimuli of interest.  
Throughout this work, comparisons have been made between pneumococcal challenge 
and stimulation with LPS – a Gram-negative component. This theme should be 
continued, but with the addition of other, more suitable Gram-positive components, 
such as lipopeptides, peptidoglycan and its components, or pneumolysin. Alternatively, 
it would be interesting to emulate the work of Lachmandas et al. who used different TLR 
agonists but also a mix of bacterial types – the Gram-negative E.coli, Gram-positive S. 
aureus and M. tuberculosis, a species that is neither Gram-positive nor -negative 
(Lachmandas et al. 2016). 
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Chapter 6 – Discussion 
6.1. Summary of thesis 
The first aim of this work was to optimise and use the Seahorse XF Analyser to analyse 
changes in glycolytic metabolism during S. pneumoniae challenge of BMDMs. This was 
achieved first through manipulation of the cell density and protocol timings, as required 
for the basic assay set-up. The appropriate concentrations of inhibitors for profiling 
assay kits were also tested, including for 2DG, oligomycin and FCCP. Following initial 
tests, the assay design was further modified, to better mimic typical cell culture 
conditions and reduce cell stress through prolonged absence of glucose. This assay 
design was used to establish glycolysis rates of BMDMs after 4 hours and 12 hours post-
stimulation, with S. pneumoniae compared to the CAM and AAM stimuli, LPS and IL-4 
respectively. There were no significant differences observed at 4 hours, with an elevated 
basal glycolysis and glycolytic capacity identified after 12 hours bacterial stimulation, 
compared to the mock condition. A novel phenomenon was also identified, whereby LPS 
stimulation did not elevate these parameters, but instead caused a considerable 
increase in non-glycolytic acidification. This has not previously been reported. The 
technique was also used to test mitochondrial oxidative stress in human MDMs, as a 
proof of concept in other cell types. While aspects of this work may not directly correlate 
with the literature, specifically regarding short-term metabolic responses to LPS, it has 
identified that LPS and S. pneumoniae induce different metabolic responses, specifically 
in terms of changes to BMDM glycolysis. 
The second aim of my work was to optimise and use NMR Spectroscopy to detect global 
changes to metabolism, during S. pneumoniae challenge of BMDMs. This technique had 
not previously been used and required extensive training and optimisation, by both the 
doctoral researcher and by the lead technician at the NMR Spectroscopy facility. The 
biggest challenges involved the reproducibility of preparations and spectral analysis; 
therefore optimisation aimed to identify appropriate cell numbers, time points, 
metabolite identification and data handling techniques. A collaborator was also sought 
for manipulation of the raw spectral data, to allow statistical metabolomic analysis to 
be done. The main, novel finding was the identification of itaconic acid in LPS-stimulated 
samples, which was absent from S. pneumoniae-stimulated cells. This hallmark of 
polarisation and altered metabolism demonstrates that S. pneumoniae induces a unique 
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variation on macrophage activation and metabolism compared to LPS with a 
combination of CAM- and some AAM-associated changes possible. This phenomenon 
has previously been described for macrophages challenged with other pathogens such 
as S. pyogenes (Goldmann et al. 2007). This thesis also demonstrates that metabolite 
profiles of macrophages challenged with S. pneumoniae are very different to those seen 
following LPS-stimulation or mock-infection, as few similarities were observed. Some 
CAM metabolic features were present in LPS-treated macrophages, but not those 
challenged with S. pneumoniae, for examples itaconic acid production, in contrast 
others such as low glutamine or glutamate were more marked after S. pneumoniae 
challenge. Thus, although both produced M1 features, these features varied. This 
further emphasised that LPS stimulation cannot be used as a universal model of the CAM 
phenotype seen during bacterial challenge, and that future experiments and literature 
should analyse specific pathogen interactions, including responses to Gram-positive 
bacterial components such as peptidoglycan, in addition to Gram-negative components 
such as LPS. This theme has been highlighted in transcriptional studies previously, which 
showed the variations in macrophage polarisation induced by different bacteria despite 
the predominance of CAM phenotypes (M. Benoit et al. 2008). These studies showed 
that some pathogens could induce predominantly AAM phenotypes. 
The final aim was to manipulate host glycolytic metabolism and assess the impact of this 
on macrophage effector functions, specifically during stimulation with S. pneumoniae. 
The use of chemical inhibitors of glycolysis proved challenging for studying initial host-
pathogen interactions, due to their disruption of bacterial growth. Therefore they were 
chiefly used to assess later, downstream responses, after initial bacterial internalisation 
by macrophages. The PPP inhibitor, DHEA, induced dampened macrophage effector 
functions; however, whether these differences demonstrate a role for the PPP in 
macrophage responses or toxicity of the inhibitor, remains unconfirmed. On the other 
hand, the glycolytic inhibitors 2DG and Iodoacetate did not induce any significant 
changes in macrophage effector functions. These two inhibitors were further tested for 
their effects during macrophage challenge with two different pneumococcal strains – 
encapsulated D39 and un-encapsulated R6. No significant differences were seen 
following use of these inhibitors, but there were noticeable differences between the 
effects induced by the different pneumococcal strains. Also, whilst 2DG caused 
differences in internalisation of the R6 strain, lower bacterial numbers in the 
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extracellular environment may also have led to this finding. These experiments 
highlighted that different bacterial strains can induce different outcomes, as 
demonstrated by the lower levels of TNFα cytokine release following D39 versus R6 
challenge, in keeping with known differences in rates of internalisation of the 
encapsulated strain (Ali et al. 2003), which have been replicated here. 
Overall, the main conclusion is that S. pneumoniae does not induce the same responses 
in BMDMs as seen for stimulation with LPS. This was true for both metabolic changes 
and macrophage effector functions. The effects of LPS stimulation on macrophage 
metabolism is increasingly well documented (Tannahill et al. 2013; Kelly & O’Neill 2015); 
however this model of macrophage activation does not necessarily predict the 
activation status induced by live bacterial infection of cell cultures, particularly when 
using Gram-positive pathogens. These differences could be due to a number of factors: 
firstly, LPS is predominantly a Gram-negative bacterial component, that is not typically 
found in Gram-positive cell wall structures (Brown et al. 2015). Therefore this stimulus 
is not applicable to work with Gram-positive bacteria and that Gram-positive 
constituents such as peptidoglycan or lipopeptides should be investigated in future 
studies. Secondly, the initial interaction with S. pneumoniae includes an array of signals 
and receptors - some of which may detect bacterial components at the surface, others 
which recognise degraded components in the intracellular environment, and further 
receptors that bind to opsonic factors, such as antibodies coating the bacterial surface 
(Koppe et al. 2012; Ali et al. 2003). The bacterium is also capable of releasing 
components, such as pneumolysin, which will further stimulate and cause responses in 
host cells (McNeela et al. 2010). Additionally, it has been shown that bacterial infection 
can cause biphasic macrophage activation, correlating with initial surface interaction 
and later phagosomal degradation (Wolf et al. 2011). On the other hand, LPS is well 
documented to activate macrophages through binding and activating TLR4-mediated 
pathways (Takeda & Akira 2001). Live S. pneumoniae and free LPS  interact with different 
numbers and groups of receptors, and different patterns of activation can occur during 
bacterial challenge. Following from this point, if different bacterial species can activate 
unique receptor subsets during infection of macrophages, they could also induce 
tailored patterns of macrophage activation. An example of this can be seen for 
macrophage infection with S. pyogenes, which has been shown to induce a combination 
of both CAM- and AAM-associated markers (Goldmann et al. 2007). It could be proposed 
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that a similar outcome is likely to exist following S. pneumoniae infection of murine 
macrophages, with a variety of activation markers being differentially expressed to 
varying extents. 
 
6.2. Model limitations  
BMDM cell culture was used as bone marrow preparations yield high cell numbers and 
this model was readily available within the Dockrell-Marriott research group. These 
primary cells also presented benefits over cell line cultures as they do not have Warburg 
metabolism, whereby glycolysis is already elevated in resting cells (Van den Bossche et 
al. 2015). However, their relevance as a model for AMs could be questioned. The 
isolation of AMs requires greater labour and yields fewer cells; therefore primary, proof 
of concept experimentation was carried out in BMDMs, with the availability to use AMs 
later in the study, when testing key findings. This is in line with the principles of the 3Rs, 
to reduce animal use in experimentation (Franco & Olsson 2014). Mouse models were 
also available for testing major findings in vivo – which was not done here but could be 
implemented upon continuation of this work. Lastly, murine BMDMs were primarily 
used for experiments, as the paradigm of CAM and AAM polarisation is much more 
established in mice than in humans, allowing for the identification of more widely 
accepted phenotypic changes (Murray & Wynn 2011). 
A second potential limitation here is the type of bacteria used. This work primarily 
addresses serotype 2 D39 S. pneumoniae. This strain was isolated from a patient in the 
early 1900s and is still shown to induce pathogenicity in murine models. However 
pneumococcal serotypes and strains have different genetic sequences and could 
therefore induce different responses in host cells (Lanie et al. 2007). Therefore different 
pneumococcal strains and/or other Gram-positive bacteria should be tested, to provide 
a wider scope and understanding of pneumococcal-macrophage interactions and 
broader host-pathogen implications. 
 
6.3. Future prospects 
In 2016, Czaplewski et al proposed 10 methods that should be developed as a priority 
for the replacement of antibiotic treatment (Czaplewski et al. 2016); one of these 
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approaches concerned immune stimulation. By understanding the specific interaction 
between bacteria and host immune cells, valuable new methods for tackling bacterial 
infections could be revealed. This knowledge could make it possible to manipulate 
immune cell responses, to improve infection outcomes and provide an alternative 
treatment to antibiotics. For example, TLR agonists could be used as preventative 
therapy for patients at risk of pneumonia, aiming to enhance local immune cell 
responses without excessive cytokine production (Walker et al. 2014). Whilst this shows 
how manipulation of immune function could be used for infection prevention, it is 
interesting to consider the therapeutic effects of immunomodulation as a treatment for 
bacterial infections. Can this occur without causing toxicity or inappropriate immune 
activation that causes inflammation-associated tissue injury? Could the natural 
microbiota be manipulated to our immune advantage, to help downregulate harmful 
inflammatory responses? Interestingly, some modulatory compounds, that chiefly act 
through TLR-based activity, are already being explored in clinics to treat bacterial 
infections – for example, Luivac, a combination bacterial lysate drug produced by Daiichi 
Sankyo, which acts as an agonist for immune cell responses to limit respiratory infection 
in children (Hancock et al. 2012). By further understanding host—pathogen interactions 
and the role of metabolic responses, this could be a new potential target in the field of 
immune therapy. Manipulating metabolic responses in immune cells, such as 
macrophages, could be one approach to tailoring activation, although this would need 
to be calibrated to the specific pathogen in question. 
Following from this, a related area of interest is the concept of trained immunity. This is 
the idea that innate immune cells are capable of immunological memory – much like 
that seen for adaptive immune cells. This phenomenon is thought to be antigen-
independent and regulated through mechanisms such as epigenetic modification (Netea 
et al. 2016). Epigenetic regulation has also been shown to have a strong connection with 
cellular metabolism, as substrates such as lactate and succinate have been shown to 
influence this process (Latham et al. 2012; Yang & Pollard 2013). Thus manipulation of 
metabolism could modulate epigenetic modifications to mediate innate immune 
responses. Despite these concepts, the idea of immunomodulation is still very much in 
its infancy, and further basic research and clinical testing is required before a broader 
range of therapies can be applied in humans. However, understanding the metabolic 
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changes that occur during host-pathogen interactions could help with infectious 
diagnostics and treatments in the future. 
Metabolomic studies have grown in number and appeared across a broad range of 
fields, and with new techniques paving the way for high-content profiling of cells, 
information in this field is only likely to increase. One such example can be seen in single-
cell studies, whereby in-depth details of metabolism and bioenergetics can be obtained, 
following strict biomass separations and even label-free systems (Vasdekis & 
Stephanopoulos 2015). This increase in hardware sensitivity has also been followed by 
the expansion of bioinformatic tools and data handling techniques (Fessenden 2016). 
This will aid development of the metabolomic field, allowing the metabolic statuses of 
both individual cells and cell populations to be uncovered with incredible detail, and 
with greater potential for disease biomarker identification. This could also help future 
development of diagnostics and new treatment approaches, both in infectious and non-
communicable diseases. The unique metabolic signatures of specific immune cells to 
pathogens, could be used both as a diagnostic approach and to help calibrate suitable 
treatments. 
 
6.4. Concluding remarks 
This research highlights the processes taken to understand the importance of 
macrophage metabolism during immune responses to pathogens, with a focus on using 
extracellular fluxomics, NMR metabolomics and metabolic inhibition methods. The 
steps taken to optimise these techniques have been shown, with the challenges of 
applying these techniques to infectious studies involving live metabolically active micro-
organisms. The overarching conclusion is that S. pneumoniae does not induce the same 
metabolic changes in macrophages as seen for LPS stimulation, and that BMDM 
responses to S. pneumoniae are not likely depend on glucose metabolism. The data also 
demonstrates that further verification of these metabolic changes is required, 
particularly considering Gram-positive bacteria and their microbial components, to 
utilise the potential of metabolic studies in infection diagnostics and therapeutics. 
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Appendix 1: Flow Cytometry of BMDMs to establish appropriate differentiation 
(Taken from EFisk MBiolSci project report) 
(A) This population of four cell groups, as separated by FSC-H and SSC-H. The black oval 
indicates gating used, to determine cells used for subsequent analysis. Here this 
encompasses 94% of the total population, excluding contaminants, debris and cells with 
unexpected morphologies.  
(B) Normalised levels of CD68 expression are shown for alveolar macrophages (AMs), wild 
type (WT) BMDMs, Mcl-1 transgenic (Tg) BMDMs, and isotype-stained mixed BMDM control. 
This indicates high level of CD68 expression in both BMDM cell lines, compared to AMs, 
suggesting appropriate macrophage differentiation occurred in BMDM cultures. 
Additionally, the isotype control shows non-specific CD68 antibody binding did not occur. 
(C) Data presented in the same manner as (B), however here the expression of F4/80 on AMs 
and BMDMs is shown. Both BMDM cell lines show high expression, and the isotype control 
confirmed this was not due to non-specific antibody binding. The AM population exhibits 
two distinct populations; a low expression subset and a high expression subset. This could be 
due to the functional role of F4/80 in activated alveolar macrophages. This data suggests 
that BMDMs are appropriately differentiated after fourteen days of culturing. 
A 
B 
C 
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A 
B 
Appendix 2: Supernatant spectra of blank wells and S. pneumoniae-containing 
media only. 
Supernatant samples taken from preparations absent of BMDM cell cultures, to act as 
baseline controls and references. After 4 hours, all wells were treated with antibiotics, to 
prevent bacterial replication and to correlate with the treatment of the cells. For NMR 
spectroscopy, supernatants were diluted 50:50 in 70% D2O PBS with 167μM TSP.  
A) Spectral profiles for blank wells (no cells, no bacteria) 
B) Spectral profiles for wells containing S. pneumoniae (MOI 10, as per infected cells).  
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ccc 
  
workspace;  % Make sure the workspace panel is showing. 
  
pnTop = 'F:\matlab\ProcessData\Emily\NMR\';%Set main directory 
fileNm = '\efisk*';%Set filenames to process '*' as a wildcard 
  
%********Option********** 
pltFig = 0;%option to plot out spectra 
ppm.limits = [11 -0.5];%display limits 
ppm.binLimits = [9 0.5];%bin spectra between these values 
ppm.noise = [11 9];%define boise region - NOT USED 
ppm.water = [5.2 4.5];%replace water region with random numbers 
ppm.ref  = 1.30;%reference peak for binning 
ppm.binWidth = 0.04;%binning width 
  
%************Spectrum alignment options in icoshift************************ 
alignMode.align = 'average'; 
alignMode.quality = 'b'; 
alignMode.options = [0 2 0]; 
  
%Start of code 
pnData = '\pdata\1\'; 
fn = '1r'; 
d = dir(strcat(pnTop,fileNm)); 
tmp = [d.isdir]; 
d = d(tmp); 
dataNms = {d.name}'; 
numDataSets = length(dataNms); 
dataArray = cell(numDataSets,2); 
  
% [~,~,dnData] = xlsread(strcat(pnTop,'ProtonData.xlsx'),'Sheet1','A2:F42'); 
%     tmp = d(1).name(1:end-1); 
%     tmp = strsplit(tmp,'\'); 
samples = struct; 
tmpStrct = struct; 
%************get spectra**************** 
for ii=1:numDataSets 
    subDir = dir(strcat(pnTop,dataNms{ii})); 
    subDir = subDir(3:end);%take off '.' and '..' directory listing 
    tmp = [subDir.isdir]; 
    subDir = subDir(tmp); 
    subDir = {subDir.name}; 
    numFiles = length(subDir); 
     
    for i2=1:numFiles 
        smplPth = [dataNms{ii},'\',subDir{i2},'\pdata\1\']; 
         
      
        tmpStrct = Open_Bruker_Raw_Data_Spect800([pnTop,smplPth],'1r'); 
        smplNm = strsplit(smplPth,'\'); 
        smplNm = smplNm{1}; 
   
        ns = tmpStrct.ns; 
        tmpStrct.ppm = linspace(tmpStrct.Offset,... 
            tmpStrct.Offset-tmpStrct.sweepwidth/tmpStrct.CF,... 
            tmpStrct.SI)'; 
        if i2==1 
           holdArray = zeros(numFiles,length(tmpStrct.raw));  
        end 
        %correct water baseline 
        %             tmp = tmpStrct.raw; 
        %             SI = numel(tmp); 
        %             matFile = sprintf('%s\\%s\\%s_%s.mat',pnTop,smplPth,smplNm,subDir{i3}); 
        %             if exist(matFile,'file') == 2 
        %                 display(sprintf('Previous base line points (%s) exists loading',matFile)); 
        %                 load(matFile,'bsPts'); 
        %                 %                     tmpPts = [1,tmp(1);bsPts;SI,tmp(SI)]; 
        %                 %                     bsCorrRl = splineBsTool(tmpPts,SI,'pchip',[3 81],0); 
        %                 fh = figure; 
        %                 ha(1) = subplot(2,1,1); 
        %                 plot(tmp,'b'); 
        %                 hold on 
        %                 %                 plot(bsPts,'rx') 
        %                 plot(bsPts,'r:'); 
        %                 title('Original') 
        %                 ha(2) = subplot(2,1,2); 
        %                 plot(tmp-bsPts,'b'); 
        %                 hold on 
        %                 plot(zeros(numel(tmp),1),'k--') 
        %                 title('Baseline corrected') 
        %                 tmpStrct.corr = tmp-bsPts; 
        % %                 linkaxes(ha,'xy') 
        %                 pause(2) 
        %                 close(fh) 
        %             else 
        %                 bsPts = []; 
        %                 [tmpStrct.corr,bsPts] = bsToolV2(tmp,'interp',3,numel(tmpStrct.raw),'pchip',[3 
81],bsPts,1); 
        %                 save(matFile,'bsPts') 
        %             end 
        holdArray(i2,:) = tmpStrct.raw;%place spectra in temporary array for alignment 
        samples.(smplNm).(sprintf('Expno_%s',subDir{i2})) =  tmpStrct; 
    end 
     
    %***********Align spectra******************** 
    alignMode.binNo = (knnsearch(tmpStrct.ppm,ppm.limits(1))):(knnsearch(tmpStrct.ppm,ppm.limits(2))); 
    trgtSpec = holdArray(1,:);%align to first spectrum 
    [alignedSpectra, ~, ~] = icoshiftV2(alignMode.align, trgtSpec,holdArray,... 
                                         alignMode.binNo, alignMode.quality,... 
                                         alignMode.options,tmpStrct.ppm); 
    samples.(smplNm).alignedSpectra = alignedSpectra; 
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    if pltFig==1%plot spectra if option on 
        figure 
        hold on 
        for i2=1:numFiles 
            plot(tmpStrct.ppm,holdArray(i2,:)) 
        end 
        set(gca,'XDir','reverse') 
        legend(subDir,'Location','NorthWest') 
        title(strrep(d(ii,1).name,'_',' ')) 
        xlim(sort(ppm.limits)) 
    end 
end 
  
%**********************Bin Spectra********************* 
if exist(sprintf('%s\\%s_BinWdth%s.mat',pnTop,'samples',strrep(num2str(ppm.binWidth),'.','p')),'file') == 2 
    reBin = 0; 
  
    reBin = questdlg(sprintf('Previous bindata loaded\nRebin?'), ... 
        'Bin data', ... 
        'Yes','No','Quit','No'); 
    if strcmp(reBin,'Quit')==1 || isempty(reBin)==1 
        display('Exiting') 
        return 
    end 
    if strcmp(reBin,'No')==1  
        load(sprintf('%s\\%s_BinWdth%s.mat',pnTop,'samples',strrep(num2str(ppm.binWidth),'.','p')),'samples') 
    end 
    if strcmp(reBin,'Yes')==1 
        reBin = 1; 
    end 
else 
    reBin = 1; 
end 
  
fldNmsL1 = fieldnames(samples); 
lvl1 = numel(fldNmsL1); 
if reBin==1 
    for ii = 1:lvl1 
        smplNm = fldNmsL1{ii};%Sample name 
         
        %Determine how many spectra to bin 
        fldNmsL2 = fieldnames(samples.(fldNmsL1{ii})); 
        tmp = strncmp(fldNmsL2,'Expno',5); 
        fldNmsL2 = fldNmsL2(tmp); 
        holdArray = samples.(fldNmsL1{ii}).alignedSpectra; 
        trgtPnts = 1:size(holdArray,2); 
         
        for i2=1:size(holdArray,1) 
             
            ppm.use = tmpStrct.ppm; 
             
            %replace water peak with random numbers 
            tmp = knnsearch(ppm.use,ppm.water(1)):knnsearch(ppm.use,ppm.water(2)); 
            holdArray(i2,tmp) = rand(numel(tmp),1)-0.5; 
             
            %bin data 
            tmp = 
binTool(holdArray(i2,:),trgtPnts,ppm.binWidth,ppm,'y',sprintf('%s, %s',smplNm,fldNmsL2{i2}));%bin target spectrum 
           
            if i2==1%only do this for the first loop 
                holdCell = cell(size(holdArray,1),4+numel(tmp.binIntegrals)); 
            end 
             
            %add sample parameters to temporary array for saving 
            holdCell(i2,1) = {smplNm};%sample name 
            holdCell(i2,2) = fldNmsL2(i2);%expno 
            holdCell(i2,3) = {0};% empty for cell concentration 
            holdCell(i2,4) = {sum(tmp.binIntegrals)};%total bin integral 
            holdCell(i2,5:end) = num2cell(tmp.binIntegrals);%place bin integrals into array 
             
            samples.(fldNmsL1{ii}).(fldNmsL2{i2}) = catstruct(samples.(fldNmsL1{ii}).(fldNmsL2{i2}),tmp);%store 
data in main structure 
        end 
         
        %************Create text file************************** 
%         tmp = ['Sample','Expno','Cell_Conc','Sum_of_Bins',arrayfun(@num2str, 1:size(holdCell,2)-4, 'unif', 0)]; 
        tmp = ['Sample','Expno','Cell_Conc','Sum_of_Bins',strsplit(sprintf('Bin%d,',1:size(holdCell,2)-4),',')]; 
        tmp=tmp(1:end-1); 
        holdCell = [tmp;holdCell]; 
        
writetable(cell2table(holdCell(2:end,:),'VariableNames',tmp),sprintf('%sData_%s.txt',pnTop,fldNmsL1{ii}),'Delimit
er','\t') 
         
        samples.(fldNmsL1{ii}).binIntegrals = holdCell;%store all bin integrals in main structure 
    end 
    
     
save(strcat(pnTop,sprintf('%s_BinWdth%s.mat','samples',strrep(num2str(ppm.binWidth),'.','p'))),'samples')%save 
all bin data 
end 
 
Appendix 3: 1H-NMR MATLAB script  
MATLAB script used to normalise, align and calculate integral regions of raw NMR data, 
courtesy of Dr. Stephen Reynolds. Green text with ‘%’ at start of line is used here to give 
information on the proceeding sections of code. 
